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ABSTRACT 
Picornaviruses are non-enveloped, positive sense single-stranded RNA viruses which cause 
many diseases ranging from slight illness to fatal meningitis and encephalitis. There are no 
vaccines against most picornaviruses so drugs need to be developed. Human parechoviruses 
(HPeVs) are being increasingly recognised as important human pathogens, but are genetically 
diverse from other picornaviruses. We therefore need to understand the details of virus 
replication to improve the opportunities to develop antiviral drugs. Viruses often rearrange the 
ER, ERGIC and Golgi to give a new membrane structures involved in viral replication and/or 
assembly. To improve our understanding of HPeV replication, we first studied the secretory 
pathway compartments and we found in HPeV-infected cells that the Golgi was rearranged and 
became more concentrated near to the replication complex. ER seemed to disappear almost 
completely. In terms of HPeV non-structural proteins, 2C had a major effect on the 
compartments and also co-localised and aggregated lipid droplets. Many viruses such as hepatitis 
C virus (HCV) and Dengue virus recruit lipid droplets to replication complexes. We found that 
lipid droplets became larger in HPeV-infected cells, but do not co-localise with replication 
complexes. To investigate the interaction between 2C and lipid droplets we made several 2C 
mutants. Mutation of NTPase domain of 2C did not change the interaction with lipid droplets. 
Instead we found that other domains, including a novel amphipathic helix are important. The 
results suggest that lipid droplets play a role in HPeV replication and so we investigated the 
effect of drugs which target lipid droplet formation and lipid homeostasis on HPeV replication. 
We demonstrated that drugs which target the enzyme DGAT1, which is involved in lipid droplet 
formation, have a potent effect on HPeV replication. Our results suggest that blocking lipid 
droplet formation is could be an important strategy for the treatment of HPeV infection. 
A C K N O W L E D G E M E N T S   P a g e  |  i i  
   
 
ACKNOWLEDGEMENTS 
All praise is due to Almighty ALLAH, whose mercy and knowledge surround every single 
known matter and even those beyond our perception in this universe. Then peace and blessing be 
upon Prophet Muhammad (peace be upon him). 
 I would like to express my sincere gratitude to my supervisors Prof. Glyn Stanway for his 
guidance, patience, motivation, support and helped all the time throughout this study. Very warm 
thanks to DR. Metodi Metodiev for his invaluable advice and comments. 
I would like to express my deepest appreciation to all of the people who have provided me with 
helpful advice and support, especially to virology lab colleagues Dr. Shaia Al Malki, Dr. Arsalan 
Salimi, Dr Naseebah Baeshen, Dr Ashjan Shami, Miss Cheryl Eno-Ibanga, Miss Marina 
Ioannou, Mr Osamah Abdullah, Mrs Natalie Gray and Mrs. Hannah Adams. Thanks also go to 
Mrs Rana Al Ghamdi for her help with the confocal microscopy.  
My heartfelt gratitude goes to the most loving people in my life, my parents for giving me 
generous care and support in each stage of my life. I would like to extend my sincerest thanks to 
my wife and children, my brothers and my sister for their sincere prayers and support.  
As this project was generously funded by the government of the Kingdom of Saudi Arabia 
through Ministry of Health, I am sincerely grateful to them for the financial support throughout 
my study. 
T A B L E  O F  C O N T E N T S   P a g e  |  I I I  
   
 
Table of Contents 
ABSTRACT ................................................................................................................................................ i 
ACKNOWLEDGEMENTS ............................................................................................................................... ii 
LIST OF TABLES ........................................................................................................................................... IX 
TABLE OF FIGURES ...................................................................................................................................... X 
LIST OF ABBREVIATIONS ........................................................................................................................... XIII 
 CHAPTER ONE...................................................................................................................................... 1 1
INTRODUCTION ........................................................................................................................................... 1 
1.1 Picornaviruses ................................................................................................................................. 1 
 Classification ................................................................................................................................ 1 1.1.1
 Medical importance .................................................................................................................... 2 1.1.2
 Human picornavirus .................................................................................................................... 2 1.1.2.1
1.1.2.1.1 Poliovirus (PV) ......................................................................................................................... 2 
1.1.2.1.2 Coxsackievirus and Echovirus .................................................................................................. 2 
1.1.2.1.3 Enterovirus 71 (EV71) .............................................................................................................. 3 
1.1.2.1.4 Human Rhinovirus (HRV) ......................................................................................................... 3 
1.1.2.1.5 Hepatovirus ............................................................................................................................. 4 
1.1.2.1.6 Parechoviruses ........................................................................................................................ 4 
1.1.2.1.7 Other human viruses ............................................................................................................... 5 
 Non-human picornavirus ............................................................................................................. 6 1.1.2.2
1.1.2.2.1 Foot-and-mouth-disease virus (FMDV).................................................................................... 6 
1.1.2.2.2 Other non-human picornaviruses ............................................................................................ 6 
 Picornavirus Molecular Biology ................................................................................................... 6 1.1.3
 Particle and Genome ................................................................................................................... 6 1.1.3.1
 Enteroviruses ............................................................................................................................... 9 1.1.3.2
 Parechoviruses .......................................................................................................................... 10 1.1.3.3
 The picornaviral life cycle .......................................................................................................... 11 1.1.4
 Summary ................................................................................................................................... 11 1.1.4.1
 Entry .......................................................................................................................................... 11 1.1.4.2
 Translation................................................................................................................................. 13 1.1.4.3
 Polyprotein processing .............................................................................................................. 13 1.1.4.4
T A B L E  O F  C O N T E N T S   P a g e  |  I V  
   
 
 Replication ................................................................................................................................. 14 1.1.4.5
 Assembly, Maturation and Release ........................................................................................... 17 1.1.4.6
 Non-structural proteins ............................................................................................................. 17 1.1.5
 Genome ..................................................................................................................................... 17 1.1.5.1
 2A, 3C and L protein .................................................................................................................. 17 1.1.5.2
 2B .............................................................................................................................................. 19 1.1.5.3
 2C and 2BC ................................................................................................................................ 19 1.1.5.4
 3A and 3AB ................................................................................................................................ 20 1.1.5.5
 3CD ............................................................................................................................................ 22 1.1.5.6
 3Dpol ......................................................................................................................................... 22 1.1.5.7
1.2 Secretory pathway ........................................................................................................................ 23 
 Introduction............................................................................................................................... 23 1.2.1
 Endoplasmic reticulum (ER) ....................................................................................................... 23 1.2.2
 Transitional ER (tER) or ER exit sites (ERES) ............................................................................... 24 1.2.3
 The ER-Golgi intermediate compartment (ERGIC) ..................................................................... 25 1.2.4
 Golgi .......................................................................................................................................... 25 1.2.5
 Transport to the Golgi ............................................................................................................... 25 1.2.5.1
 Transport through Golgi ............................................................................................................ 26 1.2.5.2
 Transport from the Golgi ........................................................................................................... 26 1.2.5.3
 Coated vesicles proteins ............................................................................................................ 26 1.2.6
 COPII vesicles ............................................................................................................................. 26 1.2.6.1
 COPI vesicles .............................................................................................................................. 27 1.2.6.2
1.3 Lipids ............................................................................................................................................. 29 
 Lipid droplets (LDs) .................................................................................................................... 29 1.3.1
 Lipid droplets formation ............................................................................................................ 32 1.3.1.1
 Lipid droplet growth .................................................................................................................. 33 1.3.1.2
 Lipid droplet proteins ................................................................................................................ 33 1.3.1.3
 Lipid droplet catabolism ............................................................................................................ 36 1.3.1.4
 Lipid droplets interact with other organelles ............................................................................ 37 1.3.1.5
1.3.1.5.1 The Endoplasmic Reticulum (ER) ........................................................................................... 37 
1.3.1.5.2 Endosomes ............................................................................................................................ 37 
1.3.1.5.3 Mitochondria and peroxisomes ............................................................................................. 38 
1.3.1.5.4 COPI and COPII ...................................................................................................................... 38 
 Lipid droplets and disease ......................................................................................................... 38 1.3.1.6
T A B L E  O F  C O N T E N T S   P a g e  |  V  
   
 
 Diacylglycerol acyltransferase (DGAT) enzymes ........................................................................ 39 1.3.2
1.4 Role of cellular lipid in viral infections ........................................................................................... 40 
 Entry .......................................................................................................................................... 40 1.4.1
 Replication ................................................................................................................................. 41 1.4.2
 Assembly ................................................................................................................................... 42 1.4.3
1.5 Remodelling of secretory pathway in viral infection ..................................................................... 43 
1.6 Antiviral Drugs ............................................................................................................................... 45 
 Antiviral drugs targeting lipids ................................................................................................... 46 1.6.1
Aims .......................................................................................................................................................... 49 
 CHAPTER TWO ................................................................................................................................... 50 2
MATERIALS AND METHODS ...................................................................................................................... 50 
2.1 Materials ....................................................................................................................................... 51 
 Chemicals and Reagents ............................................................................................................ 51 2.1.1
 Cell culture ................................................................................................................................ 51 2.1.1.1
 Virology ..................................................................................................................................... 51 2.1.1.2
 Imaging ...................................................................................................................................... 52 2.1.1.3
 Molecular biology ...................................................................................................................... 53 2.1.1.4
 Solution and buffers .................................................................................................................. 55 2.1.2
 Phosphate buffered saline buffer .............................................................................................. 55 2.1.2.1
 HEPES buffer .............................................................................................................................. 55 2.1.2.2
 Carboxy methyl cellulose (CMC) ................................................................................................ 55 2.1.2.3
 Crystal violet solution ................................................................................................................ 59 2.1.2.4
 Blocking solution ....................................................................................................................... 59 2.1.2.5
 Fixing solution ........................................................................................................................... 59 2.1.2.6
 Permeabilization solution .......................................................................................................... 59 2.1.2.7
 Antibody diluent solution .......................................................................................................... 59 2.1.2.8
 Glycine washing solution ........................................................................................................... 59 2.1.2.9
 DNA electrophoresis buffer (ELFO) ........................................................................................ 59 2.1.2.10
 Clear loading dye for agarose gels ......................................................................................... 59 2.1.2.11
 Mowiol mounting medium .................................................................................................... 60 2.1.2.12
 Isopropyl β-D-thiogalactopyranoside (IPTG) solution ............................................................ 60 2.1.2.13
 5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal) solution .................................... 60 2.1.2.14
 Luria-Bertani Broth (LB Broth) ............................................................................................... 60 2.1.2.15
 Luria-Bertani Agar .................................................................................................................. 60 2.1.2.16
T A B L E  O F  C O N T E N T S   P a g e  |  V I  
   
 
 Cell lines and viruses ................................................................................................................. 60 2.1.3
2.2 Methods ........................................................................................................................................ 62 
 Cell Culture ................................................................................................................................ 62 2.2.1
 Passaging/Splitting Cells ............................................................................................................ 62 2.2.1.1
 Cell line storage ......................................................................................................................... 62 2.2.1.2
 Molecular biology ...................................................................................................................... 63 2.2.2
 Double digestion ....................................................................................................................... 63 2.2.2.1
 Agarose gels .............................................................................................................................. 63 2.2.2.2
 Gel extraction ............................................................................................................................ 63 2.2.2.3
 Ligation of DNA fragments using T4 DNA ligase ........................................................................ 64 2.2.2.4
 Competent cells ......................................................................................................................... 64 2.2.2.5
 Transformation .......................................................................................................................... 64 2.2.2.6
 Purification of DNA using QIAprep miniprep kit ........................................................................ 65 2.2.2.7
 Purification of DNA using a Qiagen HiSpeed plasmid midi kit ................................................... 65 2.2.2.8
 Polymerase chain reaction (PCR) ............................................................................................... 66 2.2.2.9
 Ligation using the pGEM-T Easy vector.................................................................................. 67 2.2.2.10
 Transformation using the pGEM-T Easy vector ..................................................................... 67 2.2.2.11
 Colony PCR ............................................................................................................................ 70 2.2.2.12
 Purification of viral RNA using a QIAamp Viral RNA Mini Kit ................................................. 70 2.2.2.13
 Reverse transcription-PCR (RT-PCR) ...................................................................................... 72 2.2.2.14
 Virus propagation and plaque assays ........................................................................................ 72 2.2.3
 Propagation of Viruses .............................................................................................................. 72 2.2.3.1
 Plaque assay .............................................................................................................................. 72 2.2.3.2
 Drugs and generation of mutants resistant to drugs ................................................................. 73 2.2.4
 Drugs and inhibitors screening study ........................................................................................ 73 2.2.4.1
 Generation of mutants resistant to drugs and inhibitors .......................................................... 73 2.2.4.2
 Time-of-addition assay .............................................................................................................. 73 2.2.4.3
 Immunofluorescence ................................................................................................................. 74 2.2.5
 Detection of infected cells and lipid staining ............................................................................. 74 2.2.5.1
 Detection of infected cells and fatty acids staining ................................................................... 74 2.2.5.2
 Transfection of fluorescent constructs ...................................................................................... 75 2.2.5.3
2.2.5.3.1 Xfect protein transfection reagent ........................................................................................ 75 
2.2.5.3.2 Lipofectin® transfection reagent ........................................................................................... 75 
2.2.5.3.3 TurboFect transfection reagent ............................................................................................. 76 
T A B L E  O F  C O N T E N T S   P a g e  |  V I I  
   
 
 Confocal microscope ................................................................................................................. 76 2.2.5.4
 Computer analysis ..................................................................................................................... 78 2.2.6
 CHAPTER THREE ................................................................................................................................ 79 3
EFFECT OF HPeV INFECTION AND HPeV PROTEINS ON THE SECRETORY SYSTEM ..................................... 79 
3.1 Introduction .................................................................................................................................. 80 
3.2 The effect of HPeV1 infection on the secretory pathway .............................................................. 83 
3.3 Distribution of HPeV1 non-structural proteins .............................................................................. 88 
3.4 Non-structural proteins of HPeV1 and the secretory pathway ..................................................... 98 
 The ER marker (PDI) .................................................................................................................. 98 3.4.1
 The ERGIC .................................................................................................................................. 98 3.4.2
 The Golgi ................................................................................................................................... 99 3.4.3
 Lysosomes ................................................................................................................................. 99 3.4.4
 Mitochondria ........................................................................................................................... 100 3.4.5
 Peroxisomes ............................................................................................................................ 100 3.4.6
3.5 Discussion .................................................................................................................................... 113 
 CHAPTER FOUR................................................................................................................................ 117 4
THE INTERACTION BETWEEN HPeV 2C AND LIPID DROPLETS ................................................................. 117 
4.1 Introduction ................................................................................................................................ 118 
4.2 Fatty acid study ........................................................................................................................... 119 
 Virus and fatty acids ................................................................................................................ 119 4.2.1
 Non-structural proteins of HPeV1 and fatty acid..................................................................... 120 4.2.2
4.3 Lipid droplets study ..................................................................................................................... 125 
 Lipid Droplets and viruses ....................................................................................................... 125 4.3.1
 Non-structural proteins of HPeV1 ........................................................................................... 130 4.3.2
4.4 2C protein and LD ........................................................................................................................ 135 
 2C of other picornaviruses....................................................................................................... 135 4.4.1
 ATPase activity site of 2C and LD ............................................................................................. 138 4.4.2
 2C fragment and LDs ............................................................................................................... 138 4.4.3
 Location of the LD-interacting region of 2C ............................................................................. 152 4.4.4
 Cav1 and 2C of HPeV1 ............................................................................................................. 161 4.4.5
 ADRP and 2C of HPeV1 ............................................................................................................ 161 4.4.6
4.5 Discussion .................................................................................................................................... 166 
 CHAPTER FIVE .................................................................................................................................. 170 5
ANTIVIRAL DRUGS STUDY ....................................................................................................................... 170 
T A B L E  O F  C O N T E N T S   P a g e  |  V I I I  
   
 
5.1 Introduction ................................................................................................................................ 171 
 Itraconazole ............................................................................................................................. 172 5.1.1
 Brefeldin A ............................................................................................................................... 172 5.1.2
 Diacylglycerol acyltransferase inhibitor ................................................................................... 173 5.1.3
 Betulinic acid ........................................................................................................................... 173 5.1.4
5.2 Immunofluorescence study ......................................................................................................... 175 
5.3 Plaque assay ................................................................................................................................ 179 
5.4 Screening study of drugs ............................................................................................................. 179 
5.5 Time-of-addition study ................................................................................................................ 188 
5.6 Attempts to generate drug resistant mutants ............................................................................. 188 
5.7 Discussion .................................................................................................................................... 191 
 CHAPTER SIX .................................................................................................................................... 196 6
GENERAL DISCUSSION ...................................................................................................................... 196 
Future Work ............................................................................................................................................ 201 
 REFERENCES .................................................................................................................................... 204 7
 
L I S T  O F  T A B L E S   P a g e  |  I X  
   
 
LIST OF TABLES 
Table 1.1: Summary of potential antivirus drugs which target cellular lipids………………... 48 
Table 2.1: List of antibodies and labels that were used and their types and supplier…………. 54 
Table 2.2: List of restriction enzymes that were used and their target sequence and supplier.. 56 
Table 2.3: List of oligonucleotides used in this project………..………………………………… 57 
Table 2.4: List of EGFP/ m-Cherry fusion constructs used……………………………………..  58 
Table 5.1: List of all concentration of drugs that used in this study……………………………. 180 
T A B L E  O F  F I G U R E S   P a g e  |  X  
   
 
TABLE OF FIGURES  
Chapter 1 
FIGURE 1.1: Structural of picornaviruses………...………………………..……….…………… 7 
FIGURE 1.2: 3D structure for some picornaviruses………………………………..……………. 8 
FIGURE 1.3:  Summary of the life cycle of a typical picornavirus…………………………….. 15 
FIGURE 1.4: Schematic of a picornavirus genome……………………………………………… 16 
FIGURE 1.5: Schematic diagram of the 2C protein of  EV71…………………………………... 21 
FIGURE 1.6: Schematic of the secretory pathway………………………………………………. 28 
FIGURE1.7: The structure of a lipid droplet……………………………………………………. 30 
FIGURE 1.8: Lipid metabolism and LD formation in mammal and yeast…………………….. 31 
FIGURE 1.9: Some of LD formation models…………………………………………………….. 34 
Chapter 2 
FIGURE 2.1: Schematic diagram of the PCR reaction………………………………………….. 68 
FIGURE 2.2: Schematic diagram of overlap PCR………………………………………………. 69 
FIGURE 2.3: Schematic diagram of the Colony PCR reaction…………………………………. 71 
Chapter 3 
FIGURE 3.1: The effect of HPeV1 infection on the Golgi marker GM130. …………………... 85 
FIGURE 3.2: The effect of CAV9 infection on the Golgi marker GM130……………………...  85 
FIGURE 3.3: The effect of HPeV1 infection on the ER marker PDI ……………………….….  86 
FIGURE 3.4: The effect of HPeV1 infection on the ERGIC marker ERGIC-53 ……………...  87 
FIGURE 3.5: Schematic of the HPeV1 genome representing the location of the proteins 2A, 
2BC, 2B, 2C, 3A and 3C in the polyprotein…………...…………………………. 90 
FIGURE 3.6: The distribution of EGFP expressed from the pEGFP-C1 vector ……..…….….  91 
FIGURE 3.7: The distribution of mCherry expressed from the pmCherry-C1 vector………...  91 
FIGURE 3.8: The distribution of HPeV1 2A protein……………………………………………. 92 
FIGURE 3.9: The distribution of HPeV1 2B protein……………………………………………. 93 
FIGURE 3.10: The distribution of HPeV1 3A protein…………………………………………...  94 
FIGURE 3.11: The distribution of HPeV1 3C protein……………………………………………  95 
FIGURE 3.12: The distribution of HPeV1 2C protein…………………………………………...  96 
FIGURE 3.13: The distribution of HPeV1 2BC protein………………………………………… 97 
FIGURE 3.14: The effect of HPeV1 proteins (fused to mCherry) on the ER marker PDI …… 101 
FIGURE 3.15: The effect of HPeV1 proteins (fused to EGFP) on the ER marker PDI.............  102 
T A B L E  O F  F I G U R E S   P a g e  |  X I  
   
 
FIGURE 3.16: The effect of HPeV1 proteins (fused to mCherry) on the ERGIC …………..… 103 
FIGURE 3.17: The effect of HPeV1 2BC fused to EGFP on the ERGIC ………………………  104 
FIGURE 3.18: The effect of HPeV1 proteins (fused to mCherry) on the Golgi ………………   105 
FIGURE 3.19 The normal distribution of lysosomes…………………………………………….. 106 
FIGURE 3.20: The effect of HPeV1 proteins (fused to mCherry) on lysosomes ………….……  107 
FIGURE 3.21: The normal distribution of mitochondria………………………………………... 108 
FIGURE 3.22: The effect of HPeV1 proteins (fused to mCherry) on mitochondria ………….  109 
FIGURE 3.23 The normal distribution of peroxisomes…………………………………………..  110 
FIGURE 3.24: The effect of HPeV1 proteins (fused to mCherry) on peroxisomes …………....  111 
FIGURE 3.25: The effect of HPeV1 infection on the peroxisomes………………………………  112 
FIGURE 3.26: The effect of CAV-9 infection on the peroxisomes………………………………. 112 
Chapter 4 
FIGURE 4.1: The normal distribution of fatty acids (FAs) in GMK cells…………………….  121 
FIGURE 4.2: The effect of CAV9 on fatty acids (FAs) ……………………………………….... 122 
FIGURE 4.3: The effect of HPeV1 on fatty acids (FAs)………………………………………... 123 
FIGURE 4.4: The localisation of fatty acids (FAs) in cells transfected with constructs 
encoding HPeV1 proteins fused to mCherry ……...……………………………. 124 
FIGURE 4.5: The effect of CAV9 on lipid droplets (LDs) in early stages of infection ……… 126 
FIGURE 4.6: The effect of CAV9 on lipid droplets (LDs) in late stage of infection………….. 127 
FIGURE 4.7: The effect of HPeV1 on lipid droplets (LDs)  in early stage of infection……... 128 
FIGURE 4.8: The effect of HPeV1 on on lipid droplets (LDs) in late stage of infection……. 129 
FIGURE 4.9: Lipid droplets (LDs)  and pmCherry-C1 vector……………………………….. 131 
FIGURE 4.10: The effect of mCherry-2A and mCherry-3C on lipid droplets (LDs)………… 132 
FIGURE 4.11: The effect of mCherry-2B, mChery-2C and mCherry-3A on lipid droplets 
(LDs)………………………………………………………………………………. 133 
FIGURE 4.12: The effect of EGFP-2BC on lipid droplets (LDs)….…………………………....   134 
FIGURE 4.13: A neighbor-joining tree based on 2C nucleotide sequences of some members 
of the Picornaviridae family……………………………………...………………... 136 
FIGURE 4.14: Relationship of mCherry-2C of CAV9 and HRV1B with  lipid droplets (LDs) 137 
FIGURE 4.15: Multiple sequence alignment of the amino acid sequences of 2C in several 
membrans of the Picornaviridae family using protein BLAST …………...….. 140 
FIGURE 4.16: The effect of Walker A and Walker B mutations in HPeV1 2C on lipid 
droplets (LDs)……………………………………………………………………. 144 
FIGURE 4.17: The effect of combining Walker A and Walker B mutations in HPeV1 2C on 
lipid droplets (LDs)……………………………………… ………………….. 145 
FIGURE 4.18: Co-transfection of pmCherry-2CK and pmCherry-2CD mutants with 
pEGFP-2C………………………………………………..………………………...  146 
FIGURE 4.19: Schematic diagram showing the regions of the 2C protein encoded in three 
mutants…………………………………………………………………………….. 147 
T A B L E  O F  F I G U R E S   P a g e  |  X I I  
   
 
FIGURE 4.20: The distribution and effect of pmCherry-2C1, pmChery-C2 and pmCherry-
2C4 deletion mutants on lipid droplets (LDs)……..………… ………………… 148 
FIGURE 4.21: Co-transfection of pmCherry-2C1, pmCherry-2C2 and pmCherry-2C4 
mutants with pEGFP-2C…………..……………………….……………………... 149 
FIGURE 4.22: Co-transfection of pmCherry-2C1 and pmCherry-2C2 with pEGFP-2C and 
pmCherry-2C1 with pEGFP-2C2…………………………………………………   150 
FIGURE 4.23: The effect of pmCherry-2C12 mutant on lipid droplets (LDs) ………………. 151 
FIGURE 4.24. The predicted region of amphipathic helix in HCV, PV and HPeV1………….. 154 
FIGURE 4.25. The part of the HPeV1 2C protein located in a set of mCherry-2C deletion 
mutant……..……………………………………………………………………… 155 
FIGURE 4.26: The effect of pmCherry-2C7A and pmCherry-2C25A mutants on lipid 
droplets (LDs) distribution …………………………………………………… 156 
FIGURE 4.27: The effect of pmCherry-2C53A and pmCherry-2C75A mutants on lipid 
droplets (LDs) distribution ...................................................................................  157 
FIGURE 4.28: Co-transfection for pmCherry-2C53A and pmCherry-2C75A to pEGFP-2C...   158 
FIGURE 4.29: The effect of pmCherry-2C87A and pmCherry-2C129A mutants on 
lipid droplets (LDs) distribution ………………………………………..…….  159 
FIGURE 4.30: A. A predicted amphipathic helix overlapping the region found to be 
important in HPeV 2C LD localisation.……………………………………….…..…... 160 
FIGURE 4.31: The effect of pmCherry-2C87A and pmCherry-2C129A mutants on lipid 
droplets (LDs) distribution ………………….…………………………….……… 162 
FIGURE 4.32: Co-transfection of pmCherry-Cav1 and pEGFP-2C ………………………..…. 163 
FIGURE 4.33: pmCherry-ADRP and lipid droplets (LDs)…………………..…………………. 164 
FIGURE 4.34: Co-transfection of pmCherry-ADRP and pEGFP-2C/pEGFP-2BC …….…….. 165 
Chapter 5 
FIGURE 5.1: Chemical structure of drugs and inhibitor used in this study…………………… 174 
FIGURE 5.2: The effect of drugs and inhibitor on HPeV1 and CAV9 using imunoflourocent 
microscope…..…………………………………………………………………….. 176 
FIGURE 5.3: The bar chart of microscopy study of HPeV1 treated with drugs………………. 177 
FIGURE 5.4: The bar chart of microscopy study of CAV9 treated with drugs………………... 178 
FIGURE 5.5: Plaque assays of CAV9 (GMK cells) and HPeV1 (HT29 cells)….………………..  181 
FIGURE 5.6: An example of a plaque assay for HPeV1 treated with DGAT inhibitor 
A922500…………………………………………………………………………….  182 
FIGURE 5.7: An example of a plaque assay for CAV9 treated with DGAT inhibitor 
A922500……………………………………………………………………………..  183 
FIGURE 5.8: Bar chart of plaque assays done to measure the amount of virus produced at 
different drug concentrations, when the DGAT inhibitor A922500 was used… 184 
FIGURE 5.9: Bar chart of plaque assays done to measure the amount of virus produced at 
different drug concentrations, when the Betulinic acid was used.……..…….… 185 
FIGURE 5.10: Bar chart of plaque assays done to measure the amount of virus produced at 
different drug concentrations, when Itraconazole was used.…………………… 186 
FIGURE 5.11: Bar chart of plaque assays done to measure the amount of virus produced at 
different drug concentrations, when Brefeldin A was used………………….….  187 
FIGURE 5.12: Graph of HPeV titre obtained after drug was added at different times before 
(zero time) or after infection………………………………………………….…...  189 
FIGURE 5.13: Graph of CAV9 titre obtained after drug was added at different times before 
(zero time) or after infection…………………………………………………….... 190 
L I S T  O F  A B B R E V I A T I O N S   P a g e  |  X I I I  
   
 


















 RNA polymerase 
ACBD3 Acyl-coenzyme A Binding Domain Containing 3 
Acyl- CoA Acyl-coenzyme A 
ADRP Adipose differentiation-related protein 
AGPAT2 Acylglycerol-Phosphate Acyltransferase 
AiV Aichi virus 
Arf6  ADP-ribosylation factor 6 
ATGL  A dipose tissue triacylglycerol lipase 
ATPase Adenosine triphosphatase 
BetA Betulinic acid 
BFA Brefeldin A 
BMV Brome Mosaic virus 
CAR Coxsackie-adenovirus receptor 
CAV1 Caveolin 1  
CAV9 Coxsackievirus A9 
CGN Cis-Golgi network  
CMC Carboxyl methylcellulose 
CNS Central nervous system  
COPD Obstructive Pulmonary Disease 
COPI Coated vesicles proteins I 
COPII Coated vesicles proteins II 
CVB3 Coxsackievirus B3 
DAF or CD55 Decay accelerating factor 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride 
DCV Drosophila C virus 
DGAT  Diacylglycerol acyltransferase 
DGAT 
inhibitor  
Diacylglycerol acyltransferase  inhibitor (A922500) 
DLP Double-layer particle 
DMEM Dulbecco’s Modified Eagle’s Medium 
dsRNA  Double-stranded RNA 
E.coli Escherichia coli 
EGFP Enhanced green fluorescent protein 
L I S T  O F  A B B R E V I A T I O N S   P a g e  |  X I V  
   
 
eIF4E Eukaryotic translation-initiation factor 4E 
eIF-4F Eukaryotic initiation factor 4F 
EMCV Encephalomyocarditis virus 
ER Endoplasmic reticulum  
ERES ER exit sites site 
ERGIC  ER-Golgi intermediate compartment 
EV Enterovirus   
FASN  Fatty Acid Synthase 
FBS Fetal Bovine Serum  
FITM/FIT Fat storage–Inducing Transmembrane Protein 
FMDV Foot-and-mouth disease virus  
GEFs Guanine nucleotide exchange factors 
GMK Green Monkey Kidney cell line 
GTP Guanosine-5'-triphosphate 
GAP GTPase activating proteins 
HAV Hepatitis A virus 
HCMV Human cytomegalovirus  
HCV Hepatitis C virus 
HDL High-Density Lipoprotein 
HFMD Hand, foot and mouth disease  
HIV Human ImmunoDeficiency virus 
HPeV Human Parechoviruses 
HRV Human Rhinovirus  
HSPA5 Heat shock 70-kDa protein 5 
HT29 Human colon adenocarcinoma cells 
ICAM-1 Intercellular adhesion molecule-1 
IFN Type I interferon responses   
IPV Inactivated Poliovirus vaccines 
IRES Internal ribosome entry site  
ITAFS IRES transacting factors  
ITZ Itraconazole 
kD kilo Daltons 
LAMP-1 lysosomal-associated membrane protein 1  
LC3-II LC3-phosphatidylethanolamine conjugate  
LDL-R Low Density Lipoprotein Receptor 
LDs  Lipid droplets 
MHC-I Major histocompatibility complex class I 
NIH The National Institutes of Health  
NPGP Asn–Pro–Gly–Pro amino acids 
OPV Oral Poliovirus vaccine 
ORF open-reading frame  
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OSBP1  Oxysterol-binding protein 1 
PABP Poly (A) binding protein 
PC Phosphatidylcholine 
PCBP2  Poly (rC)-binding protein 
PCR Polymerase Chain Reaction 
PE Phosphatidylethanolamine  
PI4K Phosphatidylinositol 4-kinase 
PI4P Phosphatidylinositol-4-phosphate 
PM Plasma membrane 
PPARG Peroxisome Proliferator Activated Receptor 
PV Poliovirus  
PVR or CD155 poliovirus receptor 
Rab Membrane-trafficking proteins   
RGD Arginine-glycine-aspartic acid motif 
RNA Ribonucleic Acid 
SARS  Severe acute respiratory syndrome 
SNARE Soluble N-Ethylmaleimide-Sensitive Factor Activating Protein Receptor 
TG Triglycerides 
TGN Trans-Golgi network  
TIP47 Tail-interacting Protein of 47 kilo Daltons  
UTR  Untranslated regions 
VCAM-1 Vascular cell adhesion molecule-1 
VP Virus-encoded proteins 
VPg Genome-linked protein  
VSV Vesicular Stomatitis virus 
WHO The World Health Organisation 
WNV West Nile virus 
YFV Yellow Fever Virus 
αSNAP  Soluble NSF Attachment Protein 
C H A P T E R  O N E   P a g e  |  1  
   
 
 CHAPTER ONE 1
INTRODUCTION
C H A P T E R  O N E   P a g e  | 1 
 




Picornaviruses, where Pico refers to ‘small size’ and  rna refers to ‘ribonucleic acid’ (RNA), 
are assigned to class IV in the Baltimore classification (Acheson, 2007; Carter and Saunders, 
2007). These small, non-enveloped, single-stranded, positive-sense viruses belong to the family 
Picornaviridae (Knowles et al., 2012). At present, this family groups into 31 genera consisting 
of 54 species. The genera are: Aphthovirus, Aquamavirus, Avihepatovirus, Avisivirus, 
Cardiovirus, Cosavirus, Dicipivirus, Enterovirus, Erbovirus, Gallivirus, Hepatovirus, 
Hunnivirus, Kobuvirus, Kunsagivirus, Limnipivirus, Megrivirus, Mischivirus, Mosavirus, 
Oscivirus, Parechovirus, Pasivirus, Passerivirus, Potamipivirus, Rosavirus, Sakobuvirus, 
Salivirus, Sapelovirus, Senecavirus, Sicinivirus, Teschovirus and Tremovirus (Adams et al., 
2015; Adams et al., 2013; Adams et al., 2014; Adams et al., 2016; Knowles et al., 2012). Some 
of these genera contain several species, for instance Enterovirus has 12. Some species have a 
single virus serotype while other contain many, for instance the Enterovirus species Rhinovirus 
A are contains 80 serotypes (Knowles, 2016). This classification was originally based on 
morphology, physicochemical and biological properties, antigenic structures, genomic sequence 
and mode of replication although genome sequence is now the only factor considered.  Even 
serotype is usually predicted on the basis of virus sequences (Hyypia et al., 1997).  
The genome of members of the Picornaviridae family consists of RNA containing a single open 
reading frame that encodes for a large polyprotein. The polyprotein is processed by virus-
encoded proteases to generate individual structural and non-structural proteins, as well as some 
relatively stable cleavage intermediates (Wessels et al., 2006). 
Picornaviruses include many economically and socially important pathogens of humans and 
animals, such as poliovirus, enterovirus 71, rhinoviruses, hepatitis A virus, foot-and-mouth 
disease virus and parechoviruses (van der Linden et al., 2015; Whitton et al., 2005).  
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 Medical importance 1.1.2
The Picornaviridae family contains a wide variety of human and animal pathogens with varying 
clinical features including respiratory symptoms, gastroenteritis, myocarditis, rashes and 
infections of the central nervous system such as meningitis, encephalitis and paralysis (Merilahti 
et al., 2012). 
 Human picornavirus 1.1.2.1
1.1.2.1.1 Poliovirus (PV) 
The most significant picornavirus is poliovirus (PV). PV belongs to the Enterovirus genus and 
causes poliomyelitis. Poliomyelitis is actually a relatively rare complication of poliovirus 
infection as only around 1% of infections lead to this condition. Even so, epidemics of 
poliomyalitis have killed or paralysed many hundreds of thousands of people over the past 200 
years before vaccinations became available in the mid-1950s (Jurgeit et al., 2010; Whitton et al., 
2005). PV spreads by the faecal–oral route, passes through the stomach and replicates in the 
intestine. In the case of poliomyelitis, the virus enters the blood stream then infects the anterior 
spinal cord. The development of both live attenuated oral poliovirus vaccine (OPV) and 
inactivated poliovirus vaccine (IPV) against the 3 poliovirus serotypes reduced the number of 
infected patients dramatically. The World Health Organisation (WHO) has been attempting to 
complete the eradication of poliovirus for a number of years. Currently, wild poliovirus (only 
serotype 1) is circulating only in Pakistan and Afghanistan but there are also cases of circulating 
virus which has been derived from the vaccine strains (Dunn et al., 2015; Initiative, 2015). 
1.1.2.1.2 Coxsackievirus and Echovirus 
A second group of viruses of the Enterovirus genus is coxsackievirus (A and B). The first 
isolation of group A was in Coxsackie, New York, from a young boy suffering from acute 
flaccid paralysis. Group B was isolated from a patient with aseptic meningitis (Whitton et al., 
2005). Many coxsackivirus B infections are mild, but these viruses can also cause serious, even  
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fatal diseases affecting the heart, central nervous system (CNS) and pancreas, leading to 
myocarditis meningitis, encephalitis in new-borns and pancreatitis (Hyypia and Stanway, 1993; 
Stanway et al., 2000; Whitton et al., 2005). Coxsackie A viruses cause respiratory infections, 
conjunctivitis, rashes, meningoencephalitis, while coxsackievirus A16 causes hand, foot and 
mouth disease (HFMD) (Hyypia and Stanway, 1993; Stanway et al., 2000). 
Echoviruses are another group of viruses in the Enterovirus genus and are one of the most 
frequent causes of aseptic meningitis. They can also be involved in meningoencephalitis, 
paralysis, neonatal sepsis and gastrointestinal infections. Echovirus 9,11 and 30 are the most 
commonly isolated enteroviruses in specimens from all patients (Khetsuriani et al., 2006). 
1.1.2.1.3 Enterovirus 71 (EV71) 
EV71 is another cause of HFMD in young children and infants. EV71 HFMD is usually a mild 
disease with a localized rash and fever. However, in more severe cases these can be neurological 
complications, including aseptic meningitis, acute flaccid paralysis, fatal encephalitis, and 
pulmonary edema (Lei et al., 2011; Shang et al., 2013). The virus was isolated for the first time 
in 1974 and there have been several large outbreaks since then, particularly in Asia. Epidemic 
outbreaks of HFMD occur frequently in Singapore, Taiwan, Malaysia and China (Gopalkrishna 
et al., 2012; Kiener et al., 2012). More than 1,600,000 cases of EV71 infection, with more than 
500 deaths, were reported in China in 2011 (Shang et al., 2013).  
1.1.2.1.4 Human Rhinovirus (HRV) 
HRV is the most frequent cause of the common cold. This disease is usually mild but has an 
important economic impact. But it is also associated with acute and chronic bronchitis and other 
respiratory tract illnesses, as well as making asthma symptoms more severe. The National 
Institutes of Health in the USA, estimate that more than a billion cases of the common cold occur 
annually, resulting from HRV infections, costing approximately $40 billion in health care every 
year (Jurgeit et al., 2010; Whitton et al., 2005). HRV infections also make symptoms worse in 
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patients with chronic obstructive pulmonary disease (COPD) (Jurgeit et al., 2010; Wanga and 
Chen, 2007; Whitton et al., 2005). WHO predicts that COPD will become the third leading cause 
of death worldwide by the year 2030 (van der Schaar et al., 2013).    
1.1.2.1.5 Hepatovirus 
Hepatitis A virus (HAV) is member of the Hepatovirus genus. It is responsible for a relatively 
mild form of human hepatitis where an acute illness gives symptoms including jaundice or 
elevated serum transaminase levels (De Palma et al., 2008). HAV does not lead to liver cirrhosis 
and hepatocellular carcinoma as it gives an acute, not a persistent infections unlike hepatitis B 
and hepatitis C (Martin and Lemon, 2006). This virus is responsible for more than 7,000 cases of 
hepatitis in the USA annually (De Palma et al., 2008).  
1.1.2.1.6 Parechoviruses  
Human Parechoviruses (HPeV) are members of the species Parechovirus A, until recently called 
Human parechovirus. 16 types, HPeV1–HPeV16 are known (Knowles, 2016). Human 
parechovirus infections are common during early childhood. In the USA between 1983 and 
2003, a large investigation revealed that 73% of HPeV1 infection and 68% of HPeV2 infections 
occurred in children less than one year (Chang et al., 2015).  Parechoviruses usually cause mild 
respiratory or gastrointestinal illness but have been reported to sometimes cause severe 
conditions, such as flaccid paralysis and encephalitis. These serious infections are less frequent 
than those caused by enteroviruses (Harvala et al., 2014; Merilahti et al., 2012; Seitsonen et al., 
2010; Wang et al., 2012a). Parechovirus infections seem to occur relatively frequently, as at least 
95% of the adult population in the Netherlands, the USA, Canada and Germany have been 
infected at some point (Harvala et al., 2008).  In many studies, the predominant symptom caused 
by HPeV1, the most commonly isolated HPeV, is diarrhoea, although two outbreaks of 
necrotising enterocolitis were reported in 1997. In addition, HPeV1 has been linked with 
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myocarditis and other diseases, including haemolytic uraemic syndrome and an outbreak of acute 
flaccid paralysis in Jamaica (Stanway et al., 2000). 
Less is known about the impact of the other HPeV types, but except for HPeV3 the symptoms 
caused are similar to those caused by HPeV1. HPeV6 has been suggested as a causative agent of 
diarrhoea in children (Harvala et al., 2008). HPeV3 seem to have a different pattern of disease 
compared to other HPeVs, as it leads sometimes to serious disease in much younger children 
than most HPeVs. HPeV3 has been isolated from a one year old patient with transient paralysis 
in Japan and was also found in three patients with neonatal sepsis in Canada (Boivin et al., 
2005). Neonatal sepsis caused by HPeV3 been reported in several more recent studies (Benschop 
et al., 2006; Harvala et al., 2014; Khatami et al., 2014; Kolehmainen et al., 2014). HPeV4 may 
also be involved in neonatal sepsis (Kolehmainen et al., 2014).  
Although HPeV is a widespread pathogen and can cause severe diseases, it is not routinely 
detected in most laboratories because it often grows poorly in culture and typing reagents are not 
widely available (Chang et al., 2015).  
1.1.2.1.7 Other human viruses 
Aichi virus (AiV) represents the Kobuvirus genus (Aichivirus A species), and the single serotype, 
AiV-1, is associated with acute gastroenteritis in humans (De Palma et al., 2008). AiV-1 is 
distributed worldwide and has been detected in human faecal samples in Asia, Europe, South 
America and Africa. The symptoms of AiV-1 infection vary from  diarrhoea, abdominal pain, 
nausea, vomiting and fever, and it is usually present, together with enteroviruses, in faecal 
samples of gastroenteritis patients (Kitajima and Gerba, 2015). 
 
C H A P T E R  O N E   P a g e  | 6 
 
   
 
 Non-human picornavirus 1.1.2.2
1.1.2.2.1 Foot-and-mouth-disease virus (FMDV) 
Foot-and-mouth-disease virus (FMDV) is a member of the Foot-and–mouth-disease virus 
species of the Aphthovirus genus. This virus causes lesions in cloven-hoof animals such as cattle, 
swine, goat, sheep and buffalo (Grubman and Baxt, 2004; Jamal and Belsham, 2013). The 
disease is not usually fatal but reduces productivity and so is economically very important. 
FMDV caused widespread problems throughout Europe until an inactivated vaccine became 
commercially available. However, FMDV remains endemic in other parts of the world such as 
Africa and Asia. A major outbreak of the virus in the UK (2001) led to the slaughter of 6.5 
million animals and cost the UK economy around £3 billion (De Palma et al., 2008; Whitton et 
al., 2005).  
1.1.2.2.2 Other non-human picornaviruses 
Teschoviruses can affect cattle, usually leading to asymptomatic infections. They can also cause 
a neurological disorder in pigs, known as Teschen-Talfan disease (De Palma et al., 2008; 
Whitton et al., 2005). Several outbreaks of ‘teschovirus encephalomyelitis’ were reported in 
Ukraine in 1996–2005, Russia in 2004, Madagascar in 2004–2005, Belarus in 2005 and Haiti in 
2008–2009 (Boros et al., 2012).  
 Picornavirus Molecular Biology 1.1.3
 Particle and Genome 1.1.3.1
Picornaviruses are small, icosahedral, non-enveloped, positive-sense, single stranded RNA 
viruses of around 28-30 nm in diameter (Jurgeit et al., 2010). Their protein shell is composed of 
60 copies of three or four virus-encoded proteins (VP1-4 or VP0, VP1 and VP3) (Figure 1.1). 
While VP1-3 form the icosahedral shell, VP4 is on the inner surface and is probably partially in 
contact with the RNA genome (Merilahti et al., 2012) (Figure 1.2). The genomes of 
picornaviruses are around 7000–9700 nucleotides in length and encode one polyprotein which is
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FIGURE 1.1: Structural of picornaviruses. Structure of picornaviruses. (A) The 
viral capsid surface showing a pentamer (VP1, blue; VP2, red; VP3, gray; VP4, 
orange) of the EV-71 viral capsid. The yellow and green regions are epitopes 
recognised by antibodies (Taken from (Fan et al., 2015)). (B) A single EV-71 
protomer and how this relates to the rest of the capsid (VP1, blue; VP2, green; VP3, 
red; VP4, purple). The canyon is a surface depression involved in binding to cell 
receptors and the image also indicates the movement of VP4 seen after receptor 
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Foot-and-mouth disease virus Encephalomyocarditis virus  
  
Poliovirus 1 Coxsackievirus A9 
  
HAV Human parechovirus 1 
  
Ljungan virus HRV-1A 
FIGURE 1.2: 3D structure for some picornaviruses. Taken from (Filman et al., 1989; Fry et 
al., 1993; Hendry et al., 1999; Kalynych et al., 2016; Kim et al., 1989; Krishnaswamy and 
Rossmann, 1990; Wang et al., 2015). 
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cleaved by virus proteases to give a number of functionally important precursors and individual 
proteins. These include the capsid protein-encoding P1 region (encoding VP1-VP4) and non-
structural protein-encoding P2 and P3 regions (Kitamura et al., 1981; Knowles, 2016). The 
polyprotein-encoding open-reading frame (ORF) is preceded by a 5` untranslated regions which 
is covalently linked to a small viral protein (VPg) at the 5` end and followed by a 3` UTR and a 
poly A tail (Sasaki et al., 2012). The only know exception is the Dicipivirus genus where the 
genome has two open reading frames (Woo et al., 2012). Capsid monomers assemble into 
pentamers, which form the complete icosahedral shell of the virus from twelve pentamer 
subunits (Merilahti et al., 2012).  
After entry into the cellular cytoplasm, the virus RNA is translated and the polyprotein is 
cleaved. Following production of proteins required for RNA replication, the input viral RNA 
also acts as the template for the synthesis of negative-sense transcripts, which are then used to 
synthesize positive-sense genomes. Picornavirus RNA replication takes place in the cytoplasm, 
occurs on membrane-bound replication complexes and involves several different viral proteins in 
addition to the RNA polymerase (3D
pol
) (Belsham and Normann, 2008; Jurgeit et al., 2010). 
 Enteroviruses 1.1.3.2
The Enterovirus genus includes PVs, coxsackie A viruses, coxsackie B viruses, echoviruses and 
more-recently isolated viruses which are called by species and number e.g. EV-D68 to EV-A121 
(Hu et al., 2011; Knowles, 2016). Members of all 12 Enterovirus species are closely related and 
share marked similarities with respect to virus structure, genomic organization and replicative 
cycle. Differences in tropism are assumed to be based on the ability to bind to specific receptors 
for cell entry, due to differences in the structural capsid proteins encoded by the P1 region of the 
genome, and the occurrence of host-species specific cis-acting translational control elements in 
the genomic RNA (van Kuppeveld et al., 1997a). Some of the non-structural proteins are also 
involved in defining tropism e.g. the host that can be infected (Harris and Racaniello, 2005). 
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These viruses possess a deep depression (a ’canyon’) around the fivefold axis, which is involved 
in receptor interactions (Rossmann, 2002). 
Enterovirus genomes are between 7200-7500 nucleotides long and the polyprotein is processed 
to 11 final products. The 5`UTR is around 740 nucleotides long in EV-A to EV-J species and 
600 nucleotides in RV-A to RV-C. Processing of the P1 region gives VP1-VP4 and the 2A 
protein is a protease (Bonderoff et al., 2008; Hughes and Stanway, 2000; Shang et al., 2013). 
 Parechoviruses 1.1.3.3
Human parechoviruses (HPeVs) are members of the species Parechovirus A (originally Human 
parechovirus) of the genus Parechovirus. There are two other species Parechovirus B (including 
Ljungan virus) and Parechovirus C (including Sebokele virus). A virus which infects ferrets may 
form another species (Adams et al., 2015). HPeV1 and HPeV2 were isolated in 1956, were 
thought to be enteroviruses and were called echovirus 22 and 23 (Stanway and Hyypiä, 1999). 
However, several studies that investigated their molecular characteristics found that these viruses 
had unusual properties compared to other enteroviruses and the nucleotide sequence was found 
to be very different (Hyypiä et al., 1992). As a result, they were reclassified as members of a 
new genus Parechovirus in 1999 (Banerjee et al., 2004; Stanway and Hyypiä, 1999; Stanway et 
al., 1994).  
The Parechovirus genome is 7300-7600 nucleotides in length. The 5` UTR is 700 nucleotides 
long. The polyprotein is post-translationally cleaved to give 10 final proteins, structural proteins 
VP0, VP3 and VP1 derived from P1, and seven non-structural proteins 2A–2C and 3A– 3D 
(Benschop et al., 2010). The virus only has 3 structural proteins as VP0 is not cleaved to VP4 
and VP2 as seen in most picornaviruses (Stanway et al., 1994). 
The VP3 protein possesses a unique N-terminal extension of approximately 30 amino acids, 
which are predominantly positively charged (Al-Sunaidi et al., 2007; Boonyakiat et al., 2001; 
Stanway et al., 2000; Williams et al., 2009). In addition, the 2A protein is homologous to 
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cellular proteins that are involved in cell proliferation and contains Hbox and NC motifs (Hughes 
and Stanway, 2000). 
 The picornaviral life cycle 1.1.4
 Summary 1.1.4.1
A summary of the life cycle is shown in Figure 1.3. The virus attaches to receptors on the cell 
surface and enters the cell, often in vesicles. The RNA is released and the single open reading 
frame is translated to give a polyprotein. This is cleaved by virus proteases to give precursors 
then the final virus proteins. These include non-structural proteins which are needed to make 
more copies of the RNA genomes, via negative sense RNA copies. Structural proteins and the 
new RNA copies assemble to give new virus particles, there is often a final maturation step and 
then the particles leave the cell by lysis (Merilahti et al., 2012; Whitton et al., 2005).  
 Entry  1.1.4.2
The first stage of the life cycle of most viruses is attachment of the virion onto host cell surface 
receptor(s), followed by entry through the plasma membrane, usually in endocytic vesicles, into 
the cell cytosol and subsequent release of the genome. The details of these events probably play 
an important role in tissue tropism and pathogenesis. In enteroviruses, the virus often attaches to 
the host cell through binding of receptors to the virus canyon. Other virus/receptor interactions 
may then occur and open a channel to permit the externalization of VP4 and the amino end of 
VP1 (Rossmann et al., 2002; Tuthill et al., 2010). It was thought that this channel may allow 
RNA release, but it now seems likely that RNA leave the capsid at another point, near to the 2 
fold axis (Levy et al., 2010).  
Many cellular receptors for picornaviruses have been identified and these have a wide variation 
in their structures and normal physiological functions (Evans and Almond, 1998; Stanway, 
2013). Some of them are may be relatively non-specific and low-affinity, such as heparan 
sulphate, while others bind more tightly and bring about essential conformational changes to the 
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virion needed for the eventual release of the RNA. Picornavirus receptors include integrins, 
which are a family of transmembrane glycoproteins that form noncovalent heterodimers between 
α- and β- subunits and often bind to viruses via a specific arginine-glycine-aspartic acid (RGD) 
motif; members of the immunoglobulin superfamily such as coxsackie-adenovirus receptor 
(CAR), intercellular adhesion molecule-1 (ICAM-1 or CD54), the poliovirus receptor (PVR or 
CD155), vascular cell adhesion molecule-1 (VCAM-1); and the decay accelerating factor (DAF 
or CD55). β2-microglobµlin (a subunit of major histocompatibility complex class I [MHC-I] 
complex); and heat shock 70-kDa protein 5 (HSPA5, also known as glucoseregµlated protein 78-
kDa, or GRP78) have been suggested to be co-receptors or needed for later steps in entry (Joki-
Korpela et al., 2001; Merilahti et al., 2012; Rossmann et al., 2002).  
Both the enterovirus coxsackievirus A9 (CAV9) and most parechoviruses including HPeV1 
possess a receptor-binding motif, RGD, at the C-terminus of the VP1 protein through which they 
interact with cell surface integrin αVβ3 and/or αVβ6 (Heikkila et al., 2009; Joki-Korpela et al., 
2001; Merilahti et al., 2012; Seitsonen et al., 2010; Williams et al., 2004). FMDV also has a 
functional RGD motif but this is located within VP1, not at the C-terminus. Other mechanisms 
than RGD binding to integrin may occur however, upon infection with different HPeVs, such as 
HPeV3, HPeV7 and HPeV8, as the RGD motif is absent (Chang et al., 2015). CAV9 can also 
infect cells via a non-RGD mechanism as mutants with no RGD are infectious (Hughes et al., 
1995).  
Viruses can enter host cells through different internalization pathways including clathrin-
mediated endocytosis, uptake via caveolae, macropinocytosis, phagocytosis and Arf6 (ADP-
ribosylation factor 6) dependent mechanisms. For example, HRV-14 and HPeV1 both use the 
clathrin-dependent endocytotic pathway, whereas PV may release their genome through the 
plasma membrane directly after attachment to their specific receptor. Caveolae-mediated 
endocytosis has been demonstrated for echovirus 1 (Merilahti et al., 2012; Sieczkarski and 
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Whittaker, 2002). RNA release may be triggered by interaction with receptors and/or be a pH-
dependent process taking advantage of the low pH of endosomes (Mercer et al., 2010). 
 Translation 1.1.4.3
Following RNA release, the virus genome is translated. In eukaryotic cells, the 5` 7-methyl 
guanosine (m7G) cap structure at the ends of most cellular mRNAs is recognized by the 
eukaryotic translation-initiation factor 4E (eIF4E). elF4E is a component of the cap-binding 
complex eIF4F, which also includes the RNA helicases eIF4A and eIF4G. These bind several 
factors and bridge the mRNA and 40S subunit of the ribosome. The complex then moves in a 5` 
to 3` direction. Usually, when the 40S subunit complex reaches the nearest AUG codon to the 5` 
end translation begins. Initiation proteins are released, allowing the 60S ribosomal subunit to 
associate with the 40S and thus forming the 80S ribosome (Pestova et al., 1996; Poulin and 
Sonenberg, 2000). The m7G cap is absent from the 5` end of picornavirus RNAs, thus they 
cannot undergo cap-dependent translation. Translational initiation in these viruses instead 
depends on the internal ribosome entry site (IRES) (Pelletier and Sonenberg, 1988). This is a 
long (about 400 nucleotides) sequence made up of several RNA structure and translation 
initiation depends in several initiation factors as well as IRES transacting factors (ITAFS) which 
are proteins needed for internal initiation, but not for cap-dependent translation (Lin et al., 2009). 
Each member of the family Picornaviridae expresses its viral gene products through the IRES-
directed translation of a single ORF that encodes a ~250-kDa polyprotein (Whitton et al., 2005).  
 Polyprotein processing  1.1.4.4
After the large polyprotein has been translated from the single ORF, the polyprotein is processed 
by virus-encoded proteases into 10–12 final cleavage products (Figure 1.4). The protease 
cascade is initiated by one or more primary cleavage events carried out in cis. In enteroviruses 
this is carried out by 2A
pro
, cleaving at its N-terminus. Several picornaviruses have an NPGP 
motif at the 2A position and this leads to the polyprotein being made in two pieces, following 
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termination/reinitation. A series of trans cleavages gives mature polypeptides, as well as several 




 in all picornaviruses. 
Often the intermediate cleavage products have different functions from their final products 
(Ghazi et al., 1998; Sasaki et al., 2012; Whitton et al., 2005). 
 Replication  1.1.4.5
Picornaviral genome replication takes place in a viral replication complex and depends on the 
RNA-dependent RNA polymerase 3D
pol
, which is the most highly conserved polypeptide 
amongst members of the family Picornaviridae (Merilahti et al., 2012; Whitton et al., 2005) 
(Figure 1.3). The details of the mechanism of replication of picornavirus genomes is poorly 
understood. Several virus proteins are involved in the replication of viral RNA. The enzyme-
dependent RNA polymerase 3D
pol
 plays a central role in RNA replication and in vitro, this 
enzyme is involved in three reactions. First, 3D
pol
 synthesizes its primer by uridylylating the 
genome-linked protein VPg to VPg-pU(pU) and uses this nucleotide-modified protein to initiate 
chain elongation, a process that has been called ‘protein priming’. Second, 3Dpol transcribes the 
RNA templates, giving minus- and plus-strand RNA. Third, 3D
pol
 unwinds double-stranded 
RNA during chain elongation (Pfister et al., 2000). 2C has also been shown to have an RNA 
helicase and chaperone activity which may be involved in unwinding the virus RNA during 
replication (Xia et al., 2015). 
Some other proteins are involved in RNA replication. One is 3AB (the precursor of VPg), which 
stimulates RNA polymerase activity of 3D
pol
. Another is the main protease 3C (or its precursor 
protein 3CD). Cell proteins such as poly (rC)-binding protein (PCBP2) are also involved. 3CD 
and PCBP2 interact with a cloverleaf structure at the 5’ end of enterovirus RNA, giving a 
complex needed for viral RNA replication. The precursor proteins 3AB and 3CD also interact 
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FIGURE 1.3: Summary of the life cycle of a typical picornavirus. The virus attaches to a 
host cell receptor and this triggers entry, which usually occurs in a vesicle. The RNA is 
released and translated by host cell ribosomes. The polyprotein produced is processed by 
proteases. As the level of protein increases these is a switch from translation to replication of 
(-) strand RNA using the original (+) strand RNA template, followed by (+) strand RNA 
synthesis. The RNA is packaged to give a particle containing 60 copies of the capsid proteins 
VP0, VP3 and VP1. In most picornaviruses, VP0 is cleaved during a final maturation step to 
give VP4 and VP2. The mature viruses leave the cell as it is lysed. Taken from (van der 
Linden et al., 2015). 
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Figure 1.4: Schematic of a picornavirus genome. The diagram also shows the pathway to 
give the final proteins, via precursors, from the polyprotein. Non-structural proteins are 2A, 




, L. IRES, internal ribosome entry site; NTR, non-untranslated 
region; VPg, viral protein genome-linked. Taken from (Jiang et al., 2014). 
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with the 3`-UTR region of viral RNA (Banerjee et al., 2004; Pfister et al., 2000). In addition, 
cellular factors are thought to be required for membrane reorganization for picornavirus 
replication (Sasaki et al., 2012). 
 Assembly, Maturation and Release 1.1.4.6
The details of the assembly process are not clear but 5 protomers, made up of VP0, VP3 and 
VP1 are thought to assemble into pentamers and 12 pentamers can form empty particles which 
may then allow the RNA to be packaged (Li et al., 2012). In addition to the RNA and capsid 
proteins, 2C may have a role in packaging through interactions with VP3 and/or VP3 (Jiang et 
al., 2014). After assembly, VP0 is cleaved to give VP4 and VP2 in most picornaviruses and this 
is necessary for the particle to be infectious. The particles are released as the cell lyses, although 
the details of this process are not well understood (Jiang et al., 2014; van der Linden et al., 
2015). 
 Non-structural proteins 1.1.5
 Genome 1.1.5.1
A schematic of the genome is shown in Figure 1.4. Non-structural proteins are encoded 
downstream of the capsid protein-encoding region. 
 2A, 3C and L protein 1.1.5.2
The 2A protein sequence, length, and roles vary considerably among the Picornaviridae genera 
(Hughes and Stanway, 2000). In enteroviruses, the polyprotein is processed mainly by 3C
pro
. 
However, the primary cleavage event, separating the structural protein precursor from the non-




 cleaves the viral polyprotein between the C terminus 
of VP1 and its own N terminus. The 2A of most other picornaviruses does not carry out such a 
proteolytic function (Buenz and Howe, 2006). Although not proteolytic, several picornaviruses 
have a highly conserved Asn–Pro–Gly–Pro (NPGP) motif at the 2A–2B junction which has been 
linked to a “ribosomal skip” that prevents the formation of the Gly–Pro peptide bond and then 
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allows translation to continue, so the P1–2A region is made separately from the rest of the 
polyprotein (Donnelly et al., 2001; Funston et al., 2008; Hughes and Stanway, 2000; Stanway et 
al., 2000; Whitton et al., 2005). The 2A proteins of many picornaviruses, including 
parechoviruses, show homology to cellular proteins involved in the control of cell proliferation, 
and do not seem to have a protease activity (Hughes and Stanway, 2000; Stanway et al., 2000). 




cleaves eIF4G and eIF3, which are involved in cap-dependent translation 
initiation, and prevents the infected cell translating its own capped mRNA. As IRES-dependent 
translation is not cap-dependent virus translation is not inhibited. Another protein involved in 





 (Bonderoff et al., 2008; Deszcz et al., 2006; Yin et al., 2007). 3C
pro
 has also been 
shown to cleave and inactivate several transcription factors and this leads to inhibition of cellular 
transcription (Banerjee et al., 2004). 3C of enteroviruses also induces apoptosis by activating 
caspases and can block type I interferon (IFN) responses. 3C is related to the chymotrypsin 
family of proteases, but its active site is cysteine not the serine usually seen in this family of 
proteases. The enterovirus 2A
pro
 also has a chymotrypsin-like fold, but is more related to smaller 
serine proteases such as α-lytic proteinase (Seipelt et al., 1999).  
The third picornaviral protease is the Aphthovirus L protein, a cysteine protease related to papain 
(Seipelt et al., 1999). This releases itself from the P1 region of the polyprotein and also cleaves 
the eIF4G  subunit of eukaryotic initiation factor 4F (eIF-4F) leading to shutoff of cap-dependent 
host cell protein synthesis (Piccone et al., 1995). Most other L proteins in the subset of 
picornaviruses which have this protein are not proteolytically active and are released from the P1 
region of the polyprotein by 3C. One L protein which has been studied extensively is that in 
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cardioviruses and this seems to have an effect on host antivirus defences by preventing apoptosis 
and affecting interferon induction (Whitton et al., 2005).  
 2B 1.1.5.3
The 2B protein is a small, hydrophobic, membrane protein that is responsible for blocking 
cellular secretory transport, disrupting Golgi membranes and membrane permeabilisation (de 





organelles by forming pores (de Jong et al., 2008), although HAV 2B had little effect on ER and 
Golgi complex Ca
2+
 concentrations (de Jong et al., 2008). The accumulation of 2B or 2BC 
proteins in the Golgi causes cell lysis by changing the permeability of the plasma membrane 
causing disassembly of the Golgi complex (Lin et al., 2009; Sweeney et al., 2010). 
 2C and 2BC 1.1.5.4
The poliovirus 2C protein is a 37.5 kDa protein containing 329 amino acids. This protein is one 
of the most highly conserved picornavirus proteins and has several functions such as host cell 
membrane rearrangement and virus RNA encapsidation. The protein includes regions which 
interact with other viral and cellular proteins. In RNA replication, 2C has two functions, a cis-
acting guanidine-sensitive function required for initiation and a trans-acting function required for 
elongation, but the exact role of 2C is unknown (Banerjee et al., 2004; Belsham and Normann, 
2008). In addition, sequencing analysis of 2C shows similarity to several known ATPase, ATP- 
and GTP-binding proteins and viral helicases present in plus-strand RNA viruses. Both 2C and 
its precursor 2BC appear to be associated with viral RNA in infected cells in vitro (Banerjee et 
al., 2004; Teterina et al., 1997).  
On the basis of several sequence motifs and its structure, 2C is considered to be a member of the 
superfamily III helicases group of the AAA+ ATPase (Belsham and Normann, 2008; Sweeney et 
al., 2010). 2C has both ATPase and GTPase activities and 2BC is also capable of selectively 
hydrolysing ATP. However, only one study (Xia et al., 2015) has demonstrated any helicase 
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activity for a picornavirus 2C (in EV-71 and the closely related virus CAV16). The study also 
found that 2C acts as an RNA chaperone to destabilize helices from either direction and 
facilitates RNA:RNA interactions. This seems to be independent of ATP.  
A schematic of 2C is shown in Figure 1.5. 2C has a predicted N-terminal membrane-binding 
amphipathic helix, in addition to the main ATPase domain, and the ability to bind to membranes 
seems to partially correspond to this region. The AAA+ protein superfamily III helicase motifs in 
2C are the ‘Walker’ motif A, which is thought to participate in binding the phosphate moiety of 
NTP, ‘Walker’ motif B, which may chelate magnesium ions involved in NTP hydrolysis, and 
motif C (Figure 1.5) (Sweeney et al., 2010; Teterina et al., 1997).  
2C ATPase activity is inhibited by low concentrations of guanidine hydrochloride and this drug 
blocks negative strand RNA synthesis in poliovirus (Rightsel et al., 1961). The enterovirus 2C 
also contains a zinc-binding cysteine-rich motif reported to be involved in RNA replication 
(Banerjee et al., 2004; Belsham and Normann, 2008; Pfister et al., 2000). This motif is not 
present in many picornavirus 2C proteins and is absent in FMDV, the structure of which has 
been solved (Sweeney et al., 2010). Sequence analysis of 2C reveals homology to protease 
inhibitors, particularly serine protease inhibitors or ‘serpins’, which inhibit protease activity by 
binding to the catalytic pocket of proteases and blocking their ability to associate with specific 
substrates. In addition, 2C was found to be homologous to proteasome regulatory subunits from 
various organisms. This may be why 2C can regulate 3C
pro
 activity both in vitro and in vivo 
(Banerjee et al., 2004; Teterina et al., 1997). 
 3A and 3AB 1.1.5.5
3AB is a small, basic protein with multiple functions in viral RNA replication. In vitro, 3AB was 
found to stimulate the polymerase activity of 3D
pol
 as well as the self-cleavage of 3CD
pro
. 3AB 
may also form a complex with both 3CD
pro
 and the 5’ enterovirus cloverleaf RNA structure 
involved in RNA replication and act to anchor 3D
pol
 in the replication complex. 3AB has also 
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FIGURE 1.5: Schematic diagram of the 2C protein of EV71. Showing the Walker A and  
B motifs and motif C, found in the AAA+ protein superfamily III helicases. Regions of 2C 
involved with different functions are shown above the bar and mutations affecting the virus 
lifecycle are shown below the bar. 2C  consists of 319 amino acid. In enteroviruses the 2C-
encoding region is the location of the RNA structure the cre. Taken from (Xia et al., 2015). 
C H A P T E R  O N E   P a g e  | 22 
 
   
 
been shown to be the substrate for 3Dpol VPg uridylylation and involved in delivering VPg to 
replication complexes for VPg uridylylation (Lin et al., 2009; Yin et al., 2007).  
Viral proteins 3A, as well as 2B and 2C, contains an amphipathic helix and these proteins and 
their precursors bind membranes directly (Teterina et al., 2011; Wessels et al., 2006). Cleavage 
of 3AB occurs only when the precursor is bound to membranes. The C-terminus of 3A also has 
22 amino acid hydrophobic domain involved in membrane association  and this has been shown 
to be important for  poliovirus replication (Teterina et al., 2011). Amino acid changes in the 3A 
protein have been shown to alter host range and tropism in rhinoviruses (Harris and Racaniello, 
2005). The enterovirus 3A proteins inhibits endoplasmic reticulum (ER)-to-Golgi transport and 
is involved in replication complex formation (Lin et al., 2009; Wessels et al., 2006; Yin et al., 
2007). 
 3CD  1.1.5.6
3CD
pro




) is the protease involved in processing of the 
capsid proteins (Ypma-Wong et al., 1988). 3CD
pro
 is also an RNA-binding protein that binds to 
the 5’ cloverleaf of the PV RNA genome, which is needed for viral replication. In addition, 
3CD
pro
 binds in vitro to the cre structure in the 2C-encoding region in enteroviruses, which is the 
template for the uridylylation of VPg by 3Dpol (Lin et al., 2009; Yin et al., 2007).  
 3Dpol 1.1.5.7
The viral RNA-dependent RNA polymerase 3D
pol
 is needed for viral RNA replication.  3D
pol
 is a 
template- and primer-dependent RNA polymerase with RNA binding activity. It can also unwind 
dsRNA during RNA replication. 3D polymerase can also uridylylate VPg and use VPg-pUpU as 
a primer during viral RNA replication (Lin et al., 2009; Yin et al., 2007).  
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1.2 Secretory pathway 
 Introduction 1.2.1
Most positive-strand RNA viruses use host intracellular membranes of the early secretory 
pathway or structures such as mitochondria or lysosomes to make replication complexes for 
genome replication (Midgley et al., 2013; Sasaki et al., 2012). The secretory pathway involves 
the endoplasmic reticulum (ER), the ER-Golgi intermediate compartment (ERGIC) and the 
Golgi. Coronavirus replicates on a reticulovesicular network derived from the ER, Semliki 
Forest virus uses endolysosomes and lysosomes, Flock House virus genome replication takes 
place next to mitochondria. For hepatitis C virus, RNA replication takes place at ER membranes 
and lipid droplets (Inoue and Tsai, 2013; Quiner and Jackson, 2010).  
These virus-induced membrane structures help to increase the concentrations of components 
required for virus replication, provide a scaffold for anchoring the replication complexes, prevent 
the activation of host defence mechanisms that recognise dsRNA produced during virus RNA 
replication, tether viral RNA during unwinding and provide certain lipids that are required for 
genome synthesis (Miller and Krijnse-Locker, 2008; Sasaki et al., 2012).  
 Endoplasmic reticulum (ER) 1.2.2
The ER is a dynamic cytoplasmic membrane system and is the largest organelle in a cell. It is a 
major site of synthesis of secreted and membrane proteins, protein transport, protein folding, 
lipid and steroid synthesis, carbohydrate metabolism and calcium storage (Romero-Brey and 
Bartenschlager, 2016). The ER is a continuous membranous system including the nuclear 
envelope and structures made up of branched sheets and tubules. The rough ER, with ribosomes 
attached, corresponds to membrane sheets and the smooth ER is made of tubules (Inoue and 
Tsai, 2013). The rough ER is the site of translation of secretory and transmembrane proteins and 
the smooth ER has functions related to  lipid and glycogen metabolism (Inoue and Tsai, 2013).  
C H A P T E R  O N E   P a g e  | 24 
 
   
 
ER sheets are a series of stacked flat cisternae which are connected by helicoidal ramps, which 
are twisted flat membrane surfaces. This means that the packing of the sheets is very efficient 
(English and Voeltz, 2013). 
ER tubules are constantly changing shape and size. The membranes are generally more curved 
than ER sheets and have fewer ribosomes associated with them than sheets. Membrane proteins 
play a major role in the formation, maintenance and branching of both sheets and tubules 
(Schwarz and Blower, 2016).  
In addition to its role in the synthesis, modification and transport of secretory and membrane 
proteins and the synthesis and transport of several lipids, the ER interacts with many other 
organelles, such as lipid droplets, mitochondria, endosomes, peroxisomes, and phagophores 
generated during autophagy (Romero-Brey and Bartenschlager, 2016). 
Contact sites between the ER and mitochondria are involved in Ca2+ signalling, lipid 
biosynthesis and mitochondrial division, including Ca2+ entry into mitochondria and biosynthesis 
of phosphatidylcholine (PC). ER interactions with endosomes allow the exchange of lipids and 
sterols and may regulate cholesterol levels in the endocytic pathway. In addition, peroxisomes 
are made from components from the ER. A pool of vesicles containing peroxisomal proteins bud 
from the ER close to peroxisomes (English and Voeltz, 2013; Raychaudhuri and Prinz, 2008). 
 Transitional ER (tER) or ER exit sites (ERES)  1.2.3
ERES are projections of the ER, which lack ribosomes and are coated with COPII components.  
They seem to be involved in the selection and packaging of cargo (e.g. proteins) leaving the ER, 
as well as ensuring that ER resident proteins and other non-cargo materials remain in the ER. 
COPII vesicles bud off from ERES and form the next compartment in the secretory pathway, the 
ERGIC (Barlowe and Helenius, 2016; Gillon et al., 2012). 
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 The ER-Golgi intermediate compartment (ERGIC)  1.2.4
The ERGIC (also known as vesicular-tubular clusters or pre-Golgi intermediates) is a complex 
membrane system between the rough ER and the Golgi. ERGIC-53, a 53 kDa non-glycosylated 
type I membrane protein, localises to the ERGIC and is often used as a marker for this 
compartment (Appenzeller-Herzog and Hauri, 2006; Hauri et al., 2000; Szul and Sztul, 2011). 
The ERGIC is made up of two types of vesicles. One is used for anterograde transport from ER 
to Golgi when COPII-coated vesicles bud from the ERES and are transported along the 
microtubule to the cis-Golgi. There they can fuse with the first cisterna of the cis-Golgi or form a 
new cis-Golgi cisterna by fusion with Rab1. The other is due to retrograde movement from the 
Golgi back to ER, which involves COPI-coated vesicles. Recycled proteins are sent back to the 
ER and resident ERGIC proteins are retained within the ERGIC (Appenzeller-Herzog and Hauri, 
2006; Szul and Sztul, 2011). 
 Golgi 1.2.5
The main functions of the Golgi are sorting macromolecules for delivery to structures such as 
endosomes and plasma membrane or the cell exterior, as well as protein glycosylation (Midgley 
et al., 2013). The Golgi complex is made up of one or more stacks of disk-shaped cisternae that 
are connected by tubulovesicular regions (Glick and Nakano, 2009; Nakamura et al., 2012). 
Each stack of cisternae has two faces, the cis-Golgi network (CGN) which faces the ER and the 
trans-Golgi network (TGN), which faces the opposite side. The CGN receives protein and lipid 
cargos from the ER and cargo is sorted and directed to different cellular compartments in the 
TGN (Jackson, 2009; Nakamura et al., 2012).  
 Transport to the Golgi  1.2.5.1
As already described, secretory cargo proteins bud off from the ERES in COPII-coated vesicles. 
They pass through the vesicular–tubular membrane of the ERGIC to the CGN. COPI-coated 
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vesicles then bud off from the ERGIC elements to recycle components of the transport and 
sorting machinery back to the ER (Glick, 2000).  
 Transport through Golgi 1.2.5.2
Two main mechanisms are proposed for the movement of secretory cargo through the Golgi 
(Barlowe and Helenius, 2016). The stable compartments model proposes that anterograde COPI 
vesicles specifically recognise secretory cargo, transport it forward and exclude proteins that 
need to be resident in the Golgi. The cisternal maturation model proposes that both resident 
proteins and cargo are transported forward, but retrograde COPI vesicles recycle resident Golgi 
proteins back to the Golgi (Glick et al., 1997). A third model, rapid-partitioning, suggests that 
cargo can move in a bidirectional manner, in both cis-to-trans and trans-to-cis directions 
(Jackson, 2009).  
 Transport from the Golgi 1.2.5.3
Multiple types of vesicles form at the TGN. Clathrin-coated vesicles bud from the TGN and 
deliver material to the endosomal/lysosomal/vacuolar system and immature secretory granules 
detach from the TGN and then mature (Glick, 2000).  
 Coated vesicles proteins  1.2.6
Vesicles with different coats are formed in a similar way, involving coat complexes, Sar1/ARF 
GTPases, guanine nucleotide exchange factors (GEFs), and GTPase activating proteins (GAPs).  
 COPII vesicles 1.2.6.1
Budding of COPII-coated vesicles depends on the active GTP-bound form of the small GTPase 
Sar1-specific guanine nucleotide exchange factor and this process is catalyzed by the Sec12 
GEF, which is a membrane protein found in the ER. Sec12 controls Sar1 and active Sar1 directly 
binds Sec23/Sec24 to the inner heterodimeric sub-complex of the COPII coat. This then recruits 
the outer coat components (Sec13/Sec31) to the Sec23/Sec24 core and the mature coated vesicles 
bud from the ER (Midgley et al., 2013). Sar1, Sec23/24 and Sec13/31 are necessary to generate 
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COPII vesicles in vitro. At least some cargo is exported from the ER by binding to cargo 
receptors of the ERGIC-53 family that facilitate sorting into COPII vesicles (D'Arcangelo et al., 
2013; Gillon et al., 2012; Szul and Sztul, 2011). Sar1 is converted to its inactive GDP-bound 
form and COPII coats rapidly dissociate from the vesicles, which then acquire COPI 
(“COPII/COPI exchange”) before fusion with the ERGIC (Stephens et al., 2000) (Figure 1.5).  
 COPI vesicles  1.2.6.2
COPI appears to be required at more than one stage of ER-to-Golgi transport. For example, 
COPI is involved in anterograde transport after COPII/COPI exchange, movement within the 
Golgi and in the retrograde movement of components from the Golgi back to the ER. COPI is 
also required for lipid storage and lipid homeostasis (Szul and Sztul, 2011; Wang et al., 2012b). 
COPI is composed of seven coatomer subunits and an ADP ribosylation factor (ARF)-dependent 
GTPase. The subunits of COPI are αCOP, βCOP, β′COP, γCOP, δCOP, εCOP and ζCOP (Wang 
et al., 2012b). ‘Thin’ COPI vesicles are found close to the cis-Golgi and between the cis-Golgi 
and the ERES, suggesting that they recycle materials from the cis-Golgi to the ER. ‘Thick’ COPI 
vesicles are found close to medial- and trans-Golgi, suggesting that they are involved in 
retrograde trafficking within the Golgi (Szul and Sztul, 2011).  
COPI coat formation requires ARF1, which is activated on the Golgi by two related GEF, GBF1 
and BIGs. GBF1 (ARF1–GEF) is present in the cis-Golgi and BIG is located in the trans-Golgi 
(Midgley et al., 2013). 
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FIGURE 1.6: Schematic of the secretory pathway. Secretory cargos are synthesized in the 
ER, exit the ER at ERES in COPII-coated vesicles, and are transported to ERGIC. Cargos are 
sorted from the ERGIC and move to the Golgi. Cargos are sorted at the TGN (trans Golgi 
network) for delivery to the plasma membrane (PM) and early and late endosomes. Colours 
indicate the known coats: COPII (blue), COPI (green), and clathrin (red). Taken from (Szul 
and Sztul, 2011). 
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1.3 Lipids 
Many viruses interact with and exploit host cell lipids at different stages of the virus replication 
including entry, nucleic acid replication and budding of new enveloped particles (Martin-Acebes 
et al., 2013). The effects on lipids include changes to the composition, fluidity, and curvature of 
membrane compartments. Particularly extensive changes are seen in cells infected with positive 
sense RNA viruses where specific membrane compartments are induced by viruses and used to 
generate replication complexes (Chukkapalli et al., 2012). 
 Lipid droplets (LDs) 1.3.1
LDs are dynamic cytoplasmic organelles present in most cells and are the most important storage 
organelles for neutral lipids. The size and number of LDs varies between cell types, for example 
up to 100 μm in diameter in white adipocytes but only up to 100–200-nm in many other cells. 
LDs consist of a hydrophobic core of neutral lipids (triglycerides (TG) and cholesterol esters 
(CE), surrounded by a phospholipid monolayer, embedded in which are several associated 
proteins (Guo et al., 2009; Herker and Ott, 2012; Walther and Farese, 2012) (Figure 1.7). LDs 
interact with several amphipathic molecules (Walther and Farese, 2012).  
LDs can have several functions, apart from lipid storage for future energy generation.  The stored 
lipids can also be the raw materials for making new membranes and the starting point for making 
specific lipids. CEs in steroidogenic cell LDs are used for steroid synthesis, and arachidonic acid 
esters present in mast cell LDs are used in eicosanoid synthesis. In hepatocytes, the lipid ester in 
LDs is utilized for lipoprotein formation (Fujimoto et al., 2008). LDs are reported to be involved 
in esterification of excess free fatty acids (FAs) and free CEs, which prevents toxicity of these 
molecules (Fujimoto et al., 2008; Suzuki et al., 2011). Lipid synthesis is summarised in Figure 
1.8. 
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FIGURE1.7: The structure of a lipid droplet. A hydrophobic core of 
neutral lipids (triglycerides and sterol esters) is surrounded by a phospholipid 
monolayer which interacts with proteins, particularly members of the 
perilipin family. Taken from (Guo et al., 2009). 
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FIGURE 1.8: Lipid metabolism and LD formation in mammal and yeast. LD 
biogenesis requires coordination of acyl-CoA synthetases (green box), neutral lipids 
(orange box), phospholipid remodeling (purple box), phospholipid synthesis (blue 
box), and the function of accessory proteins (grey box). The enzymes involved in 
these pathways are indicated with red (mammal) and yellow letters (yeast). Taken 
from (Pol et al., 2014). 
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Proteins can also be stored temporarily in LDs, for example some membrane proteins targeted 
for degradation (Fujimoto et al., 2008; Guo et al., 2009; Walther and Farese, 2012). Lipidated 
apolipoprotein B-100 and α-synuclein (which contribute to Lewy bodies in Parkinson’s disease) 
accumulates on LDs when proteasomal degradation or autophagy are inhibited. This suggests 
that LDs may sequester these proteins to prevent them from forming insoluble aggregates before 
they can be effectively degraded (Suzuki et al., 2011).  
Enzymes involved in LD formation are mainly found in the ER, but not diacylglycerol 
acyltransferase 2 (DGAT2), which localised to LDs. Examples of these enzymes are acyl-
coenzyme A (acyl- CoA) and DGAT 1 and 2, which synthesize TG and acyl-CoA cholesterol 
acyltransferase (ACAT) 1 and 2 that generate SEs. Other hydrophobic lipids found in LDs 
include retinyl esters (in LDs of hepatic stellate cells and in the retina), wax esters and ether 
lipids and long-chain isoprenoids (Walther and Farese, 2012).  
The main surface phospholipids of LDs are phosphatidylcholine (PC), phosphatidylethanolamine 
(PE) and phosphatidylinositol. LDs have much less  phosphatidylserine and phosphatidic acid 
than other membranes but more lyso-PC and lyso-PE. LDs of white adipocytes contain large 
amounts of free cholesterol as they acts as a cholesterol sink for the whole body (Fujimoto et al., 
2008; Walther and Farese, 2012).  
Several kinds of proteins are present on the LD surface. These are structural proteins (e.g. 
perilipin family members), lipid-synthesis enzymes [e.g. acetyl coenzyme A (CoA) carboxylase, 
acyl-CoA synthetase and acyl-CoA], lipases [e.g. adipose tissue triacylglycerol lipase (ATGL)] 
and membrane-trafficking proteins (e.g. Rab5, Rab18 and ARF1) (Guo et al., 2009).  
 Lipid droplets formation 1.3.1.1
Formation of LDs take place in the ER (Guo et al., 2009; Pol et al., 2014). How they form is not 
fully understood. ER budding, where LDs grow from the ER bilayer and either remain connected 
or bud off, is one possibility; bicelle formation, in which neutral lipids accumulate between the 
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leaflets of the ER membrane and nascent LDs are excised from the membrane is another 
suggestion. Vesicular budding, in which a bilayer vesicle forms, followed by filling of the space 
between the bilayes with neutral lipids, could also occur. Finally, ‘eggcup’ model has been 
proposed in which a LD grows within a concave depression of the ER through transport of 
neutral lipids from the ER (Robenek et al., 2006) (Figure1.9). 
 Lipid droplet growth 1.3.1.2
If LDs remain attached to the ER, newly synthesized lipids and proteins can diffuse to them, but 
if they are detached they need to be transported through membrane connections or via vesicles. 
Neutral lipids can be made in LD cores by enzymes such as DGAT2 which catalyzes the final 
step of TG synthesis. Sterolesters are made in the ER. The increase in the volume of neutral 
lipids in LD cores requires more phospholipids at the surface and so there needs to be a lot of co-
ordination of processes during LD growth (Guo et al., 2009; Walther and Farese, 2012).  
Fusion of LDs can also occur and lead to an increase in size. Soluble N-ethylmaleimide-sensitive 
factor activating protein receptor (SNARE) proteins are found in LDs and are required for 
fusion. In LD fusion, the total volume of lipid esters appears to remain constant and the resulting 
LD regains the spherical shape immediately, suggesting that these are highly dynamic structures 
(Bostrom et al., 2007).  
 Lipid droplet proteins  1.3.1.3
LD proteins can be classified into five groups: (i) small GTPases that regulate vesicle formation 
and movement; (ii) motor proteins that move vesicles on the cytoskeleton (kinesin and myosin); 
(iii) N-ethylmaleimide-sensitive factor (NSF), soluble NSF attachment protein (αSNAP), the 
SNARE and SNAP23 are needed for LD docking and fusion; (iv) vesicular traffic proteins that 
regulate cargo sorting and vesicle budding such as ARF1, membrane, Sar1, Sec21, COPs, and 
Sec22; and (v) unknown function membrane traffic proteins (VAT1, Rap1, P22, and TIP47) 
(Zehmer et al., 2009). 
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FIGURE 1.9: Some of LD formation models. These include ER budding,  bicelle formation 
and vesicular budding. Taken from (Meester et al., 2011). 
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The best studied are PAT proteins, which include perilipin, adipose differentiation-
related protein (ADRP), tail-interacting protein of 47 kD (TIP47), S3-12 and 
MLDP/OXPAT/PAT-1 (Fujimoto et al., 2008). Perilipins are not essential for LD formation, but 
are important for regulating lipid metabolism at LDs (Listenberger et al., 2007; Walther and 
Farese, 2012). Unphosphorylated perilipin protects the lipid dropl[et from lipase activity (Beller 
et al., 2008). 
ADRP is present on the surface of LDs from the earliest time of their synthesis and helps to 
regulate lipid storage during LD formation. Over-expression of ADRP causes an increase in 
neutral lipid mass and LD accumulation, showing an important function in LD regulation. This is 
related to reduced TAG turnover and TAG secretion in cells over-expressing ADRP. 
Suppression of ADRP expression in mice significantly reduces hepatic TAG accumulation 
(Listenberger et al., 2007).  
TIP47 may also protect against lipolysis by affecting the LD surface (Suzuki et al., 2011; Beller 
et al., 2008; Bickel et al., 2009; Fujimoto et al., 2008; Vogt et al., 2013).  
Other proteins such as Rab18 (a small GTPase) localize to LDs and influence interactions with 
the ER. MLDP/OXPAT/PAT-1 also inhibits lipolysis in LDs, and S3-12 (which may be related 
to lipid storage) is expressed almost exclusively in the adipocyte (Fujimoto et al., 2008).  
The movement of LDs is driven by microtubule motor proteins, kinesin and dynein. Erk-
mediated phosphorylation of dynein increases the association of this motor protein with LDs. 
The ability of LDs to form and grow is dependent on motor proteins and microtubules and 
dynein neutralizing antibodies and the microtubule inhibitor nocodazole inhibit fusion of LDs 
(Zehmer et al., 2009).  
Caveolins, which form the coats of caveolae, play a role in cholesterol trafficking (Fujimoto et 
al., 2008; Le Lay et al., 2006). In adipocytes, caveolae seem to produce TGs and caveolae can 
bud and transport to LDs. PTRF/cavin-1, a peripheral membrane protein essential for caveolae 
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formation, is also thought to be linked with LD functions and lipid storage in adipocytes (Suzuki 
et al., 2011). Caveolin-1 binds glycolipids and fatty acids and contributes to intracellular lipid 
transport. As well as caveolae, Caveolin-1 localises to the Golgi, but in the presence of excess 
lipid it is endocytosed  and translocates to the LD. Rab18 is thought to regulate the interaction 
between LDs and the ER and overexpression of Rab18 expels ADRP from the LD and brings 
LDs closer to the ER (Fujimoto et al., 2008). ARF1/COPI proteins are required for LD 
localization of the major TG lipase ATGL (Wilfling et al., 2014). 
There are various different mechanisms to explain how proteins target LDs. These include long 
membrane-embedded domains that enter and exit the membrane on the same side of the lipid 
monolayer; embedding an amphipathic helix internal protein domain that penetrates the LD with 
hydrophobic spans; lipid anchors; and interaction with other LD-bound proteins (Guo et al., 
2009; Walther and Farese, 2012).  
 Lipid droplet catabolism  1.3.1.4
Lipolysis is the process of breaking down LDs to form FAs and lipids. In adipocytes it is 
initiated by hormonal, nutritional or inflammatory (such as tumor necrosis factor-α) signals. 
Firstly, catecholamines bind to β-adrenergic G-protein-coupled receptors at the plasma 
membrane and stimulate adenylyl cyclase. This generates cAMP which activates protein kinase 
A, then phosphorylates perilipin A.  Perlipin A activates adipose triglyceride lipase (ATGL) and 
recruits phosphorylated HSL to the LD surface. ATGL and HSL then hydrolyze triacylglycerols 
to FAs and monoacylglycerols, which are further broken down to glycerol and FAs (Guo et al., 
2009; Herker and Ott, 2012; Suzuki et al., 2011; Walther and Farese, 2012). During lipolysis, 
LDs shrink as the core lipids are broken down. The surface then needs to shrink but it is 
unknown if excess proteins and phospholipids are resorbed into the ER or degraded. The 
released FAs can be used in several ways, including being incorporated into new TGs, broken 
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down to provide energy by β-oxidation, used to make membrane lipids, exported or become 
involved in cell signalling (Guo et al., 2009; Walther and Farese, 2012).  
Lipids in LDs can also be degraded by lipases within lysosomes during macroautophagy, 
induced by nutrient deprivation or hormonal signals. LDs are surrounded by a membrane bilayer 
containing the activated LC3-II protein (Walther and Farese, 2012). Regulation of lipolysis 
seems to be the primary function of perilipins by recruiting or preventing the access of lipases to 
LDs (Pol et al., 2014). 
 Lipid droplets interact with other organelles 1.3.1.5
LDs often interact with the ER, mitochondria and peroxisomes, both in adipocytes and in non-
adipocytes.  
1.3.1.5.1 The Endoplasmic Reticulum (ER) 
LD biogenesis takes place in the ER membrane and LDs form and grow by incorporating lipid 
esters synthesized in the ER (Suzuki et al., 2011; Zehmer et al., 2009). There are also other 
interactions not related to the ER origin of LDs. LD-ER contacts induced by the GTP/GDP state 
of Rab18 or knockdown of ADRP bring about  the reverse movement of lipids from LDs to ER, 
which can presumably occur naturally  (Suzuki et al., 2011; Zehmer et al., 2009). LD-ER contact 
sites seems to be involved in replication of some viruses, possibly by allowing lipid movement 
between these organelles (Zehmer et al., 2009). 
Seipin and the fat storage–inducing transmembrane protein (FITM/FIT) are two ER resident 
proteins involved in LD formation, possibly through membrane-spanning helices which could 
interact with LDs. Removal of seipin in yeast and in fibroblasts results caused a large variation in 
size of LDs (Pol et al., 2014).  
1.3.1.5.2 Endosomes 
The interaction between LDs and endosomes seems to be important for normal membrane traffic 
and several proteins involved in trafficking are found in LDs. Endosome carrying high-density 
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lipoprotein (HDL) associate with LDs and Rab5/Rab11. Rab GTPases may therefore regulate 
interactions between LDs and endosomes. LDs also contain proteins known to mediate SNARE-
dependent membrane-membrane fusion (Zehmer et al., 2009).  
1.3.1.5.3 Mitochondria and peroxisomes  
A physical link between mitochondria/peroxisomes and LDs allows the import of fatty acids for 
β-oxidation (Suzuki et al., 2011). LDs and mitochondria co-localise in skeletal muscle cells, 
which have a high lipid requirement for energy production. This interaction is enhanced when 
energy requirements are increased. Caveolae protein, caveolin-1, plays a role in maintaining the 
interaction between LDs and mitochondria (Zehmer et al., 2009).  
In some cases, peroxisomes in contact with LDs form structures called “gnarls” that push into 
the LD core. This association may allow the products of lipolysis to be fed into the β-oxidation 
pathway in peroxisomes (Zehmer et al., 2009). LDs and  phagosomes may interact by a briefer, 
kiss-and-run type contact and this could be  important for supplying phagosomes with lipids 
(Suzuki et al., 2011). 
1.3.1.5.4 COPI and COPII 
COPI protein, but not COPII, is needed to use lipid stores in LDs. Presumably there is some 
trafficking between ER and LDs using COPI vesicles. Blocking this pathway changes the levels 
of TIP47 and ATGL on the LD surface implying that it is a specific process (Beller et al., 2008).  
 Lipid droplets and disease 1.3.1.6
Excessive lipid storage in LDs is associated with many metabolic diseases as cells cannot store 
enough lipid to prevent a toxic effect by some lipid precursors. Unesterified lipids, such as 
cholesterol or FAs, can trigger inflammatory responses that result in tissue damage, fibrosis, 
scarring and potentially organ failure. Obesity involves excess lipid storage in LDs in the adipose 
tissue and complications such as type 2 diabetes mellitus seem to be one problem of this excess 
storage. Therapies that target LDs could block lipid absorption in the small intestine and so LD 
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formation, enhance breakdown rather than storage of lipids or, alternatively, increase LD 
capacity in adipocytes or macrophages to store toxic lipids and prevent associated inflammation 
and tissue damage (Krahmer et al., 2013). 
Atherosclerosis is associated with deposition of lipids in tissues, specifically cholesterol derived 
from apo B-containing lipoproteins in arterial walls. Excess cholesterol is taken up and esterified 
by macrophages. Cholesterol esters are stored in LDs until they can be mobilized and sent to 
high-density lipoproteins, which are transported to the liver for clearance of cholesterol from 
bile. Excess lipid overloads this system (Krahmer et al., 2013; Walther and Farese, 2012). 
Absence or deficiency of white adipose tissue (lipodystrophy) results in LD deficiency and there 
are a number of genetic causes such as mutations in genes that encode acylglycerol-phosphate 
acyltransferase (AGPAT2), seipin (BCSL2) or caveolin 1 (CAV1). Partial lipodystrophy can be 
caused by defective lamin A/C (LMNA), peroxisome proliferatoractivated receptor-γ (PPARG), 
Akt2/protein kinase B (AKT2) and endoprotease Face-1 (ZMPSTE24) (Garg and Agarwal, 
2009).  
Some tumor cells and associated inflammatory cells have prominent LDs, which could be related 
to increased FA synthesis or impairments in FA oxidation (Pan et al., 2012). Clinical studies 
suggest that chronic HCV infection is associated with various disorders of lipid metabolism 
resulting in accumulation of LDs in the liver (steatosis) and reduced serum beta-lipoprotein 
levels (Fukasawa, 2010). 
 Diacylglycerol acyltransferase (DGAT) enzymes  1.3.2
Acyl CoA diacylglycerol acyltransferase (DGAT; EC 2.3.1.20) is a microsomal enzyme 
involved in the metabolism of cellular glycerolipids. Its substrates are diacylglycerol (DAG) and 
fatty acyl CoAs (Camus et al., 2013). DGAT is involved in a number of lipid-related processes 
(Cases et al., 1998). Both DGAT1 and DGAT2 are essential in LD biogenesis. Both enzymes are 
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found in the ER and when cells take up of fatty acids, DGAT2 (but not DGAT1) localizes to LDs 
(Herker et al., 2010).  
1.4 Role of cellular lipid in viral infections 
Among the cellular factors required by viruses, lipids play an important role in both enveloped 
and non-enveloped virus infections. Cellular lipids are important to viral infection particularly 
for membrane fusion during the entry process, replication and budding of the virus. Exploitation 
of host cell lipids plays an important role in efficient replication of RNA viruses (Chukkapalli et 
al., 2012; Heaton and Randall, 2011).  
 Entry 1.4.1
The first step of a viral infection is entry into a host cell and involves attachment of the virus 
particle to a specific receptor(s) located on the cell surface (Martin-Acebes et al., 2013). Several 
viruses bind to lipid molecules, including members of the Polyomaviridae family which bind 
directly to ganglioside. Influenza virus and human immunodeficiency virus also bind to 
gangliosides (Ewers and Helenius, 2011; Izquierdo-Useros et al., 2012; Meisen et al., 2012). The 
rhabdovirus vesicular stomatitis virus (VSV) interacts with negatively charged phospholipids 
during entry (Schlegel et al., 1983) and HCV requires lipid trafficking receptors such as low 
density lipoprotein receptor (LDL-R) as indirect viral receptor (Agnello et al., 1999). Influenza 
A virus, human West Nile virus (WNV) and herpes virus 6 require cholesterol in the virus 
envelope for efficient entry (Heaton and Randall, 2011; Martin-Acebes et al., 2013). In addition, 
lipid rafts have been associated with various endocytic mechanisms exploited by viruses. These 
include the coronavirus SARS virus, murine leukemia virus, herpes simplex virus, Japanese 
encephalitis virus, SV40 and echovirus 1. Foot-and-mouth disease virus (FMDV) and human 
rhinovirus type 2 also require cholesterol for efficient entry (Martin-Acebes et al., 2013). The 
use of cholesterol and lipid rafts for viral entry into cells has also been documented for 
coxsackievirus B3 (CVB3) infection (Coyne and Bergelson, 2006). 
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Many viruses depend on phosphatidylinositol (PI)-3 kinase signaling for internalization. This 
sorts the virus particles into an endosomal compartment which is then endocytosed. Specific 
lipids may influence the compartment of entry and uncoating, for instance dengue virus (DENV) 
fuse with late endosomes containing the late endosome-specific lipid species bis 
(monoacylglycero) phosphate (Heaton and Randall, 2011; Martin-Acebes et al., 2013).  
The plasma membrane also exhibits clusters of other lipids like phosphatidylinositol 4,5- 
bisphosphate (PI(4,5)P2), which has an important role in clathrin-mediated endocytosis and also 
plays a role in HIV-1 entry (Barrero-Villar et al., 2008). FMDV require this phospholipid in the 
plasma membrane for internalization (Martin-Acebes et al., 2007). 
 Replication 1.4.2
Cell membranes from the ER, Golgi, endosomes, lysosomes, peroxisomes and mitochondria can 
be used to form replication complexes for positive-stranded RNA viruses. These viruses can also 
exploit LDs for their replication (Heaton and Randall, 2011; Martin-Acebes et al., 2013). Viral 
and cell proteins are needed to recruit these membranes. Host proteins may be involved through 
biosynthesis of membrane components or providing the support for the membranes. Brome 
mosaic virus (BMV) replication requires the host gene OLE1, which affects membrane fluidity. 
BMV also utilize ACB1-encoded acyl CoA binding protein (ACBP), which promotes lipid 
synthesis for efficient replication (Lee et al., 2001; Zhang et al., 2012).  
Many viruses require cholesterol and FAs for their RCs. For example, WNV manipulates a 
cholesterol biosynthesis pathway by 3-hydroxymethyglutaryl-CoA reductase, redistributes 
cellular cholesterol to replication sites and reduces cholesterol at the plasma membrane to 
deactivate antiviral signalling (Mackenzie et al., 2007). Furthermore, yellow fever virus (YFV) 
and DENV proteins bind to fatty acid synthase (FASN) and relocalizes it to sites of viral 
replication (Heaton et al., 2010; Perera et al., 2012). 
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Specific phospholipids also play a key role in viral replication. For example, HCV NS5A 
expression stimulates cellular phosphatidylinositol-4-phosphate (PI4P) production by ER-
associated phosphatidylinositol-4 kinases (PI4K) III-alpha. Enterovirus, 3A protein recruits the 
Golgi isoform PI4-kinase III-beta. Viral proteins of Aichivirus interact with acyl-coenzyme A 
binding domain containing 3 (ACBD3), which can interact with and recruit PI4KB to RCs. 
Further, the PV RNA polymerase 3Dpol physically binds PI4P, which could influence both its 
association with cellular membranes and its ability to synthesize RNA (Reiss et al., 2011; Sasaki 
et al., 2012). 
DENV infection consumes LDs and stimulates β-oxidation (Heaton and Randall, 2010). The FA 
oxidation enzyme dodecenoyl coenzyme A delta isomerase is essential for HCV replication 
(Rasmussen et al., 2011). On the other hand Human cytomegalovirus (HCMV) appears to reduce 
β-oxidation (Seo et al., 2011). Several viruses also manipulate peroxisomes during replication, 
either for β-oxidation of fatty acids or for other purposes (Chukkapalli et al., 2012). 
 Assembly 1.4.3
Many enveloped viruses acquire their lipid membrane by budding through a cellular membrane. 
For example, DENV and WNV acquire an envelope through budding into the ER, whilst 
influenza and HIV acquire an envelope by budding from the plasma membrane. Synthesis of 
fatty acids has also been associated with envelope formation in viruses (Martin-Acebes et al., 
2013). HCMV stimulates fatty acid synthesis in order to enhance the assembly of infectious 
HCMV virions (Munger et al., 2008). 
Lipid signalling also helps organize HIV budding sites by recruiting the major HIV structural 
protein, Gag. The localization of Gag to lipid rafts at the plasma membrane is dependent on the 
interactions of Gag with the lipid signalling molecule PI-(4,5)-bisphosphate, which is enriched at 
the plasma membrane (Chukkapalli et al., 2008). Similarly, the trafficking of influenza virus 
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glycoproteins to the plasma membrane and subsequent budding, depends on the interaction of 
virus components with lipid rafts (Nayak et al., 2009). 
In some viruses, LDs contribute towards the assembly. DENV and HCV are good illustrations 
of this. HCV core protein enhances the accumulation of LDs in the perinuclear region, 
potentially enhancing an interaction between the HCV core and DGAT-1, and as result promotes 
LD formation (Heaton and Randall, 2011; Martin-Acebes et al., 2013). In non-enveloped viruses, 
myristoylation of VP4 protein in PV and FMDV has been shown necessary for correct capsid 
assembly (Goodwin et al., 2009; Moscufo et al., 1991). 
1.5 Remodelling of secretory pathway in 
viral infection  
Several enveloped and non-enveloped viruses, belonging to both RNA and DNA virus families, 
rearrange cell compartments to generate novel structures for replication and assembly (Inoue and 
Tsai, 2013). The ER is often involved and there can be a great change in ER morphology. 
(Pierini et al., 2009). Other targeted membranes include the Golgi apparatus and mitochondria. 
These membranes may provide a structural framework for replication, and different 
compartments may be important for some viruses if they produce both genomic and sub-genomic 
RNA or positive and negative sense RNA. In some viruses the replication complex may be 
generated by a cellular autophagic process (Cherry et al., 2006). 
HCV promotes the formation of an ER-derived membranous matrix (membranous web) that is 
important for viral replication and assembly. DENV generates vesicle packets and complex 
membranes to facilitate genome replication and virus assembly (Inoue and Tsai, 2013).  
In HCV, web formation is thought to initiate when the ER membrane-bound viral non-structural 
protein NS5A recruits and activates PI4KIIIα, thus increasing the local concentration of PI4P 
which might itself be an important membrane constituent that supports membranous web 
structural integrity. It is thought that PI4P may recruit downstream effector proteins such as 
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oxysterol-binding protein 1 (OSBP1) to form a sterol-rich environment surrounding the 
membranous web, that is essential for HCV replication. Moreover, DENV’s non-structural 
protein NS4A rearranges the ER membrane, leading to the formation of vesicle packets and 
convoluted membranes. It also uses LDs for particle formation.  In rotavirus, the ER also 
supports virus assembly during the late stage of this process. A viral intermediate containing the 
core shell and middle layer is called a double-layer particle (DLP), and a mature infectious 
particle harbouring all three layers is referred to as a triple-layer particle (TLP). DLP-to-TLP 
morphogenesis is intimately associated with the ER (Inoue and Tsai, 2013). 
Enteroviruses utilize ER exit sites to form tubular structures that extend into the cytoplasm to 
anchor the viral replication machinery on the cytoplasmic membrane of the ER. The formation of 
enterovirus replication organelles also specifically requires COPI, which is recruited to 
replication complexes via inhibition of ARF1 GTPase by the virally-encoded 3A protein 
(Morosky et al., 2016). PV 3A protein binds GBF1 and modulates recruitment of ARF1 effectors 
to favour phosphatidylinositol 4-kinase (PI4K) over COPI components. It may also inhibit ER-
to-Golgi transport by stabilizing ARF1-GDP-GBF1 complexes, reducing the supply of Arf1-
GTP for COPI coats. This creates membranes lacking COPI and enriched for PI4P, which 
promotes membrane binding of viral RNA-dependent RNA polymerases and formation of the 
viral replication complex (Midgley et al., 2013; Pierini et al., 2009). 
PV-induced membrane vesicles have also been linked to COPII-dependent vesicle trafficking. 
The 2B, 2C and 3A proteins interact with each other and the other replication proteins and bring 
about membrane association of RNA replication proteins (den Boon et al., 2010). In FMDV, 
secretion is blocked by the 2BC protein rather than 3A. The 2B and 2BC of enteroviruses also 
slow secretion when expressed alone in cells. These proteins can therefore affect membrane 
traffic and for 2C, this may involve binding to ER membrane protein reticulon 3, which is 
involved in ER-to-Golgi trafficking and is required for replication (Pierini et al., 2009).  
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COPI activity is required for EV11 and HCV replication. The COPI inhibitor Brefeldin A (BFA) 
inhibits RNA replication in PV and EV11, but not FMDV and encephalomyocarditis virus 
(EMCV) infection and only partially inhibits HPeV1. Genome-wide RNA interference screening 
revealed that picorna-like virus, Drosophila C virus (DCV), also recruited COPI proteins to 
achieve viral replication (Wang et al., 2012b). For enterovirus 71 (a BFA-sensitive 
picornavirus), COPI but not COPII has been shown to be required for infection (Midgley et al., 
2013).  
1.6 Antiviral Drugs 
The use of vaccines to prevent disease, or drugs to inhibit viral replication, are the two main 
strategies currently used to combat viral infections (van der Schaar et al., 2013). For viruses with 
multiple serotypes, vaccines are not useful and antiviral drugs are required. Many targets have 
been studied as antiviral treatments. Traditionally, viral proteins such as proteases, polymerases 
and integrases have been targets for classical anti-viral agents. Enterovirus inhibitors have been 
developed against the HRV protease 3C (Jurgeit et al., 2010).  
Despite considerable research, there are no clinically–used antivirals against picornaviruses (van 
der Schaar et al., 2013; Whitton et al., 2005; Zuo et al., 2016). Pleconaril is an example of a drug 
that has the potential to treat acute and chronic picornavirus infections. This compound binds to 
a hydrophobic pocket of the enteroviral and rhinoviral capsids, inducing conformational changes 
that alter binding to the cognate viral receptor. Furthermore, it has shown promise against 
neonatal enteroviral hepatitis and multisystem CVB infection in preterm newborns, and was used 
to successfully treat enterovirus infection in two infants with severe combined 
immunodeficiency. The drug was under investigation in a phase II clinical trial, but  the 
emergence of drug-resistant viral variants was a problem (Whitton et al., 2005). Targeting host 
cell proteins is an attractive strategy as it is thought that drug resistant mutants would be less of a 
problem than drugs which target virus proteins. A potential disadvantage of host-targeting 
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compounds is that interference with a cellular target may be associated with toxic side effects. 
Alisporivir is a compound that binds to the host factor cyclophillin, and is an example of a safe 
host-targeting antiviral agent that has successfully passed phase II clinical trials for treatment of 
HCV (van der Schaar et al., 2013). 
 Antiviral drugs targeting lipids 1.6.1
Different strategies can be used to disrupt viral infection, for example targeting one of the many 
specific lipids used in the viral replication cycle. Chemical compounds, or even antibodies, can 
be used to target lipids integrated into the viral particle, in order to inhibit enveloped virus 
replication Table 1.1 (Martin-Acebes et al., 2013). In addition, inhibitors of enzymes that 
catalyse lipid metabolic fluxes in viral infections can be used to target lipid metabolism as an 
antiviral strategy (Munger et al., 2008).  
An example of these inhibitors is statins, which are cholesterol biosynthetic pathway inhibitors. 
Statins are commonly used in the treatment of cardiovascular disease and the treatment of 
patients with different statins (i.e. lovastatin, simvastin or fluvastin) has significantly decreased 
the level of viremia, of IL-6 and TNF-alpha in the patients with chronic HCV (Mihaila et al., 
2009). A combination of statin/caffeine effectively ameliorated lung damage and inhibited viral 
replication in influenza virus (Liu et al., 2009). Lovastatin also inhibits Respiratory syncytial 
virus (RSV) infection both in cultured cells and in mice (Gower and Graham, 2001). Another 
antiviral that targets cholesterol is U18666A, which suppressed HCV replication in the replicon 
cell lines (Takano et al., 2011). Using U18666A with DENV infection retarded viral trafficking 
in the cholesterol-loaded late endosomes/lysosomes and suppressed de novo sterol biosynthesis 
in treated infected cells (Poh et al., 2012). 
Many drugs target fatty acid biosynthesis, such as 5-tetradecyloxy-2-furoic acid (TOFA). TOFA 
inhibits the biosynthesis of fatty acids acetyl-CoA carboxylase (ACC) and has been shown to 
block replication of HCMV and influenza A virus. Treatment with trans-4-carboxy-5-octyl-3-
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methylene-butyrolactone (C75), an inhibitor of FASN (the key enzyme of fatty acid biosynthetic 
pathway), also resulted in inhibition of the replication in HCMV, influenza A virus, DENV, 
yellow fever virus (YFV), WNV, HCV CVB3 and PV (Martin-Acebes et al., 2013).  
PIK93 is an inhibitor of PI4KIIIβ and has been shown to impair replication of enteroviruses (van 
der Schaar et al., 2013). Enviroxime-like compounds (e.g. T-00127-HEV1 and GW5074) are a 
group of antivirals that inhibit enterovirus replication, for which mutations conferring drug 
resistance mapped to the same region of the enteroviral protein 3A (Arita et al., 2011). However, 
a recent study has associated the antiviral activity of a representative 4-anilino quinazoline (AL-
9) with the inhibition of PI4KIIIα during HCV infection (Bianco et al., 2012).  
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Table 1.1: Summary of potential antivirus drugs which target cellular 
lipids*. 
Target lipid Inhibitor Antiviral activity against 
Cholesterol 
Statins HIV, HCV, influenza 
U18666A DENV, HCV 
Fatty acids 
TOFA HCMV, Influenza 
C75 
HCMV, DENV, YFV, WNV, 
Influenza, HCV, CVB3 
Cerulenin DENV, WNV, PV, CVB3 
Arachidonate HCV 
Oleic acid PV 
PI4P 
Enviroxime-like PV, AiV 
PIK93 PV, CVB3, CVB5 
AL-9 HCV 
Sphingolipids Myriocin Hepatitis B virus, HCV 
Multiple Valproic acid 
VACV, WNV, SFV, SINV, 
ASFV, VSV, LCMV, USUV 
*Taken from (Martin-Acebes et al., 2013). 
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Aims 
Human parechoviruses (HPeVs) are important pathogens which can cause serious diseases, but 
have been studied relatively little. They are also relatively different from better-studied human 
and animal pathogens, such as enteroviruses and FMDV, and identifying similarities and 
differences from these viruses may identify potential targets for antivirus agents which could be 
effective against many different picornaviruses. The aim of the work described in this thesis was 
to understand the changes to the host cell which occur during HPeV infection, particularly the 
secretory system which is modified by picornaviruses to generate replication complexes.  
The specific objectives were: 
To find which components of the secretory system were affected by infection and identify the 
virus proteins involved in the changes. 
To study further a previously observed interaction between HPeV 2C and lipid droplets to define 
which regions of the protein are involved. 
To investigate if drugs which target cellular lipid metabolism can inhibit HPeV infection. 
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2.1 Materials 
 Chemicals and Reagents 2.1.1
Many chemicals and other reagents were used during this project for the cell culture, virology, 
imaging and molecular biology experiments that were performed. These chemicals and reagents 
are listed here to enable other researchers to be able to identify exactly which materials were 
used.   
 Cell culture  2.1.1.1
- Dulbecco's Modified Eagle's Medium high glucose (DMEM, Sigma-Aldrich). 
- McCoy's 5A Medium (Life Technologies).  
- Opti-MEM Reduced Serum Medium (Life Technologies). 
- Phosphate buffered saline Dulbecco A tablets (PBS, Oxoid Limted). 
- MEM non-essential amino acid 100x Solution (Sigma-Aldrich).  
- Penicillin-streptomycin with 10,000 units penicillin and 10 mg streptomycin per ml 
(Sigma-Aldrich).  
- Fetal bovine serum (FBS, Sigma-Aldrich).  
- Trypsin-EDTA (0.25%) (Gibco, by Life Technologies).  
- Accutase solution (Sigma-Aldrich).  
- Dimethyl sulfoxide minimum ≥99.5% (DMSO, Sigma-Aldrich).  
- 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HEPES (Sigma-Aldrich).  
 Virology 2.1.1.2
- Carboxymethylcellulose sodium (CMC, Sigma-Aldrich).  
- Ethanol, absolute (Fisher BioReagents).  
- Crystal violet, pure, indicator (ACROS Organics). 
- Itraconazole ≥98% (TLC) (Sigma-Aldrich).  
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- Betulinic acid ≥98% (HPLC) (Sigma-Aldrich).  
- Brefeldin A from Penicillium brefeldianum, ≥99% (HPLC and TLC) (Sigma-Aldrich).  
- DGAT-1 Inhibitor, A 922500 (Sigma-Aldrich).  
 Imaging  2.1.1.3
- Triton X-100 (Sigma-Aldrich).  
- Saponin (Sigma-Aldrich).  
- Glycine (Fisher BioReagents).  
- Tween 20 (Sigma-Aldrich).  
- Albumin, from bovine serum (Sigma-Aldrich).  
- Formaldehyde, 37% by weight (Fisher Chemical).  
- Vectashield hard set, antifade mounting medium with DAPI (1.5 µg/ml) (H-1500, Vector 
laboratories).  
- Hoechst 33342, trihydrochloride, trihydrate (Invitrogen).  
- Analytical grade glycerol (Sigma-Aldrich).  
- Mowiol 488 reagent (Calbiochem). 
- Xfect protein transfection reagent (Clontech Laboratories).  
- Lipofectin reagent (Invitrogen).  
- TurboFect transfection reagent (Thermo Scientific).  
- HCS (high content screening) LipidTOX (Deep Red neutral, Invitrogen).  
- BODIPY 500/510 C4, C9 (5-butyl-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene-3-
nonanoic acid) (Life Technologies).  
- BODIPY 493/503 (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene) 
(Molecular probes).  
- Lysotracker DNA 26 (Life Technologies).  
- Mitotracker (green) (Molecular probes). 
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- All antibodies used are listed in Table 2.1. 
 Molecular biology 2.1.1.4
- Agarose (Protein Electrophoresis Grade) (Fisher BioReagents).  
- Calcium chloride dihydrate, ≥99% (CaCl2, Sigma-Aldrich).  
- Tris base (Fisher BioReagents).  
- Ethylenediamine-N, N,N’,N’,-tetraacetic acid (EDTA, Surechem Products).  
- Isopropanol (Fisher BioReagents).  
- Ampicillin sodium salt (Sigma-Aldrich).   
- Kanamycin sulfate from Streptomyces kanamyceticus (Sigma-Aldrich).  
- Water, nuclease-free (Thermo Scientific).  
- SafeView nucleic acid stain (NBS biologicals).  
- Isopropyl β-D-thiogalactopyranoside solution (IPTG, Sigma-Aldrich).  
- 5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal, Sigma-Aldrich).  
- Agar bacteriological (Oxoid Limted).  
- dNTP mix (10mM) (Fermentas Life Sciences).  
- T4 DNA ligase (5 weiss u/µl) (Thermo Scientific).   
- pEGFP-C1 vector (Chemicon).  
- pmCherry-C1 (Clontech).  
- Dimethyformamide (Sigma-Aldrich).  
- Sodium chloride (NaCl, Sigma-Aldrich).  
- Tryptone (Sigma-Aldrich).  
- Yeast extract (Sigma-Aldrich). 
- QIAprep spin miniprep kit (Qiagen).  
- HiSpeed plasmid midi Kit (Qiagen).  
- QIAquick gel extraction kit (Qiagen).   
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Table 2.1: List of antibodies and labels that were used and their types and supplier. 
Antibody/ label Type Supplier 
Anti-CAV9 450-
11G-8A-5E 
Mouse monoclonal primary antibody Millipore 
Anti-HPeV particles Rabbit polyclonal primary  antibody  
Gift from Prof. T. 
Hyypiä 
Anti-PDI* RL90 Mouse monoclonal  primary antibody abcam 
Anti-GM130* 
EP892Y 
Rabbit polyclonal primary antibody abcam 
Anti-ERGIC-53 B-9 Mouse monoclonal primary antibody 
Santa Cruz 
Biotechnology 
Anti-dsRNA J2* Mouse monoclonal primary antibody 
English & Scientific 
Consulting Kft., Hősök 
tere 2, 3044 Szirák, 
Hungary 
Alexa Fluor 405 
Goat polyclonal secondary antibody to 
mouse IgG 
Life technologies 
Alexa Fluor 405 
Goat polyclonal secondary antibody to 
rabbit IgG 
Life technologies 
Alexa Fluor 488 
Goat polyclonal secondary antibody to 
mouse IgG 
Life technologies 
Alexa Fluor 488 
Goat polyclonal secondary antibody to 
rabbit IgG 
Life technologies 
Alexa Fluor 555 
Goat polyclonal secondary antibody to 
mouse IgG 
Life technologies 
Alexa Fluor 568 
Goat polyclonal secondary antibody to 
rabbit IgG 
Life technologies 
PDI: Protein disulfide isomerase an ER marker 
GM130: cis-Golgi Marker 
dsRNA: duble strand RNA 
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- QIAamp Viral RNA Mini Kit (Qiagen).  
- Taq DNA polymerase (Thermo Scientific).  
- Pfu DNA polymerase (Thermo Scientific).  
- pGEM-T easy vector system I (Promega).  
- SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase 
(Invitrogen). 
- All restriction enzymes used are listed in Table 2.2. 
- All oligonucleotides used are listed in Table 2.3. They were custom-made by Fisher or 
Sigma and were dissolved in DNase free water to a final concentration of 100 μM. 
- All constructs encoding the protein of interest fused to a fluorescent protein are listed in 
Table 2.4 
 Solution and buffers 2.1.2
 Phosphate buffered saline buffer 2.1.2.1
Tablets of PBS (6) were added to 600 ml of deionized water (DI water) to prepare 1X PBS 
buffer, and then autoclaved. 
 HEPES buffer 2.1.2.2
To prepare a HEPES solution (500 mM), HEPES (12 g) was dissolved in 100 ml DI water and 
was adjusted to pH 7.4 with 10N NaOH. The solution then was autoclaved.   
 Carboxy methyl cellulose (CMC) 2.1.2.3
To prepare a 2% CMC solution, 2 g of CMC was dissolved in 100 ml of DI water then 
autoclaved. 
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Table 2.2: List of restriction enzymes that were used and their target  sequence and 
supplier. 
Enzyme Target and cleavage Supplier 
XhoI (10 U/µl) 
5`..C↓TCGAG..3` 
3`..GAGCT↑C..5` 
Thermo Fisher Scientific 
SalI (10 U/µl) 
5`..G↓TCGAC..3` 
3`..CAGCT↑G..5` 
Thermo Fisher Scientific 
EcoRI (10 U/µl) 
5`..G↓AATTC..3` 
3`..CTTAA↑G..5` 
Thermo Fisher Scientific 
HindIII (10 U/µl) 
5`..A↓AGCTT..3` 
3`..TTCGA↑A..5` 
Thermo Fisher Scientific 
BamHI (10 U/µl) 
5`..G↓GATCC..3` 
3`..CCTAG↑G..5` 
Thermo Fisher Scientific 
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Table 2.3: List of oligonucleotides used in this project. The oligonucleotides were used 
to make HPeV1 constructs unless stated otherwise. 





Forward 2C K146 AGGTGAGCCAGGACAAGGAGCATCTTTCTTG
ACCCACA 
Reverse 2C K146 TGTGGGTCAAGAAAGATGCTCCTTGTCCTGG
CTCACCT 
Forward 2C D188 GATAATCAGGACATTCATTTGATTGCTGACTT
GGGTCAAACAAGA 




Forward 2C GAATTCTGGACCTTTTAAAGGATTCAATG 
Forward 2C 7A AGAATTCTGAAGTTTCCACAGCATTTAGGCA
TATAGACT 
Forward 2C 25A AGAATTCTATCAAAGATATGGTTCTTAGTGTT
TTCAAACCCA 
Forward 2C 53A GAATTCTTGTAGTATCCTTGATTATGCCTC 
Forward 2C 75A GAATTCTCAAGATTTCTACCAAAGGTATTC 
Forward 2C 87A GAATTCTGCCAAGTTCAAGCCAATCATG 
Forward 2C 129A GAATTCTAGAATTGAGCCCATTGGCATTTG 
Reverse 2C C1 GTCGACGTAGAAATCTTGAGTCTTCATCTTAG 
Reverse 2C C2 GTCGACTTTTTGTAATTGTCTGGAGAGGGTG 
Forward 2C Internal CTTGACCCACACCCTCTCCAGAC 
Forward CAV92A GTGTCATAGGCATCGTAACCATGGGAG 
Reverse CAV92C AGGAGACTCTTTTCCATCAGGGTTCTG 
Forward CAV92C CAGACCCAGATCACTTTGATGGCTAC 
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Table 2.4: List of EGFP/ m-Cherryfusion constructs used. cDNA 
encoding virus proteins 2A, 2B, 2BC, 2C, 3A or 3C, from either 
HPeV1 or CAV-9, were provided within vectors encoding EGFP or 
mCherry. 2C1, 2C2 and 2C4 refer to different parts of the HPeV1 2C 
protein. Constructs encoding the cellular proteins caveolin 1 (fused to 
mCherry) or ADRP (fused to RFP) were also used. 
Construct Provided by 
pEGFP- 2A HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2B HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2C HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2BC HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 3A HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pmCherry- 3C HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pmCherry- 2C1 HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pmCherry- 2C2 HPev1 Prof. Glyn Stanway and Arsalan Salimi 
pmCherry- 2C4 HPeV1 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2BC CAV9 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2C CAV9 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 2B CAV9 Prof. Glyn Stanway and Arsalan Salimi 
pEGFP- 3A CAV9 Prof. Glyn Stanway and Arsalan Salimi 
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 Crystal violet solution 2.1.2.4
To prepare a 0.5% crystal violet solution, 0.5 g of crystal violet was added to 495 ml DI water 
and 5 ml of absolute ethanol. 
 Blocking solution  2.1.2.5
To prepare a 1% blocking solution, 0.1 g of BSA and 200 µl FBS were added to 10 ml of 1X 
PBS buffer and mixed well. 65 µl of Tween 20 was then added.  
 Fixing solution 2.1.2.6
To prepare a 4% formaldehyde fixing solution, 5 ml of 37% formaldehyde was added to 50 ml of 
1X PBS buffer. 
 Permeabilization solution 2.1.2.7
Triton X-100 (125 µl) of was added to 50 ml of 1X PBS buffer and 65 µl of Tween 20 to give a 
final concentration of Triton of 0.25%. In the case of lipid staining, a 0.1% solution of saponin 
was made, by adding 0.1 g of saponin to 100 ml of 1X PBS. 
 Antibody diluent solution 2.1.2.8
Bovine serum albumin (BSA, 0.1 g) was added to 10 ml 1X PBS buffer and 65 µl Tween 20. 
 Glycine washing solution 2.1.2.9
Glycine (0.375 g) was added to 50 ml 1X PBS and mixed well until it dissolved.                                       
 DNA electrophoresis buffer (ELFO) 2.1.2.10
For a 50X ELFO stock, 242 g of Tris and 100 ml of 0.5 M EDTA (pH 8.0) were added to 
approximately 600 ml of DI water. The pH was adjusted to 7.7 with glacial acetic acid then the 
solution was made up to 1 l. 1X ELFO was used to make agarose gels and running buffer and 
was made by diluting the 50X stock. 
 Clear loading dye for agarose gels    2.1.2.11
Glycerol (50 ml) was added to 200 µl of 0.5 M EDTA (pH 8.0) and 49.8 ml DI water. 
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 Mowiol mounting medium  2.1.2.12
Analytical grade glycerol (6 g) and Mowiol (2.4 g) were added to 6 ml distilled water and stirred 
with a clean stir bar, then 12 ml of 2 M Tris buffer (pH 8.5) were added and incubated in a water 
bath at 50-60oC for 10 minutes until the Mowiol powder went into solution.  The solution was 
centrifuged at 4000 rpm for 15 minutes to pellet any undissolved Mowiol and the supernatant 
was carefully removed without disturbing the pellet. The supernatant was aliquoted into 1.5 ml 
centrifuge tubes, covered with aluminium foil and stored at -20oC. 
 Isopropyl β-D-thiogalactopyranoside (IPTG) solution 2.1.2.13
IPTG (1.2 g) was added to 50 ml DI water then the solution was filter-sterilized, aliquoted into 
1.5 ml centrifuge tubes and stored at -20oC. 
 5-Bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-Gal) 2.1.2.14
solution 
X-Gal (100 mg) was dissolved in 2 ml dimethyl-formamide. The tube was covered with 
aluminium foil and was stored at -20oC.  
 Luria-Bertani Broth (LB Broth) 2.1.2.15
LB Broth powder (20 g) was dissolved in 1 l distilled water. The solution was adjusted to pH 7.0 
with 5 M NaOH then autoclaved.  
 Luria-Bertani Agar  2.1.2.16
Agar (1.48 g) was dissolved in 100 ml of LB broth and was autoclaved. To produce antibiotic 
plates, the agar was melted in a boiling water bath, allowed to cool to 50oC and stock 
ampicillin or kanamycin solutions were added to give a final concentration of 100 µg/ml and 50 
µg/ml respectively. 
 Cell lines and viruses  2.1.3
African green monkey kidney epithelial (GMK) and human prostate cancer (PC3) cells were 
provided by Prof. Glyn Stanway. The human colon adenocarcinoma cell line (HT29) was 
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provided by Dr Ralf Zwacka. Human parechovirus (HPeV1), Harris strain, was recovered from 
the cDNA clone pHPeV1 (Nateri et al., 2000). Coxsackievirus A9 (CAV9), Griggs strain, was 
recovered from the cDNA clone pCAV9 (Hughes et al., 1995).  
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2.2 Methods 
 Cell Culture 2.2.1
 Passaging/Splitting Cells  2.2.1.1
Cells were observed using a microscope to ensure they were confluent and healthy. The old-
medium was discarded and cells washed twice with 1X PBS for 2 minutes. Then 500 μl of 0.25% 
trypsin-EDTA was added and the flask was placed on a rocking platform for 5 minutes. The flask 
was tapped and checked under the microscope to ensure cells detached. DMEM (20 ml containing 
10% FBS, 1% MEM non-essential amino acid and 1% Penicillin-Streptomycin) was added to the 
flask and the cell suspension was divided into 4 new 50 ml flasks (25 cm2). These were incubated 
in a 5% CO2 incubator at 37oC. Cells were passaged weekly. 
 Cell line storage  2.2.1.2
Old medium of a confluent cell line was discarded and the cells were washed twice with 1X PBS. 
Trypsin-EDTA (500 μl of a 0.25% solution) was added and the flask was placed on a rocking 
platform for 5 minutes. The flask was tapped to detach the cell and 1 ml of FBS was added and 
mixed. A 1 ml aliquot of the mixture was placed in a cryo tube and 111 μl of DMSO was added. 
The tube was placed in an insulated container, to ensure slow freezing, for three day at -80oC, then 
stored at -80oC.  
To recover the cells, the tube was thawed and the cell suspension was transferred to a flask 
containing 4 ml of new medium and 500 μl FBS and incubated in a 5% CO2 incubator at 37oC. 
The medium was changed next day and the cells observed until they became confluent. The cells 
were then propagated as described in section 2.2.1.1. 
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 Molecular biology 2.2.2
 Double digestion   2.2.2.1
The two restriction enzymes (2 μl of each) were added to 5 μl of suitable buffer (one where 
enzymes cut efficiently). DNA (5 μl, 1 µg) and DNase free water (36 μl) were added and 
incubated for one hour at 37oC. The reaction were separated on a 1% agarose gel and the correct 
band was cut from the gel and extracted using a Qiaquick gel extraction kit gel (QIAGEN). 
 Agarose gels 2.2.2.2
Agarose gel electrophoresis was used to size DNA fragments and purify them. Agarose powder 
(0.5 g) was added to 50 ml of 1X ELFO buffer and melted in a microwave until the agarose 
completely dissolved and the solution become clear. The agarose solution was allowed to cool 
down for 5 minutes then SafeView (2 μl) was added just before pouring into the casting tray. The 
gel tray had a comb to form the walls. After the gel had set it was placed in the electrophoresis 
unit which was filled with enough 1X ELFO to cover it. The comb was removed and 5 μl (for 
analysis or 50 μl for purification) of each sample was loaded onto the gel. The gel was run at 80-
150V for 10-15 minutes and the DNA was observed using a blue light LED transilluminator. A 
scalpel was used to cut out bands from agarose gels and purify the DNA for cloning.   
 Gel extraction 2.2.2.3
Extraction of DNA from agarose gel slices was performed using a QIAquick gel extraction kit 
according to the manufacturer instructions. Buffer QG (300 µl) was added to a slice of agarose gel 
containing the DNA in a 1.5 ml  microcentrifuge tube and was incubated at 50oC for 10 minutes. 
The tube was vortexed every 2-3 minutes until the gel slice completely dissolved. Isopropanol 
(100 µl) was added to the tube and was mixed, then the solution was transferred to the QIAquick 
column and was centrifuged for one minute at 13000 rpm. The flow-through was discarded and 
the QIAquick column placed back into the same tube. For washing 750 µl of buffer PE was added 
and was re-centrifuged and the flow-through was discarded. The QIAquick column was placed 
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into a clean 1.5 ml microcentrifuge tube and 50 µl of buffer EB was added to elute the DNA. The 
column was left for one minute and was then centrifuged at 13000 rpm for one minute. The tube 
was labelled and stored at -80oC. 
 Ligation of DNA fragments using T4 DNA ligase 2.2.2.4
In a 1.5 ml microcentrifuge tube on ice, 2 µl of T4 ligase buffer, 1 µl of T4 DNA ligase, 3 µl of 
the vector (50 ng pmCherry-C1/ pEGFP-C1/ pGEM-T easy), up to 9 µl of insert DNA (1:3 molar 
ratio of vector to insert) and DNase-free water  to the final volume 50 µl were mixed gently by 
pipetting. The mixture was incubated overnight in4oC then a 5 µl aliquot of the mixture was used 
for transformation. 
 Competent cells 2.2.2.5
A frozen stock of Top10 E.coli was streaked out onto an LB plate without antibiotics and 
incubated overnight at 37oC. A single colony was picked and was grown in 10 ml of LB broth 
overnight in a shaking incubator at 37oC.  
An aliquot (200 μl) of the overnight culture was added to 10 ml LB broth Top10 and grown for 2 
hours in a shaking incubator at 37oC. The cells were centrifuged for 10 minutes at 4,000 rpm and 
the supernatant was discarded and resuspended in 5 ml ice-cold 0.1 M CaCl2 for 30 minutes. Then 
the cells were recentrifuged, the supernatant was discarded and resuspended in 500 μl ice-cold 
CaCl2 for an hour. At this point the competent cells were ready to use in transformation. 
 Transformation 2.2.2.6
An aliquot (5 µl) of the transforming DNA construct was added to 100 µl of competent cells in a 
1.5 ml microcentrifuge tube on ice and was incubated for 30 minutes. Then the tube was 
incubated in a water bath at 42oC for one minute (heat shock) and then was placed back in ice for 
2 minutes. LB broth (250 µl) was added and incubated for one hour at 37oC in a shaking 
incubator. A 100 µl aliquot of the mixture was spread on LB plates (with appropriate antibiotic 
added, 100 μg/ml ampicillin or 50 μg/ml kanamycin).  
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 Purification of DNA using QIAprep miniprep kit 2.2.2.7
A single colony was picked from the transformation plate and was incubated in 10 ml LB medium 
with antibiotic overnight in a 37oC shaking incubator. Then it was centrifuged at 3000 rpm for 10 
minutes and the pellet was resuspended in 250 µl of buffer P1 and was transferred to a 1.5 ml  
microcentrifuge tube. Buffer P2 (250µl) was added and the tube was inverted 4-6 times to mix. 
Buffer N3 (350 µl) was added and the tube was inverted immediately 4-6 times, then centrifuged 
for 10 minutes at 13000 rpm. The supernatant was applied to a QIAprep column in a 1.5 ml 
microcentrifuge tube and re-centrifuged for 60 seconds and the flow-through was discarded. The 
QIAprep spin column was washed with 750 µl of PE buffer and centrifuged for 60 seconds. The 
flow-through was discarded and the column re-centrifuged for 60 seconds to remove residual 
wash buffer. The QIAprep column was placed in a clean 1.5 ml microcentrifuge tube and the 
DNA was eluted by adding 50 µl of buffer EB and after one minute was centrifuged for one 
minute. The purified DNA was stored at -80oC. 
 Purification of DNA using a Qiagen HiSpeed plasmid midi kit 2.2.2.8
A single colony was picked from a plate and was incubated in 10 ml LB medium containing the 
appropriate selective antibiotic for 6 hours at 37oC in a shaking incubator. The culture was 
transferred to 200 ml LB medium containing the appropriate selective antibiotic and was 
incubated overnight. The bacterial cells were harvested by centrifugation at 6000 rpm for 15 
minutes at 4oC and the supernatant was discarded and the pellet was resuspended in 6 ml of 
buffer P1 by vortexing until no cell clumps remain. Buffer P2 (6 ml) was added and mixed 
thoroughly by vigorously inverting the sealed tube 4–6 times and incubated at room temperature 
for 5 minutes. During the incubation the cap was screwed onto the outlet nozzle of the QIAfilter 
Midi cartridge. Buffer P3 (6 ml) was added, mixed immediately then the sample was poured into 
the barrel of a QIAfilter cartridge and was incubated at room temperature for 10 minutes. During 
the incubation a HISpeed column was equilibrated with 4 ml buffer QBT and the column was 
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allowed to empty by gravity flow. The cap was removed from the QIAfilter outlet nozzle and the 
plunger was gently inserted into the cartridge. The lysate was then filtered into the HISpeed tip. 
The HISpeed tip was washed with 20 ml buffer QC and the DNA was eluted with 5 ml buffer QF 
and was precipitated by adding 3.5 ml isopropanol and incubating for 5 minutes. During the 
incubation the plunger from a 20 ml syringe was removed and attached to the QIAprecipitator 
Midi Module. The QIAprecipitator was placed over a waste bottle and the eluate/isopropanol 
mixture was transfered into the 20 ml syringe then the plunger was inserted. By using constant 
pressure the eluate/isopropanol mixture was filtered through the QIAprecipitator. The 
QIAprecipitator was removed from the 20 ml syringe and the plunger was pulled out, then it was 
re-attached and 2 ml of 70% ethanol was added to wash the DNA. The QIAprecipitator was 
removed from the 20 ml syringe and the plunger pulled out and reattached again and the 
membrane was dried by pressing air through the QIAprecipitator quickly and forcefully. The 
outlet nozzle of the QIAprecipitator was dried with absorbent paper to prevent ethanol carryover. 
The plunger from a new 5 ml syringe was removed and attached to the QIAprecipitator onto the 
outlet nozzle. Over a 1.5 ml microcentrifuge tube 1 ml of buffer TE was added to the 5 ml syringe 
and the plunger was inserted and the DNA was eluted into a 1.5 ml  microcentrifuge tube. The 
DNA was stored at -80oC. 
 Polymerase chain reaction (PCR) 2.2.2.9
For each 50 µl PCR reaction 1 μl of DNA template (10 ng), 1 μl of each forward and reverse 
primer (at a concentration of 100 µM), 5 μl MgSO4 buffer (final concentration 2 mM), 1 μl dNTP 
(final concentration 0.2 mM), 1 μl of pfu DNA polymerase and 40 μl DNase free water were 
placed in PCR machine. The thermocycling profile of the PCR reaction consisted of an initial 
denaturation step at 95oC for 5 minutes, followed by 35 cycles of denaturation (95oC for one 
minute), annealing (45oC - 55oC for one minute) and extension (72oC for 1-3 minutes). A final 
extension step of 72oC for 5 minutes was included to complete the PCR (Figure 2.1). In the final 
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stage, 2 μl  of Taq DNA polymerase was added for 15 min at 72oC to add an A residue to the 3’ 
terminus of the PCR product, so it can be ligated to pGEM-T-Easy. The reaction products were 
run on a 1% (w/v) agarose gel and extracted using Qiaquick Gel extraction kit gel.  
Single mutations were achieved by performing PCR with a pair of overlapping oligonucleotide 
primers that include a mutation in their sequence together with two other primers. As a result, two 
fragments were produced. These fragments were fused together by overlapping PCR (Figure 2.2). 
 Ligation using the pGEM-T Easy vector  2.2.2.10
The purified PCR product were ligated into the pGEM-T Easy cloning vector using the reagent 
provided by the manufacturers. A 10 μl final reaction volume consisted of 1 μl (50 ng) of pGEM-
T Easy DNA, 2 μl of the purified PCR product (20-50 ng), 1 μl T4 DNA ligase, 5 μl of 2x rapid 
ligation buffer and 1 µl DI water. The reaction was mixed and incubated at room temperature for 
one hour. 
 Transformation using the pGEM-T Easy vector  2.2.2.11
An aliquot of the pGEM-T Easy ligation reaction (5 µl) was added to 100 µl of competent cells in 
a 1.5 ml microcentrifuge tube on ice and was incubated for 30 minutes. Then the tube was 
incubated in a water bath at 42oC for one minute (heat shock) and then was placed back in ice for 
2 minutes. LB broth (250 µl) was added and incubated for one hour at 37oC in a shaking 
incubator. An aliquot (100 µl) of the mixture was spread on LB plates containing 100 μg/ml 
ampicillin, 100 mM IPTG and 50 mg/ml X-Gal. The plates were incubated overnight and 3-5 
white colonies were picked for DNA purification or colony PCR. 
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Hold 1 Hold 2 35 Cycles 
Denaturation Annealing Extension 
FIGURE 2.1: Schematic diagram of the PCR reaction using pfu polymerase. An 
initial denaturation step at 95oC for 5 minutes to activate the polymerase enzyme was 
followed by 35 cycles of denaturation (94oC for one minute), annealing (45oC - 55oC for 
one minute) and extension (72oC for 2 minutes). A final extension step of 72oC for 5 
minutes was included to complete the PCR. The annealing temperature depends on the 
melting temperature of the primers and the length of the 72C extension may vary based 
on the length of the amplified DNA fragment. 
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FIGURE 2.2: Schematic diagram of overlap PCR. Designed overlapping oligonucleotide 
primers (Forward and Reverse primers) include a mutation in their sequence. Two separate PCR 
reactions are performed. One has Forward primer + Reverse mutagenesis primer (A) and other 
has Forward mutagenesis primer + Reverse primer (B). As a result two fragments are produced. 
These fragments are fused together by overlapping PCR. A and B are combined and are melted 
and annealed in the first cycle of the second PCR. One of the results is an overlap between the 
top strand of product A and the bottom strand of product B. The overlap region acts as primers 
which can be extended to complete the dsDNA and ″fuse″ the two products, containing the 
mutation (*). The PCR reaction contains Forward and Reverse primers which lead to the 
amplification of the correct product during the rest of the PCR reaction. 
2nd PCR 
Site of desired single mutation 
* 
Forward primer Reverse mutagenesis primer 







Combine A and B. Melt and anneal. 
* 
* 
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 Colony PCR  2.2.2.12
Colony PCR was used as a preliminary screen to identify colonies transformed with the correctly 
constructed DNA. In a PCR tube, 5 μl of 10x reaction buffer, 3 μl MgCl2 (final concentration 2.5 
mM), 1 μl dNTPs (final concentration 0.2 mM), 1 μl of each desired primer (100 µM), 0.5 μl 
DNA Taq polymerase and 38 μl of DNase free water were mixed. One colony was touched with a 
yellow tips and swirled in the PCR mixture which was then placed in the PCR machine. The 
thermocycling profile of the PCR reaction consisted of an initial denaturation step at 95oC for 2 
minute, followed by 30 cycles of denaturation (94oC for one minute), annealing (50oC for one 
minute) and extension (72oC for 2 minutes). A final extension step of 72oC for 5 minutes was 
included to complete the PCR (Figure 2.3).   
 Purification of viral RNA using a QIAamp Viral RNA Mini 2.2.2.13
Kit 
Buffer AVL (560 µl) containing carrier RNA was pipetted into a 1.5 ml microcentrifuge tube and 
140 µl supernatant of virus-infected cells was added. The tube was mixed by pulse-vortexing for 
15 seconds and was incubated at room temperature for 10 minutes. The tube was briefly 
centrifuged to remove drops from the inside of the lid and 560 µl of ethanol (96–100%) was 
added, mixed by pulse-vortexing for 15 seconds and was briefly centrifuged. Half of the solution 
(630 µl) was added to the QIAamp Mini column and centrifuged for 1 minute at 8000 rpm. The 
QIAamp Mini column was placed into a clean 2 ml collection tube and another 630 µl of the 
solution was added and recentrifuged. Buffer AW1 500 µl) was added to the QIAamp Mini 
column and centrifuged for 1 minute at 8000 rpm. The QIAamp Mini column was placed in a 
clean 2 ml collection tube, 500 µl of  buffer AW2 was added and the column was centrifuged for 
3 minutes at 14,000 rpm. The QIAamp Mini column was placed in a clean 1.5 ml microcentrifuge 
tube and 60 µl of buffer AVE was added and centrifuged for 1 minute at 8000 rpm to elute the 
DNA. The DNA was stored at -80C.  
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Hold 1 Hold 2 30 Cycles 
Denaturation Annealing Extension 
FIGURE 2.3: Schematic diagram of the Colony PCR reaction. An initial denaturation 
step at 95C for 2 minutes, was followed by 30 cycles of denaturation (94C for one 
minute), annealing at 50C for one minute and extension 72C for 2 minutes. A final 
extension step of 72C for 5 minutes was included to complete the PCR.   
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 Reverse transcription-PCR (RT-PCR) 2.2.2.14
Per 50 µl PCR reaction 5 μl of RNA, 1 μl of forward and reverse primers (100 µM), 25 μl 
reaction mix, 1 μl RT/Taq and 17 μl DNase free water were mixed and placed in a PCR machine. 
The machine was programed to give an initial RT step of 30 minutes. The thermocycling profile 
of the PCR reaction consisted of an initial denaturation step at 94C for 2 minutes, followed by 
35 cycles of denaturation (94C for 30 seconds), annealing (45C for one minute) and extension 
(68C for 2 minutes). A final extension step of (68C for 5 minutes) was included to complete 
the PCR. The reaction products were run on a 1% (w/v) agarose gel and extracted using 
Qiaquick Gel extraction kit gel. The products were sequenced, using the same primers used for 
RT-PCR, by Source Bioscience. 
 Virus propagation and plaque assays 2.2.3
 Propagation of Viruses 2.2.3.1
Confluent cells in a flask were infected by adding 10 μl of stock virus to the medium and were 
placed on a rocking platform for 45 minutes then incubated at 37oC for 2-3 days. The flask was 
frozen and thawed three times then the supernatant stored at -80oC in 500 µl aliquots in 1.5 ml 
microcentrifuge tubes. 
 Plaque assay  2.2.3.2
The medium from a confluent monolayer of cells was removed and replaced with 1 ml of fresh 
medium. Serial 10-fold dilutions of CAV9 and HPeV1 virus were made (102, 103 and 104) using 
DMEM medium. Aliquots (100 µl) of each dilution was added to the cell monolayer in a 25 cm2 
flask or a 6 well plate and the flask or plate was placed on a rocking platform for 45 minutes at 
room temperature. CMC solution (2%) was melted in a microwave, added to medium (1 ml 
CMC : 2 ml medium) and incubated in a water bath 45oC to keep it liquid. Part of the mixture (4 
ml) was added to the flask (or 2 ml to each well of a 6 well plate), mixed and kept at room 
temperature until set. The flask or plate was incubated at 37oC for 4-5 days. The flask or plate 
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was washed with 1 ml of 1X PBS then cells were stained with 0.1% crystal violet for 10 minutes. 
Finally, cells were washed with 1X PBS. 
 Drugs and generation of mutants resistant to drugs 2.2.4
 Drugs and inhibitors screening study 2.2.4.1
Confluent cells at the time of infection in 6 well plates were used. Different serial concentration 
of drugs or inhibitors in culture medium were prepared and incubated with cells for 30 minutes 
before infection. Cells were infected with CAV9 or HPeV1 (MOI 10) and the plate was placed 
on a rocking platform for 45 minutes then incubated at 37°C for 36 or 42 hours. The cells were 
frozen and thawed three times and stored at -80°C. A plaque assay were applied to quantify the 
level of virus. In other experiments, cells were pre-treated with the drugs and then plaque assays 
were performed as described 2.2.3.2.   
 Generation of mutants resistant to drugs and inhibitors 2.2.4.2
An attempt was made to generate drug-resistant mutants by passaging virus on cells line in the 
presence of the drugs or inhibitors. For each round of passaging, cells in 6 well plates were 
infected with (10 µl of previous passaging for HPeV1 and 100 µl of a 102 dilution of CAV9) in 
the presence of increasing concentrations of drugs or inhibitors. In the first round of infection 0.1 
MOI was used. Viral RNAs from passage 6 were extracted from the culture supernatants using a 
QIAamp viral RNA minikit. The RNAs were subjected to amplification using SuperScript III 
one-step reverse transcription-PCR (RTPCR) kits.  
 Time-of-addition assay 2.2.4.3
A time-of-addition assay was performed to study the mechanism of drugs and inhibitors. Cells 
were seeded in a 6 well plate 24 hours before the experiment. Old medium was removed and 0.5 
ml of fresh medium was added. The drugs or inhibitor was added to one well which was the zero 
time point, and incubated for 30 minutes. All the cells were infected with virus and the plate 
were placed on a rocking platform for 45 minutes. The drugs or inhibitors were added at 1, 3, 5 
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and 8 hours post- infection. The plate was incubated at 37C incubators for (36 hours for CAV9 
and 42 hours for HPeV1). The plate was frozen-then-thawed three times and a plaque assay was 
applied. 
 Immunofluorescence 2.2.5
 Detection of infected cells and lipid staining 2.2.5.1
A suspension of GMK or HT29 cells (2 ml) was seeded into each well of a 6 well plate 
containing a glass coverslip 24 hours before the experiment. After 24 hours, 1.5 ml of the 
medium was removed and cells were infected with 100 μl CAV9 or HPeV1 (MOI 10) and were 
placed on a rocking platform for 45 minutes then incubated for 8 hours at 37C. Cells were fixed 
with 4% formalin for 20 minutes at room temperature and were washed with glycine washing 
solution for 5 minutes and permeabilized with Saponin 0.1% for 20 minutes. They were washed 
with PBS for 10 minutes and blocked with blocking solution for 30 minutes, then washed with 
PBS for 10 minutes. Primary antibodies to CAV9 or HPeV-1 (50 µl of a 1:100 dilution of 
primary antibody) was placed onto the coverslip, covered by parafilm and kept overnight at 4oC. 
Secondary antibody (50 µl of a 1:200 dilution of secondary antibody) was added and incubated 
for 2 hours at 4oC, then the cells were washed with PBS for 10 minutes. For lipid staining, cells 
were incubated with BODIPY 493/503 for 10 min then cells were washed twice with PBS. The 
coverslips were mounted with hard set mounting medium containing DAPI (1.5 µg/ml).  
 Detection of infected cells and fatty acids staining 2.2.5.2
Cells were seeded to 6 well plates containing glass coverslips 24 hours before the experiment as 
described in section 2.2.4.1. Cells were washed with DMEM serum-free medium and infected 
with 50 µl of virus in serum-free medium with 50 mM HEPES. The plate was placed on a 
rocking platform for 30 minutes then incubated in a 37oC incubator. After 2, 6, or 8 hours, in one 
well was the medium was replaced with fresh pre-warmed medium containing 0.4 µM BODIPY 
500/510 for 30 minutes. Cells were fixed with 4% formalin for 20 minutes at room temperature 
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and were washed with glycine washing solution for 5 minutes and permeabilized with Saponin 
0.1% for 20 min. They were washed with PBS for 10 minutes, blocked by blocking solution for 
30 minutes and washed in PBS for 10 minutes. Antibody staining was carried out as described in 
section 2.2.5.1.  
 Transfection of fluorescent constructs 2.2.5.3
Three different transfection reagents were used to study the distribution of the florescent protein 
functions and gave similar transfection rates. 
2.2.5.3.1 Xfect protein transfection reagent 
In a 1.5 ml microcentrifuge tube 5 µl (5 µg) of the constructs was added to 100 µl Xfect reaction 
buffer and mixed. Xfect Polymer (1.5 μl) was added the reaction and incubated for 10 minutes at 
room temperature.  The tube was centrifuged briefly to collect the contents at the bottom of the 
tube. The solution was added to 50–70% confluent cells at the time of transfection in wells of a 6 
well plate containing glass coverslips and placed on a rocking platform for 5 minutes then 
incubated at 37oC incubator for 4 hours. The solution were replaced with 2 ml fresh DMEM 
medium, and the plate was returned to the 37oC incubator until the time of analysis. If live cells 
were visualized, cells were stained with 0.5 μl Hoechst 33342 per 1 ml of warm DMEM medium 
and incubated at 37°C for 20 minutes then washed twice with 1X PBS and coverslips were 
mounted using Mowiol mounting medium. If fixed cells were visualized, the cells were fixed 
with 4% formalin for 20 minutes at room temperature and were washed with glycine washing 
solution for 5 minutes. The coverslips were mounted with hard set mounting medium with DAPI 
(1.5 µg/ml). 
2.2.5.3.2 Lipofectin® transfection reagent 
Opti-MEM reduced serum medium (100 μl) was added to two 1.5 ml microcentrifuge tubes (tube 
A and tube B). In tube A 1-2 μg of the construct were added and in tube B 2-20 µl of 
Lipofectin® reagent was added. Both tubes were incubated for one hour at room temperature 
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then the contents of tube B were combined with tube A, mixed gently and incubated for 20 
minutes at room temperature. During the incubation, 50–70% confluent cells, at the time of 
transfection, in a 6 well plate containing glass coverslips were washed once with Opti-MEM 
reduced-serum medium. Opti-MEM reduced-serum medium (800 μl) was added to the tube A+B 
and the whole sample transferred to one of the wells. The plate was incubated at 37°C for 24 
hours then the medium was replaced with 2 ml DMEM medium and was incubated for another 
24 hours until time of analysis. Cell visualizing was carried out as described in section 2.2.5.3.1. 
2.2.5.3.3 TurboFect transfection reagent 
In a 1.5 ml microcentrifuge tube 1 µg of the construct was added to Opti-MEM reduced serum 
medium (100 µl), 2 μl of TurboFect transfection reagent was added and the tube was mixed. The 
tube was incubated for 20 minutes at room temperature. The mixture was added to 900 μl of 
medium. 50–70% confluent cells, at the time of transfection, in a 6 well plate containing glass 
coverslips were covered with the mixture. The plate was placed on a rocking platform for 5 
minutes and was then incubated in a 37°C incubator for 24-48 hours. Cells were fixed with 4% 
formalin for 20 minutes at room temperature and were washed with glycine washing solution for 
5 minutes. The coverslips were mounted with hard set mounting medium with DAPI (1.5 µg/ml). 
 Confocal microscope 2.2.5.4
To record several probes in a single specimen, multichannel fluorescence microscopy using 
multiple fluorochromes of different excitation and emission wavelengths were used (Landmann, 
2002). 
Cells were visualized using a Nikon A1si confocal microscope used with a plan apochromatic 
VC1.4 N.A. 60x magnifying oil-immersion objective. Images were acquired in three channels, 
using one-way sequential line scans. The emission for DAPI was collected at 450/50 nm with a 
PMT gain of 118 and the excitation at 400 nm with laser power 7.2 arbitrary units. GFP was 
excited at 488 nm with laser power 5.8 and the emission was collected at 525/50 nm with a PMT 
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gain of 90. mCherry was excited at 560 nm with laser power 3.2, and collected at 595/50 nm 
with a PMT gain of 121. The pinhole size was 47.5 μm, approximating 1.2 times the Airy disk 
size of the 1.4 N.A. objective at 525 nm. Scan speed was ¼ frames/s (galvano scanner). Scanner 
zoom was centred on the optical axis and set to a lateral magnification of 60 nm/pixel. Axial step 
size was 105 nm, with 80-100 image planes per z-stack. Identical settings were used for all 
acquired datasets, Following Nyquist–Shannon reconstruction theorem (Nyquist, 1928; Shannon, 
1949). 
A minimum of 4 cells were imaged for each experiment, taken from 10 fields-of-view. For 
localisation studies, each experiment was repeated at least twice and representative images have 
been chosen.  For 2C mutants, three dimensional (3D) images were acquired in three channels, 
using one-way sequential line scans. In some images, the DAPI stain was faint or lost due to 
technical problem with the DAPI filter of the confocal microscope. 
Colocalisation experiments are based on the detection of the spatial overlap of one fluorescently-
labelled molecule e.g. a protein, with another molecule tagged with a fluorophore emitting at a 
different wavelength. There are two ways to assess colocalization between fluorescence channels 
(Dunn et al., 2011; Adler and Parmryd, 2010). The co-occurrence method simply considers the 
presence of both fluorophore signals in individual pixels.  For a more quantitative analysis of 
colocalisation, there are statistical methods to determine the overlap globally, including the use 
of advanced intensity-based correlation coefficients (Obara et al., 2013). 
In the work described in this thesis, colocalisation was usually assessed qualitatively, using 
overlaid images from green and red channels, which show overlapping regions as yellow, 
allowing colocalisation to be inferred. In several cases, including all the analysis of the HPeV1 
2C mutants, colocalization was characterized more quantitatively by calculating the Pearson’s 
correlation coefficient, using NIS-Elements AR 4.13.01 (Build 916) software to analyse the 
degree of colocalization. 
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 Computer analysis 2.2.6
NIS-Elements AR 4.13.01(Build 916) software was used for image acquisition. EXCEL 2010 
from Microsoft was used to analyse data and graphs. ExPASy - Translate tool 
https://www.expasy.org/translate/ and Multiple Sequence Alignment by CLUSTALW 
http://www.genome.jp/tools/clustalw/ were used to analyse the sequencing results. NetWheels 
(http://lbqp.unb.br/NetWheels/) was used to produce helical wheel projections of potential 
amphipathic helices. 
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 CHAPTER THREE 3
EFFECT OF HPeV INFECTION AND 
HPeV PROTEINS ON THE 
SECRETORY SYSTEM 
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3.1 Introduction 
In mammalian cells, there is extensive trafficking of proteins and lipids between intracellular 
compartments (Watson and Stephens, 2005). The early secretory pathway consists of the 
endoplasmic reticulum (ER), the ER–Golgi intermediate compartment (ERGIC) and the Golgi as 
well as the transport vesicles that shuttle between them (Midgley et al., 2013). The ER is the first 
compartment and is the largest organelle in a cell. It is a highly dynamic membrane system and 
is the major site of many processes such as protein synthesis and transport, protein folding, lipid 
and steroid synthesis, carbohydrate metabolism and calcium storage (Romero-Brey and 
Bartenschlager, 2016). The ERGIC is the second compartment and is the initial site of protein 
sorting. The Golgi is important for sorting and packaging of macromolecules for delivery to 
endosomes, the plasma membrane or the cell exterior (Barlowe and Helenius, 2016).  
Vesicles carry cargos through the early secretory pathway and their formation is dependent on 
the function of two membrane coat complexes, COPI and COPII, and requires the GTPase Sar1, 
Arf1 and Rab proteins. Cargo traffic from the ER to Golgi (anterograde) through the ERGIC is 
due to COPII-coated vesicles, which form at ER exitsite (ERESs), then COPI-coated vesicles 
(Gazina et al., 2002; Sharp et al., 2010). 
COPI-coated vesicles are also involved in retrograde trafficking from the ERGIC and Golgi to 
the ER. COPI coat formation requires the GTPase ADP-ribosylation factor 1 (Arf1) which is 
activated on the Golgi by two related GEFs called GBF1 and BIGs (Sharp et al., 2010). Rab 
proteins also regulate the secretory pathway and are involved in vesicle formation, transport, 
tethering, docking and membrane fusion (Gazina et al., 2002; Midgley et al., 2013).  
Lysosomes are organelles found in the cytoplasm of most cells. Lysosomes degrade 
macromolecules or infecting pathogens from the secretory, endocytic, autophagic, and 
phagocytic membrane-trafficking pathways, which are essential for innate immunity recognition, 
antigen presentation, and pathogen elimination (Ju et al., 2015; Luzio et al., 2007).  
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Mitochondria are involved in many cellular metabolic processes including ATP production, 
calcium homeostasis, cell proliferation, programmed cell death, and the synthesis of amino acids, 
nucleotides, and lipids. Mitochondria play a central role in host antiviral responses, and a number 
of viral proteins localise in mitochondria and interact with mitochondrial proteins (Ohta and 
Nishiyama, 2011). 
Peroxisomes are found in almost all eukaryotic cells and are surround by a single membrane 
(Baker et al., 2015).  Functionally and morphologically, peroxisomes are complex organelles 
that play a central role in diverse metabolic processes and interact with other organelles such as 
the ER, mitochondria and lipid droplets. One important function of peroxisomes is β-oxidation 
where a very long fatty acid chain and dicarboxylic acids is degraded (Baker et al., 2015; 
Odendall and Kagan, 2013). 
In positive-strand RNA viruses, RNA synthesis involves cytoplasmic membranes, but different 
cellular membranes can be used by different viruses. The ER, trans-Golgi, endosomes, 
mitochondria or lysosomes are known as sources for virally induced membranes (Suhy et al., 
2000). These membrane structures are used for several reasons, such as concentrating 
components needed for virus replication, providing a scaffold to anchor replication complexes, 
hiding dsRNA and so avoiding host defence mechanisms which respond to dsRNA, tethering 
viral RNA during unwinding and providing lipids needed for genome synthesis (Miller and 
Krijnse-Locker, 2008; Sasaki et al., 2012). Hepatitis E virus may utilize modified early secretory 
pathway membranes for replication (Perttilä et al., 2013). Dengue virus non-structural protein 
NS4A rearranges the ER membrane, leading to the formation of vesicle packets and convoluted 
membranes (Inoue and Tsai, 2013). 
Remodelling of the secretory system seems to depend on different non-structural proteins in 
different viruses. 2B, 2BC, or 3A (but not 2C) of PV disrupt protein trafficking and cell surface 
protein expression. Expression of 2B and 2C or of the 2BC precursor (but not 3A) is sufficient to 
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inhibit trafficking between the ER and Golgi in FDMV (Sweeney et al., 2010). In FMDV-
infected cells, the ER remained largely intact but the Golgi and ERGIC was disrupted (Midgley 
et al., 2013).  
Not much is known about the effect of HPeV infection on the secretory system. It has been 
reported that none of the HPeV1 non-structural proteins studied was able, alone or when  
combined, to induce changes in the intracellular morphology similar to those seen in HPeV 
infected cells (Krogerus et al. 2007). The individual distribution of the proteins was also not 
affected when they combined. 
The effects of picornavirus infection on structure such as the mitochondria, lysosome and 
peroxisomes have not been studied extensively. In this study we looked at the effect of human 
parechovirus infection on the secretory system and re-investigated the role of the non-structural 
proteins in these effects as well as the effects on mitochondria, lysosome and peroxisomes.
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3.2 The effect of HPeV1 infection on the 
secretory pathway 
We studied the effect of HPeVI infection on the ER, ERGIC, and Golgi using antibodies against 
dsRNA (mouse monoclonal) or HPeV1 (rabbit polyclonal) to identify infected cells. Antibodies 
against the marker proteins PDI (ER marker, mouse monoclonal antibody), ERGIC-53 (ERGIC 
marker, mouse monoclonal antibody) and GM130 (cis Golgi marker, rabbit polyclonal antibody) 
were used to mark the compartments. Confluent HT29 cells at the time of infection were 
prepared in 6 well plates containing glass coverslips. The cells were infected with HPeV1 (MOI 
10) for 8 hours at 37˚C and were fixed, followed by permeabilization and blocking and a double 
antibody labelling stain were used. All primary antibodies were incubated overnight at 4˚C. The 
cells were washed and treated with the appropriate secondary antibody (1:500) and incubated for 
2 hours at 4˚C. The cells were washed again and incubated with polyclonal antibody against 
HPeV1 (1:50) or monoclonal antibody against dsRNA (1:100) overnight then were washed and 
treated with secondary antibody (1:500). Slides were then visualized using a Nikon A1 si 
confocal microscope. At least 10 fields were observed for each slide and 4 typical cells were 
imaged. The images presented are the most representative of the cells observed. 
In HPeV-infected cells dsRNA, presumably in replication complexes, accumulated near the 
nucleus and was concentrated in large foci. Whereas the anti-HPeV1 antibody gives staining 
throughout the cytoplasm. The GM130 seems to distribute mostly to one side of the nucleus in 
uninfected cells (Figure 3.1), while in infected cells it seems to redistribute and become more 
concentrated near to, but largely separate from replication complexes. To compare with another 
relatively diverse picornavirus, coxsackievirus A9 (CAV9) was used. GMK cells were used as 
CAV9 does not infect HT29 cells. The GM130 distribution was different from that seen in 
uninfected HT29 cells where it was more localised in one perinuclear region (Figure 3.2). 
Infection with CAV9 caused a large reduction in the intensity of GM130 staining, with just a few 
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spots around the nucleus. The CAV9 replication complexes were seen as dots through the 
cytoplasm and did not seem to co-localise with the GM130 (Figure 3.2). 
PDI seems to be distributed around the nucleus in uninfected cells (Figure 3.3). Interestingly, in 
some cells infected with HPeV1 the stain almost completely disappears, while in others it is 
reduced. The ERGIC-53 appears as dots in the cytoplasm in uninfected cells. In cells infected 
with HPeV1 the stain is slightly weaker and the number of dots is reduced in some cells as the 
staining is more diffuse (Figure 3.4). Infection with HPeV1 therefore changes the distribution of 
the Golgi, ERGIC and the ER markers, suggesting these structures are altered.  
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FIGURE 3.1: The effect of HPeV1 infection on the Golgi marker GM130. HT29 cells were 
grown on coverslips and infected with HPeV1 for 8 hr. Double staining with antibody was used. 
The polyclonal rabbit antibody to GM130 was recognised with a red secondary antibody 
labelled with Alexa Fluor 568. The mouse monoclonal antibody to dsRNA was recognised with 
a green secondary antibody labelled with Alexa Fluor 488. Nuclei were stained with DAPI in 
the mounting medium. Images were visualized using a Nikon A1 confocal microscope. The 
blue filter detects the nucleus, the green filter detects dsRNA in infected cells and the red filter 
detects GM130. The white arrow indicates an uninfected cell and the yellow arrows indicate 
infected cells (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells, the GM130 is redistributed in infected cells and is concentrated near to 
replication complexes. The scale bar shown is 10 µm. 
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FIGURE 3.2: The effect of CAV9 infection on the Golgi marker GM130. GMK cells were 
grown on coverslips and infected with CAV9 for 8 hr. Double staining with  antibody was used. 
The polyclonal rabbit antibody to GM130 was recognised with a red secondary antibody 
labelled with Alexa Fluor 568. The mouse monoclonal antibody to dsRNA was recognised with 
a green secondary antibody labelled with Alexa Fluor 488. Nuclei were stained with DAPI in 
the mounting medium. Images were visualized using a Nikon A1 confocal microscope. The 
blue filter detects the nucleus, the green filter detects dsRNA in infected cells and the red filter 
detects GM130. The white arrow indicates an uninfected cell and the yellow arrows indicate 
infected cells (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells, the GM130 staining is reduced to just a few relatively weak spots in infected 
cells. The scale bar shown is 10 µm.   
10 µm 
10 µm 
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FIGURE 3.3: The effect of HPeV1 infection on the ER marker PDI. HT29 cells were grown 
on coverslips and infected with HPeV1 for 8 hr. Double stainingwith antibody was used. The 
mouse monoclonal antibody to PDI was recognised with a green secondary antibody labelled 
with Alexa Fluor 488. The rabbit polyclonal antibody to HPeV1 was recognised with a red 
secondary antibody labelled with Alexa Fluor 568. Nuclei were stained with DAPI in the 
mounting medium. Images were visualized using a Nikon A1 confocal microscope. The blue 
filter detects the nucleus, the green filter detects PDI and the red filter detects cells infected with 
HPeV1. The white arrow indicates an uninfected cell and the yellow arrows indicate infected 
cells (identified by the presence of HPeV proteins). Compared to uninfected cells, the PDI 
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FIGURE 3.4: The effect of HPeV1 infection on the ERGIC marker ERGIC-53. HT29 cells 
were grown on coverslips and infected with HPeV1 for 8 hr. Double staining with antibody was 
used. The mouse monoclonal antibody to ERGIC-53 was recognised with a green secondary 
antibody labelled with Alexa Fluor 488. The rabbit polyclonal antibody to HPeV1 was 
recognised with a red secondary antibody labelled with Alexa Fluor 568. Nuclei were stained 
with DAPI in the mounting medium. Images were visualized using a Nikon A1 confocal 
microscope. The blue filter detects the nucleus, the green filter detects PDI and the red filter 
detects infected cells with HPeV1. The white arrow indicates an uninfected cell and the yellow 
arrows indicate infected cells (identified by the presence of HPeV proteins) with slightly 
weaker, more diffuse ERGIC-53 staining. The scale bar shown is 10 µm. 
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3.3 Distribution of HPeV1 non-structural 
proteins  
To investigate which HPeV non-structural proteins could be involved in the changes to the 
Golgi, the ER and ERGIC, several EGFP/ mCherry fusions were used to confirm the results 
(Figure 3.5). EGFP constructs of 2A, 2B, 2C, and 3A were available (Salimi, 2015). mCherry 
constructs of these proteins were made by using double digestion with appropriate restriction 
enzymes. EGFP-2BC and mCherry-3C were produced by amplifying these coding regions from 
a HPeV1 clone and ligating into pEGFP-C1 or pmCherry-C1.  
First we studied the distribution of the non-structural proteins alone in GMK cells line. 50–70% 
confluent cells were used for transfection in 6 well plates containing glass coverslips. They were 
transfected with non-structural protein constructs using X-fect or Lipofectin transfection reagents 
(the same reagent for each set of experiments). The results were visualised using a Nikon A1 si 
confocal microscope. 
The distribution of EGFP expressed from pEGFP-C1 vector and mCherry expressed from 
pmCherry-C1 vector is shown in Figure 3.6. and Figure 3.7. Both of them are diffuse in the 
cytoplasm and the nucleus. mCherry-2A and EGFP-2A were also seen diffusely in the cytoplasm 
and nucleus (Figure 3.8). mCherry-2B, EGFP-2B (Figure 3.9), mCherry-3A and EGFP-3A 
(Figure 3.10) formed a reticular pattern in the cytoplasm. In some cells these also accumulated in   
perinuclear locations (data not shown). mCherry-3C caused major change to the cells, including 
rounding of the cell and contraction of the nucleus as seen in Figure 3.11. In some cells the 
nuclear staining was lost or was dispersed through the cell. These changes are possibly due to 
apoptosis.  
The most interesting distribution was shown by both EGFP-2C and mCherry-2C (Figure 3.12). 
The fluorescence was mainly localised in a few large and bright spots in the cytoplasm. The 
distribution of EGFP-2BC was variable. In some cells, it was very similar to the 2C distribution, 
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but in others it had a more diffuse, dot-like or reticular appearance in the cytoplasm (Figure 
3.13).  
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FIGURE 3.5: Schematic of the HPeV1 genome representing the location of the 
proteins 2A, 2BC, 2B, 2C, 3A and 3C in the polyprotein. The fusion constructs used 
to analyse cellular distribution coloured as the red box indicates mCherry and green 
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FIGURE 3.6: The distribution of EGFP expressed from the pEGFP-C1 vector. GMK cells 
were transfected with pEGFP-C1 using Xfect. Cells were visualized after fixation with formalin 
of 24 hours after transfection. Images were obtained with a Nikon AR Confocal Fluorescence 
Microscope. The blue filter detects the nucleus and the green filter detects EGFP. The yellow 
arrow indicates a cell transfected with pEGFP-C1, showing diffuse EGFP staining in the 
cytoplasm and the nucleus. The scale bar shown is 10 µm. 
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FIGURE 3.7: The distribution of mCherry expressed from the pmCherry-C1 vector. 
GMK cells were transfected with mCherry using Xfect. Cells were visualized after fixation 
withformalin 24 hours after transfection. Images were obtained with a Nikon AR Confocal 
Fluorescence Microscope. The blue filter detects the nucleus and the red filter detects mCherry. 
The yellow arrow indicates a cell transfected with pmCherry-C1 showing diffuse mCherry 
staining in the cytoplasm and the nucleus. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 3.8: The distribution of HPeV1 2A protein. GMK cells were transfected with A) 
pEGFP-2A and B) pmCherry-2A from HPeV1 using Xfect. Cells were visualized after fixation 
with formalin 24 hours after transfection. Images were obtained with Nikon AR Confocal 
Fluorescence Microscope. The blue filter detects the nucleus, the green filter detects EGFP-2A 
and the red filter detects mCherry-2A. The yellow arrows indicate transfected cells. Both 
EGFP-2A and mCherry-2A show a diffuse staining pattern in the cytoplasm and nucleus. The 
scale bar shown is 10 µm.  
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FIGURE 3.9: The distribution of HPeV1 2B protein. GMK cells were transfected with A) 
pEGFP-2B and B) pmCherry-2B from HPeV1 using Xfect. Cells were visualized after fixation 
with formalin 24 hours after transfection. Images were obtained with Nikon AR Confocal 
Fluorescence Microscope. The blue filter detects the nucleus, the green filter detects EGFP-2B 
and the red filter detects mCherry-2B. The yellow arrows indicate transfected cells. Both 
EGFP-2B and mCherry-2B show a reticular staining pattern in the cytoplasm. The scale bar 
shown is 10 µm. 
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FIGURE 3.10: The distribution of HPeV1 3A protein. GMK cells were transfected with A) 
pEGFP-3A and B) pmCherry-3A from HPeV1 using Xfect. Cells were visualized after fixation 
with formalin 24 hours after transfection. Images were obtained with Nikon AR Confocal 
Fluorescence Microscope. The blue filter detects the nucleus, the green filter detects EGFP-3A 
and the red filter detects mCherry-3A. The yellow arrows indicate transfected cells. Both EGFP-3A 
and mCherry-3A show a reticular staining pattern in the cytoplasm. The scale bar shown is 10 µm. 
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FIGURE 3.11: The distribution of HPeV1 3C protein. GMK cells were transfected with 
pmCherry-3C from HPeV1 using Xfect. Cells were visualized after fixation with formalin 24 
hours after transfection. Images were obtained with Nikon AR Confocal Fluorescence 
Microscope. The blue filter detects the nucleus and the red filter detects mCherry-3C. The 
yellow arrows indicate transfected cells. mCherry-3C causes a major change to the cells, 
including rounding of the cell and contraction of the nucleus.  The scale bar shown is 10 µm. 
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FIGURE 3.12: The distribution of HPeV1 2C protein. GMK cells were transfected with A) 
pEGFP-2C and B) pmCherry-2C from HPeV1 using Xfect.  Cells were visualized after fixation 
with formalin 24 hours after transfection. Images were obtained with Nikon AR Confocal 
Fluorescence Microscope. The blue filter detects the nucleus, the green filter detects EGFP-2C 
and the red filter detects mCherry-2C. The yellow arrows indicate transfected cells. Both EGFP-
2C and mCherry-2C are located in a few large and bright spots in the cytoplasm. The scale bar 
shown is 10 µm. 
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FIGURE 3.13: The distribution of HPeV1 2BC protein. GMK cells were transfected with 
pEGFP-2BC from HPeV1 using Xfect.  Cells were visualized after fixation with formalin of 24 
hours after transfection. Images were obtained with Nikon AR Confocal Fluorescence 
Microscope. The blue filter detects the nucleus and the green filter detects EGFP-2BC. The 
yellow arrows indicate transfected cells. EGFP-2BC shows two different patterns A) a reticular 
staining pattern in the cytoplasm, B) a few large spots, similar to the 2C staining pattern seen in 
Figure 3.12. The scale bar shown is 10 µm. 
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3.4 Non-structural proteins of HPeV1 and 
the secretory pathway 
After we studied the distribution of the HPeV1 non-structural proteins in GMK cells, we 
investigated the effect of these proteins on the ER, ERGIC and Golgi and any co-localisation. 
50–70% confluent GMK cells were used and transfected with non-structural proteins using 
Turbofect transfection reagent. The cells were fixed after 24-48 hours then stained with 
monoclonal anti-PDI or ERGIC antibody or polyclonal antibody to GM130.  
 The ER marker (PDI)  3.4.1
For some non-structural proteins we used both EGFP and mCherry constructs. PDI seems to 
have a perinuclear distribution in un-transfected cells and no change in this distribution was 
caused by mCherry-2A and EGFP-2A (Figure 3.14 and 3.15). In some cells transfected with m-
Cherry-2B and EGFP-2B the PDI stain has a lower concentration than untransfected cells but 
there was not much effect. mCherry-2C has a large effect on the PDI marker in some cells the 
ER seemed to be almost completely destroyed (Figure 3.14). In other cells the effect was less 
(data not shown) and EGFP-2C also has less effect, although EGFP-2BC also caused loss of the 
PDI stain in some cells (Figure 3.15). m-Cherry-3A seems to change the distribution of PDI and 
partly co-localise to it. m-Cherry-3C shows a possible apoptosis affect to transfected cell which 
have very condensed nuclei. This affects PDI distribution, but the effect may not be specific as 
the cell morphology is badly disrupted (Figure 3.14). The results show that 2C or 2BC can cause 
similar changes to the ER seen in HPeV1-infected cells (Figure 3.3). 
 The ERGIC 3.4.2
The ERGIC marker ERGIC-53 seems to be located through the cytoplasm but is clustered into 
many clear dots in cells that are untransfected (Figure 3.16). No change in this structure in cell 
was seen when cells were transfected with mCherry-2A. mCherry-2B partly co-localises to 
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ERGIC in transfected cells but causes no clear difference to ERGIC structure.  mCherry-2C does 
not cause any clear difference to the ERGIC and does not colocalise. mCherry-3A seems to 
change the distribution of ERGIC by condensing it close to the nucleus. There is also some co-
localisation between mCherry-3A and the ERGIC marker. mCherry-3C has a major effect on the 
ERGIC, which seem to completely disappear in transfected cells. However, this may not be 
specific as the cell morphology is badly disrupted (Figure 3.16). EGFP-2BC also seemed to 
cause disruption of the ERGIC (Figure 3.17).  
 The Golgi  3.4.3
This cis-Golgi marked GM130 distributes mostly to one side of the nucleus in untransfected 
(Figure 3.18). mCherry-2A has little effect on the distribution of GM130. On other hand, 
mCherry-2B seems to cause the loss of most of the Golgi marker. mCherry-2C seems to cause 
collapse of the Golgi to a small number of structures near to the nucleus. mCherry-3A seems to 
cause the loss of most of the Golgi marker. The marker is also not seen in cells transfected with 
mCherry-3C, but again these cells show major changes in morphology. 
Overall, all the non-structural proteins except 2A seem to have a large effect on Golgi structure 
(Figure 3.18). 
 Lysosomes  3.4.4
For more investigation on secretory pathways, we studied the effect of non-structural proteins on 
lysosomes. In this investigation the fluorescence intensities recorded for the non-structural 
protein fusions were decreased to clearly observe the interactions. In addition, live cells were 
imaged, rather than fixed ones. Under these conditions, the distribution recorded for 2B and 3A 
fusions was much more punctate than that seen in the work shown in Figures 3.9-3.18. The 
lysosome stain shows foci throughout the cytoplasm (Figure 3.19). There are fewer foci in cells 
transfected with mCherry-2A. The foci seem larger and more intense in cells transfected with 
mCherry-2B. mCherry-2C causes a reduction in number and intensity of foci. mCherry-3A 
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causes an increase in the intensity and number of foci and like mCherry-2B, there seems to be 
some co-localisation. mCherry-3C has little effect (Figure 3.20). 
 Mitochondria  3.4.5
Mitotracker 20 ng/ml was used to visualise mitochondria. Again, in this investigation the 
fluorescence intensities recorded for the non-structural protein fusions were decreased to clearly 
observe the interactions and live cells were imaged. In transfected cells mitochondria were 
localised in a network of foci throughout the cytoplasm (Figure 3.21). None of the HPeV1 
proteins had a significant effect on this distribution apart from 2A and 3C (Figure 3.22). 
mCherry-2A seemed to reduce the size of the network, while the network was broken down into 
more individual foci by mCherry-3C, but again the cells were highly disrupted by mCherry-3C 
and so the effect on mitochondria may not be specific. 
 Peroxisomes  3.4.6
An EGFP-peroxisome construct was made by cutting pEGFP-C1 with HindIII and BamHI and 
ligating in a pair of overlapping oligonucleotides. These changed the C-terminal sequence of 
EGFP to TKL, which is a peroxisomes target sequence (Brocard and Hartig, 2006). The 
constructs gave the expected punctate distribution in the cytoplasm (Figure 3.23), but some 
nuclear staining was seen in some cells and this complicated the results when it was co-
transfected with HPeV1 mCherry constructs (Figure 3.24). mCherry-2C seemed to increase the 
size and intensity of the peroxisome spots (Figure 3.24). mCherry-2B had little effect and 
mCherry-2A, -3A and -3C caused some disruption to the pattern but this was unclear. None of 
the proteins co-localised with the peroxisomes. 
Interestingly, infection with both HPeV1 and CAV9 seems to disrupt the peroxisomes pattern 
(Figure 3.25 and 3.26). 
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FIGURE 3.14: The effect of HPeV1 proteins (fused to mCherry) on the ER marker PDI. 
GMK cells were grown on coverslips and transfected with mCherry fusion constructs using Turbofect. 
48 hours after transfection, a monoclonal antibody to PDI and a green secondary antibody labelled 
with Alexa Fluor 488 were used to observe the ER. Nuclei were stained with DAPI in the mounting 
medium. Images were visualized using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry fused to 2A, 2B, 2C, 3A or 3C and the green filter detects PDI/ 
secondary antibody. The arrows indicate transfected cells (which show an mCherry signal). mCherry-
2A and mCherry 2B (white arrows) have little effect on PDI staining compared to non-transfected 
cells in the field. Staining is almost completely destroyed by mCherry-2C (yellow arrow). The PDI 
distribution is changed by mCherry-3A (blue arrow), which also partly co-localises to it. mCherry-3C 
(red arrow) causes major disruption to the cell structure, including nuclear condensation. The scale bar 
shown is 10 µm.   
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FIGURE 3.15: The effect of HPeV1 proteins (fused to EGFP) on the ER marker PDI. 
GMK cells were grown on coverslips and transfected with EGFP fusion constructs using 
Turbofect. 48 hours after transfection, a monoclonal antibody to PDI and a red secondary 
antibody labelled with Alexa Fluor 568 were used to observe the ER. Nuclei were stained 
with DAPI in the mounting medium. Images were visualized using a Nikon A1 confocal 
microscope. The blue filter detects the nucleus, the red filter detects PDI/ secondary 
antibody, and the green filter detects EGFP fused to 2A, 2B, 2C, and 2BC. The arrows 
indicate transfected cells (which show an EGFP signal). EGFP-2A and EGFP-2B (white 
arrows) have little effect on PDI staining compared to non-transfected cells in the field. 
Staining is almost completely destroyed by EGFP-2C and EGFP-2BC (yellow arrows). The 
scale bar shown is 10 µm. 
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FIGURE 3.16: The effect of HPeV1 proteins (fused to mCherry) on the ERGIC. GMK 
cells were grown on coverslips and transfected with mCherry fusion constructs using Turbofect. 48 
hours after transfection, a monoclonal antibody to ERGIC and a green secondary antibody labelled 
with Alexa Fluor 488 were used to observe ERGIC. Nuclei were stained with DAPI in the mounting 
medium. Images were visualized using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry fused to 2A, 2B, 2C, 3A and 3C the green filter detects 
ERGIC/ secondary antibody.  The arrows indicate transfected cells (which show an mCherry signal). 
mCherry-2A and mCherry-2C (white arrows) have little effect on PDI staining compared to non-
transfected cells in the field. mCherry-2B has a slight effect on ERGIC (yellow arrow). The ERGIC 
distribution is changed by mCherry-3A (blue arrow), which also partly co-localises to it. mCherry-
3C (red arrow) causes major disruption to the cell structure, including nuclear condensation. The 
scale bar shown is 10 µm.   
10 µm 
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FIGURE 3.17: The effect of HPeV1 2BC fused to EGFP on the ERGIC. GMK cells 
were grown on coverslips and transfected with EGFP fusion construct using Turbofect. 48 
hours after transfection, a monoclonal antibody to ERGIC and a red secondary antibody 
labelled with Alexa Fluor 568 were used to observe ERGIC. Nuclei were stained with DAPI 
in the mounting medium. Images were visualized using a Nikon A1 confocal microscope. 
The blue filter detects the nucleus, the red filter detects ERGIC/ secondary antibody and the 
green filter detects EGFP fused to 2BC. The arrow indicates a transfected cell (which shows 
an EGFP signal). The transfected cell has a much weaker ERGIC staining than the 
untransfected cells in the field and the distribution is changed. The scale bar shown is 10 
µm.  
10 µm 
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FIGURE 3.18: The effect of HPeV1 proteins (fused to mCherry) on the Golgi. GMK 
cells were grown on coverslips and transfected with mCherry fusion constructs using Turbofect. 48 
hours after transfection, a polyclonal antibody to GM130 and a green secondary antibody labelled 
with Alexa Fluor 488 were used to observe Golgi. Nuclei were stained with DAPI in the mounting 
medium. Images were visualized using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry fused to 2A, 2B, 2C, 3A and 3C the green filter detects 
GM130/ secondary antibody. The arrows indicate transfected cells (which show an mCherry signal). 
mCherry-2A (white arrow) has little effect on GM130 staining compared to non-transfected cells in 
the field. The GM130 distribution is mostly lost by mCherry-2B or mCherry-3A (yellow arrows). 
mCherry-2C changed the distribution to a small number of structures near to the nucleus (blue 
arrow). mCherry-3C (red arrow) causes major disruption to the cell structure, including nuclear 
condensation. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 3.19 The normal distribution of lysosomes. GMK cells were grown on coverslips 
and stained with green lysotracker. Nuclei were stained with Hoechst 33342. Images were 
visualized using a Nikon A1 confocal microscope. The blue filter detects the nucleus and the 
green filter detects lysosomes. The  white arrows indicate the distribution of lysosome stain as 
foci throughout the cytoplasm. The scale bar shown is 10 µm.  
10 µm 
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FIGURE 3.20: The effect of HPeV1 proteins (fused to mCherry) on lysosomes. GMK 
cells were grown on coverslips and transfected with mCherry fusion constructs using Turbofect. A 
green lysotracker stain was used and the nuclei were stained with Hoechst 33342. Live images were 
visualized using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the red filter 
detects mCherry fused to 2A, 2B, 2C, 3A and 3C and the green filter detects lysosmoes. The arrows 
indicate transfected cells (which show an mCherry signal). mCherry-2A and mCherry 2C (white 
arrows) have some effect on lysosome staining  and the number of foci are less compared to non-
transfected cells in the field.  The stain distribution is changed by mCherry-2B and mCherry-3A 
(yellow arrows) to larger and more intense, which also partly co-localises to both of them. mCherry-
3C (red arrow) causes major disruption to the cell structure, including nuclear condensation. The 
scale bar shown is 10 µm. 
10 µm 
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FIGURE 3.21: The normal distribution of mitochondria. GMK cells were grown on 
coverslips and stained with green mitotracker. Nuclei were stained with Hoechst 33342. Live 
images were visualized using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus and the green filter detects mitochondria. The  white arrows indicate the distribution of 
mitochondria stain as a network of foci throughout the cytoplasm. The scale bar shown is 20 
µm. 
20 µm 
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FIGURE 3.22: The effect of HPeV1 proteins (fused to mCherry) on mitochondria. 
GMK cells were grown on coverslips and transfected with mCherry fusion constructs using 
Turbofect. A green mitotracker stain were used and the nuclei were stained with Hoechst 33342. 
Live images were visualized using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry fused to 2A, 2B, 2C, 3A and 3C and the green filter detects 
mitochondria. The arrows indicate transfected cells (which show an mCherry signal). mCherry-2A 
shows a reduced of the size of the network (yellow arrows). mCherry 2B, mCherry-2C and 
mCherry-3A (white arrows) have little effect on mitochondria staining compared to non-transfected 
cells in the field. mCherry-3C (red arrow) causes major disruption to the cell structure, including 
nuclear condensation. The scale bar shown is 20 µm. 
20 µm 
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FIGURE 3.23: The normal distribution of peroxisomes. GMK cells were grown on 
coverslips and transfected with EGFP-peroxisome using Turbofect.  Nuclei were stained with 
DAPI in the mounting medium. Images were visualized using a Nikon A1 confocal microscope. 
The blue filter detects the nucleus and the green filter detects peroxisome. The white arrows 
indicate the distribution of peroxisomes construct  as a  punctate distribution in the cytoplasm. 
The scale bar shown is 10 µm. 
10 µm 
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FIGURE 3.24: The effect of HPeV1 proteins (fused to mCherry) on peroxisomes. GMK 
cells were grown on coverslips and co-transfected with mCherry fusion constructs and EGFP-
peroxisome using Turbofect. Nuclei were stained with DAPI in the mounting medium. Images were 
visualized using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the red filter 
detects mCherry fused to 2A, 2B, 2C, 3A and 3C and the green filter detects EGFP-peroxisome. The 
arrows indicate transfected cells (which show an mCherry signal). The peroxisome distribution is 
changed by mCherry-2A and mCherry-3A (yellow arrows). mCherry 2B, (white arrow) has no 
effects on peroxisomes distribution compared to non-transfected cells in the field. mCherry-2C 
seemed to increase the size and intensity of the spots (blue arrow).  mCherry-3C (red arrow) causes 
major disruption to the cell structure, including nuclear condensation. The scale bar shown is 10 
µm.  
10 µm 
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FIGURE 3.25: The effect of HPeV1 infection on the peroxisomes. HT29 cells were grown 
on coverslips and transfected with EGFP-peroxisome using Lipofectin reagent and then infected 
with HPeV1 for 8 hr. A monoclonal antibody against dsRNA was used and recognised with a 
secondary antibody labelled with Alexa Fluor 555. Nuclei were stained with DAPI in the 
mounting medium. Images were visualized using a Nikon A1 confocal microscope. The blue 
filter detects the nucleus, the green filter detects EGFP-peroxisome and the red filter detects 
dsRNA HPeV1 replication complexes. The white arrow indicates an uninfected cell and the 
yellow arrows indicate infected cells (identified by the presence of dsRNA in replication 
complexes). Compared to uninfected cells, HPeV disrupts the peroxisome pattern. The scale bar 
shown is 10 µm. 







FIGURE 3.26: The effect of CAV9 infection on the peroxisomes. GMK cells were grown on 
coverslips and transfected with EGFP- peroxisome using Turbofect reagent and then infected 
with CAV-9 for 8 hr. A monoclonal antibody against dsRNA was used and recognised with a 
secondary antibody labelled with Alexa Fluor 555. Nuclei were stained with DAPI in the 
mounting medium. Images were visualized using a Nikon A1 confocal microscope. The blue 
filter detects the nucleus, the green filter detects EGFP- peroxisome and the red filter detects ds 
RNA of CAV9 replication complexes. The white arrow indicates an uninfected cell and the 
yellow arrow indicates an infected cell (identified by the presence of dsRNA in replication 
complexes). Compared to uninfected cells, CAV9 disrupts the peroxisome pattern. The scale 
bar shown is 10 µm. 
10 µm 
10 µm 
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3.5 Discussion 
Cells transfer protein, lipid and other components between intracellular compartments using the 
early secretory pathway which consists of the ER, the ERGIC and the Golgi as well as the 
transport vesicles (coated with COPI or COPII) that shuttle between them (Midgley et al., 2013; 
Watson and Stephens, 2005). 
Viruses often rearrange cell compartments to give new membrane structures involved in viral 
replication and/or assembly (Inoue and Tsai, 2013). This concentrates materials needed for virus 
replication, holds replication complexes in place, and in the case of RNA viruses prevents 
dsRNA being recognised by the cell and so preventing defence responses triggered by dsRNA 
(Miller and Krijnse-Locker, 2008; Sasaki et al., 2012).  
Studies of several different positive-strand RNA viruses have suggested the ER, Golgi, 
endosomes or lysosomes as sources for these structures needed for replication (Salonen et al., 
2005; Suhy et al., 2000). The use of cellular membranes from the secretory system for 
generating replication complexes also potentially affects protein secretion and cell-surface 
protein expression. Preventing MHC class 1 expression at the cell surface could be one way that 
the virus avoids host cell defence mechanisms (Belov, 2014). 
HPeVs are being increasingly recognised as important human pathogens, but are genetically 
diverse from several picornaviruses. We therefore need to understand the details of virus 
replication to improve the opportunities to develop antiviral drugs. In this study, we first 
investigated the effect of HPeV1 infection on some compartments of the secretory pathway. 
Our results agreed with previous work on HPeV infection which showed that infection has a 
large effect on the ER (Krogerus et al., 2003). These authors also found that HPeV infection 
caused Golgi fragmentation, as observed in our study. Our study used HT29 cells (human colon 
carcinoma), while the previous work used A549 cells (human lung carcinoma and as similar 
results were obtained, it suggests that loss of the ER and Golgi fragmentation are key features of 
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HPeV infection. In cells infected with CAV9 the Golgi marker GM130 was generally reduced 
and dispersed. This pattern seen was similar to that in previous work on enteroviruses (Cornell et 
al., 2006; Mousnier et al., 2014).  
Infection with another picornavirus, FMDV, has little effect on the ER, but again leads to Golgi 
disruption and also causes a change to the distribution of the ERGIC. Even cells with low levels 
of FMDV infection showed these changes, suggesting that the ERGIC and Golgi are disrupted 
early after infection and before major changes are detected in the ER (Midgley et al., 2013; 
Wang, 2012). These observations and analysis of cell proteins involved in the secretory pathway 
suggest that ER exit sites are important in replication complex formation (Midgley et al., 2013). 
The difference between FMDV infection (ER remains intact) and HPeV infection (ER disrupted) 
suggests that HPeV replication complexes are produced from different components of the 
secretory pathway and it would be interesting to identify the source and mechanism, as they do 
not seem to contain ER, ERGIC or Golgi markers. 
The origin of the poliovirus replication complex is not entirely clear and may involve lysosome, 
ER, and Golgi components (Schlegel et al., 1996; Suhy et al., 2000). There are many hypotheses 
for the formation of these structures during poliovirus infection (Reid et al., 2015). Autophagic 
vesicles is one suggestion as early PV infection show 2BC and 3A proteins co-localise with 
lysosomal-associated membrane protein 1 (LAMP-1) and LC3-phosphatidylethanolamine 
conjugate (LC3-II) (Jackson et al., 2005). Inhibiting autophagy decreases the amount of virus 
produced during infection with the related viruses, HRV-2 and HRV-14 (Klein and Jackson, 
2011). It is interesting that in our experiments, both HPeV1 2B and 3A seemed to partially co-
localise with lysosomes and this may suggest some involvement of these structures in replication 
complex formation. 
During early infection, COPII-coated vesicles may be used to generate replication complexes by 
blocking anterograde transport and accumulating and relocating these vesicles. Infection with 
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poliovirus and expression of 3A blocks ER-Golgi protein transport (Choe et al., 2005; Richards 
et al., 2014). Poliovirus 2B has been found to co-localise with Sec13 and Sec31, which are 
components of the COPII vesicles and it was shown that infection with poliovirus results in a 
transient increase in COPII vesicles (den Boon et al., 2010). However, other work shows no co-
localisation between dsRNA and Sec31 (Richards et al., 2014). In EV-71 COPI, but not COPII, 
is required for replication and EV-71 2C protein might locate COPI to the viral replication 
complex (Wang et al., 2012b).  Poliovirus replication complexes may also originate from the 
COPI secretory pathway as poliovirus infection is sensitive to brefeldin A (BFA). BFA inhibits 
the activation of the small GTPase Arf1 by interacting with specific guanine nucleotide exchange 
factors (GEFs) (Behnia and Munro, 2005; Irurzun et al., 1992). Poliovirus 3A protein binds 
GBF1 and recruits it to virus-induced vesicles but does not recruit Arf1 (Belov et al., 2008). 3A 
protein of CVB3 also induces the recruitment of GBF1 to membranes (Richards et al., 2014; 
Sharp et al., 2010). HRV-2 or HRV-14 3A recruited PI4KIIIβ to replication sites but do not bind 
to GBF1 (Dorobantu et al., 2015). This suggests that even very similar viruses may use different 
host factors for replication. Viruses could possibly switch between these factors as brefeldin A 
resistant mutants of poliovirus can be generated easily and these presumably do not require 
GBF1 (Crotty et al., 2004; Viktorova et al., 2015). HPeV infection is only partially blocked by 
brefeldin A, while EMCV infection is resistant, again emphasizing that there are differences in 
host factor requirements between different picornaviruses (Gazina et al., 2002). 
To understand which virus proteins were responsible for the changes to the secretory pathway 
seen in infected cells, individual HPeV proteins were expresses as fusions with mCherry or 
EGFP. There was no difference in the localization regarding the fluorescent protein used (EGFP 
or mCherry). This suggests that the fluorescent proteins are not affecting the distribution of the 
virus proteins. 2C has the most distinctive distribution, large spots in the cytoplasm and this was 
previously suggested to be due to localisation to lipid droplet (Krogerus et al., 2007). We 
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confirmed this using a different lipid droplet dye, which also revealed that the lipid droplets were 
greatly increased in size in the presence of HPeV 2C. The distributions of the other HPeV1 non-
structural proteins was similar to that previously reported. 2A, 2B, 2C, 2BC, and 3A non-
structural proteins previously (Krogerus et al., 2003). 
In FMDV, 2B plus 2C, or the 2BC precursor (but not 3A) can block trafficking of proteins 
between the ER and Golgi and their expression on the cell surface in FDMV (Sweeney et al., 
2010). We did not study the effect on secretion, but 2C/2BC seemed to affect all the 
compartments, especially the ER and this suggests that it would have a strong effect on secretion 
as in FMDV, rather than 3A as in enteroviruses. However, fragmentation of the Golgi without 
blocking of protein secretion in HRV-1A and HRV-16 have been reported and so the effect of 
our observed changes on secretion may not be predictable (Mousnier et al., 2014; Quiner and 
Jackson, 2010). 
In conclusion, some picornaviruses change the distribution of secretory pathway compartment 
and we found in this study that HPeV1 infection affects the Golgi and ERGIC, and almost 
completely destroys the ER in the HT29 cell line. 2B, 2BC/2C and 3A are the main non-
structural proteins that affect the secretory pathway in picornaviruses. For HPeV1 we found that 
2C affects all these compartments and 3A also has an effect on some of them.  
It would be interesting to investigate the basis of changes to understand HPeV infections more 
fully and possibly identify new targets for antivirus drugs. 
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 CHAPTER FOUR 4
THE INTERACTION BETWEEN 
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4.1 Introduction 
2C protein is relatively highly conserved among picornaviruses and has been implicated in 
replication complex formation and several steps during viral replication. These include host cell 
membrane rearrangement and encapsidation. 2C includes regions which interact with other viral 
and cellular proteins (Banerjee et al., 2004; Belsham and Normann, 2008). 2C has been assigned 
as a member of the superfamily III helicases group of the AAA+ ATPases although no helicase 
activity has been shown for picornavirus 2C proteins except EV-71 and the closely related virus 
CAV16 (Belsham and Normann, 2008; Sweeney et al., 2010; Xia et al., 2015). It has a predicted 
N-terminal membrane-binding amphipathic helix and  nucleoside triphosphate (NTP) binding 
protein motifs, found in the central portion of 2C, including the ‘Walker’ motif A, involved in 
binding the phosphate to NTP, ‘Walker’ motif B, which may chelate Mg+2 involved in NTP 
hydrolysis, and motif C (Sweeney et al., 2010; Teterina et al., 1997).  
In enterovirus-infected cells, 2C protein is associated with vesicles surrounding the viral RNA 
replication complexes and may be involved in the formation of the replication complex. During 
poliovirus infection, 2C and its precursor 2BC, migrate to the ER where they induce the 
formation of vesicles that bud off and become the site of viral RNA synthesis (Palmenberg et al., 
2010; Teterina et al., 1997). 
Lipids and associated molecules and structures such as fatty acids, lipid droplets and 
phosphoinositide are being increasingly recognised to be involved in many stages of the viral life 
cycle such as entry, replication, assembly and exit by budding (Chukkapalli et al., 2012; Martin-
Acebes et al., 2013; van der Schaar et al., 2016).  
Lipid droplets (LD) are dynamic cytoplasmic organelles found in most cells. They are the most 
important storage site for neutral lipids. They consist of a hydrophobic core of neutral lipids 
(triglycerides (TG) and cholesterol esters (CE)), surrounded by a phospholipid monolayer (Guo 
et al., 2009; Herker and Ott, 2012; Walther and Farese, 2012). Lipid stored in LDs have several 
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functions, including  energy generation, providing building components for membrane synthesis 
and being the starting point to synthesize specific lipids. LDs can also be used for protein 
storage, for example to temporarily store unfolded membrane proteins before proteasomal 
degradation (Fujimoto et al., 2008; Guo et al., 2009; Walther and Farese, 2012). LDs also 
contain their own specific proteins on the surface including structural proteins (e.g. proteins of 
the perilipin family), lipid-synthesis enzymes, lipases and membrane-trafficking proteins (e.g. 
Rab5, Rab18 and ARF1) (Guo et al., 2009). 
Many viruses including hepatitis C virus (HCV), Dengue virus, West Nile virus and Rotavirus 
(RV) have been reported to use LDs in replication complexes formation (Gaunt et al., 2013). The 
core protein of HCV was reported to localise to LDs and the capsid protein of Dengue virus also 
associates to LDs, which is necessary for efficient viral replication (Saka and Valdivia, 2012). It 
was previously reported that HPeV 2C, interacts with LDs (Krogerus et al., 2007) and this 
observation was confirmed in our laboratory (Salimi, 2015). Expression of individual HPeV non-
structural proteins described in chapter 3, shows that 2C localises in large perinuclear foci, 
presumably lipid droplets. The aims of this work described in this chapter is to understand the 
basis of this interaction, how it plays a role in HPeV infection and if this interaction occurs in 
related viruses. 
4.2 Fatty acid study 
 Virus and fatty acids 4.2.1
Firstly, we analysed the effect of HPeV1 or CAV9 infection on intracellular lipid using the lipid 
marker BODIPY 500/510 C4-C9. GMK or HT29 cells were seeded in 6 well plates containing 
glass coverslips 24 hours before the experiment and were confluent before the start of the 
experiment. Cells were infected with CAV9 or HPeV1 at MOI 10. At time intervals (2, 6, 8 
hours) the medium was replaced with fresh pre-warmed medium with 0.4 µM BODIPY 500/510 
C4-C9 for 30 minutes (Nchoutmboube et al., 2013). Cells were fixed and virus infected cells 
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were identified with a dsRNA antibody. The results are shows in Figures 4.1- 4.3. There seem to 
be no consistent differences between uninfected and infected cells. 
 Non-structural proteins of HPeV1 and fatty acid 4.2.2
We next investigate if the non-structural proteins of HPeV1 interact with fatty acids. Cells were 
transfected with Turbofect, then stained with BODIPY 500/510 C4- C9. The results are shown in 
Figure 4.4. There seemed to be some co-localisation between FA and HPeV 2B and 3A. In the 
case of 2C, some of the FA stain is located in foci and these correspond to the concentrations of 
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FIGURE 4.1: The normal distribution of fatty acids (FAs) in GMK cells. GMK cells 
were grown on coverslips and washed with DMEM serum-free medium. Cell were grown in 
serum-free medium with 50mM HEPES for 30 minutes then the medium was replaced with 
fresh pre-warmed medium with 0.4 µM BODIPY 500/510 for 30 minutes. Cells were fixed 
and washed with glycine and permeabilized with Saponin then blocked. The coverslips were 
mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon 
A1 confocal microscope. The blue filter detects the nucleus and the green filter detects FAs. 
The white arrows show the normal distribution of FAs as a diffuse staining pattern in the 
cytoplasm. The scale bar shown is 10 µm. 
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FIGURE 4.2: The effect of CAV9 on fatty acids (FAs). GMK cells were seeded in 6 well 
plates containing glass coverslips and were confluent before the start of the experiment. 
Cells were washed with DMEM serum-free medium and infected with CAV9 (MOI 10) in 
serum-free medium with 50mM HEPES. At 2, 6, or 8 hours the medium was replaced with 
fresh pre-warmed medium with 0.4 µM BODIPY 500/510 for 30 minutes. Cells were fixed, 
permeabilized and blocked. dsRNA monoclonal antibody, followed by secondary antibody 
labelled with Alexa Fluor 555 was used to identify infected cells. The coverslips were 
mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon 
A1 confocal microscope. The blue filter detects the nucleus, the green filter detects FAs and 
red filter detects dsRNA. The white arrows indicate uninfected cells and the yellow arrows 
indicate infected cells (identified by the presence of dsRNA in replication complexes). 
Compared to uninfected cells, there is no consistent difference between uninfected and 
infected cells at 2, 6 and 8 hours post infection. The scale bar shown is 10 µm. 
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FIGURE 4.3: The effect of HPeV1 on fatty acids (FAs). HT29 cells were seeded in 6 well 
plates containing glass coverslips and were confluent before the start of the experiment. 
Cells were washed with DMEM serum-free medium and infected with HPeV1 (MOI 10) in 
serum-free medium with 50mM HEPES. At 2, 6, or 8 hours the medium was replaced with 
fresh pre-warmed medium with 0.4 µM BODIPY 500/510 for 30 minutes. Cells were fixed, 
permeabilized and blocked. dsRNA monoclonal antibody, followed by  secondary antibody 
labelled with Alexa Fluor 555 was used to identify infected cells. The coverslips were 
mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon 
A1 confocal microscope. The blue filter detects the nucleus, the green filter detects FAs and 
red filter detects dsRNA. The white arrows indicate uninfected cells and the yellow arrows 
indicate infected cells (identified by the presence of dsRNA in replication complexes). 
Compared to uninfected cells, there is no consistent difference between uninfected and 
infected cells at 2, 6 and 8 hours post infection. The scale bar shown is 10 µm. 
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FIGURE 4.4: The localisation of fatty acids (FAs) in cells transfected with constructs 
encoding HPeV1 proteins fused to mCherry. GMK cells were grown on coverslips and 
transfect with HPeV1 constructs for 24-48 hours using Turbofect. A fresh pre-warmed medium with 
0.4 µM BODIPY 500/510 was added for 30 minutes and washed twice with PBS. The coverslips 
were mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon 
A1 confocal microscope. The blue filter detects the nucleus, the red filter detects mCherry of 2A, 
2B, 2C, 3A and, 3C and the green filter detects FAs. The arrows indicate transfected cells (which 
show an mCherry signal). mCherry-2A (white arrow) has no effect on FAs staining compared to 
non-transfected cells in the field. mCherry 2B, and mCherry-3A (yellow arrows) seemed to be co-
localised with FA. Some of the FA stain is located in foci by mCherry-2C (blue arrow), and these 
correspond to the concentrations of 2C. mCherry-3C (red arrow) causes major disruption to the cell 
structure, including nuclear condensation. The scale bar shown is 10 µm. 
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4.3 Lipid droplets study 
 Lipid Droplets and viruses 4.3.1
We then investigated LDs in infected cells. Cells were infected for 0, 2, 4, 6, 8, or 10 hours then 
fixed. LDs were identified by staining with BODIPY 493/503 at a final concentration of 10 
mg/ml (Wolins et al., 2001) and infected cells by using dsRNA antibody. 
LDs show spherical structures in the cytoplasm in uninfected GMK cells and cells in the early 
stage of infection with CAV9 (0, 2 and 4 hours post infection) (Figure 4.5). CAV9 replication 
complexes are visible at 4 hours and do not co-localise with LDs. Later post-infection (6, 8, and 
10 hours) this distribution seem to be less in infected cells and no LDs are visible 10 hours post-
infection (Figure 4.6). 
LDs show spherical structures in the cytoplasm in the HT29 cell line and are brighter than those 
seen in GMK cells. The LDs distribution become less 4 hours post-infection (Figure 4.7). LDs 
become more concentrated near to the dsRNA 6, 8, and 12 hours post-infection in some cells but 
seem not to be present in some infected cells (Figure 4.8). Again the LDs do not co-localise with 
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FIGURE 4.5: The effect of CAV9 on lipid droplets (LDs) in early stages of infection. 
GMK cells were seeded in 6 well plates containing glass coverslips and were confluent 
before the start of the experiment. Cells were infected with 50 µl of CAV9 (MOI 10) and 
incubated for 0, 2, 4 hours and after each incubation the cells were fixed, permeabilized and 
blocked. dsRNA monoclonal antibody was added after incubation overnight and washing, 
this was detected with secondary antibody labelled with Alexa Fluor 555. Cells were stained 
with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then cells were 
washed twice with PBS. The coverslips were mounted with hard set mounting medium with 
DAPI. Images were visualized using a Nikon A1 confocal microscope. The blue filter 
detects the nucleus, the green filter detects neutral lipids in LDs and red filter detects 
dsRNA. The white arrows indicate uninfected cells and the yellow arrow indicates an 
infected cell (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells, there is no consistent difference in LD distribution in infected cells at 4 
hours post infection. The infected cells only become visible 4 hours after infection. The 
scale bar shown is 10 µm. 
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FIGURE 4.6: The effect of CAV9 on lipid droplets (LDs) in late stages of infection. 
GMK cells were seeded in 6 well plates containing glass coverslips and were confluent 
before the start of the experiment. Cells were infected with 50 µl of CAV9 (MOI 10) and 
incubated for 6, 8, 10 hours and after each incubation the cells were fixed, permeabilized 
and blocked. dsRNA monoclonal antibody was added after incubation overnight and 
washing, this was detected with secondary antibody labelled with Alexa Fluor 555. Cells 
were stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then 
cells were washed twice with PBS. The coverslips were mounted with hard set mounting 
medium with DAPI. Images were visualized using a Nikon A1 confocal microscope. The 
blue filter detects the nucleus, the green filter detects neutral lipids in LDs and red filter 
detects dsRNA. The white arrows indicate uninfected cells and the yellow arrows indicate 
infected cells (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells in the field, the LD distribution seems to be less in infected cells than in 
uninfected cells at 6 and 8 hours post infection. No LDs are visible at 10 hours post-
infection. The scale bar shown is 10 µm. 
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FIGURE 4.7: The effect of HPeV1 on lipid droplets (LDs) in early stages of infection. 
HT29 cells were seeded in 6 well plates containing glass coverslips and were confluent 
before the start of the experiment. Cells were infected with 50 µl of HPeV1 (MOI 10) and 
incubated for 0, 2, 4 hours and after each incubation the cells were fixed, permeabilized and 
blocked. dsRNA monoclonal antibody was added after incubation overnight and washing, 
this was detected with secondary antibody labelled with Alexa Fluor 555. Cells were stained 
with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then cells were 
washed twice with PBS. The coverslips were mounted with hard set mounting medium with 
DAPI. Images were visualized using a Nikon A1 confocal microscope. The blue filter 
detects the nucleus, the green filter detects neutral lipids in LDs and red filter detects 
dsRNA. The white arrows indicate uninfected cells and the yellow arrows indicate infected 
cells (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells, there is no consistent difference in LD distribution in infected cells at 4 
hours post infection. The infected cells only become visible 4 hours after infection. The 
scale bar shown is 10 µm. 
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FIGURE 4.8: The effect of HPeV1 on lipid droplets (LDs) in late stages of infection. 
HT29 cells were seeded in 6 well plates containing glass coverslips and were confluent 
before the start of the experiment. Cells were infected with 50 µl of HPeV1 (MOI 10) and 
incubated for 6, 8, 12 hours and after each incubation the cells were fixed, permeabilized 
and blocked. dsRNA monoclonal antibody was added after incubation overnight and 
washing, this was detected with secondary antibody labelled with Alexa Fluor 555. Cells 
were stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then 
cells were washed twice with PBS. The coverslips were mounted with hard set mounting 
medium with DAPI. Images were visualized using a Nikon A1 confocal microscope. The 
blue filter detects the nucleus, the green filter detects neutral lipids in LDs and red filter 
detects dsRNA. The white arrows indicate uninfected cells and the yellow arrows indicate 
infected cells (identified by the presence of dsRNA in replication complexes). Compared to 
uninfected cells, LDs become more concentrated and located near to the dsRNA 6, 8, and 12 
hours post-infection. The scale bar shown is 10 µm. 
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 Non-structural proteins of HPeV1 4.3.2
To continue our investigation with LDs, we examined the effect of HPeV1 non-structural 
proteins. The constructs shown in (Figure 3.5) were used and were transfected into GMK cells 
using TurboFect. GMK cells were used as they have a better transfection efficiency and 
morphology for imaging than HT29 cells. LDs were detected with BODIPY 493/503.  
We first examined BODIPY 493/503 and pmCherry-C1 vector as a control. The LD stain 
showed spherical structures in the cytoplasm. mCherry is diffuse in the cytoplasm and nucleus 
and there is no change in the distribution of LDs compared with untransfected cells (Figure 4.9).  
The distribution and/or the number of LDs in cells transfected with mCherry-2A or mCherry-3C 
were similar to untransfected cells (Figure 4.10). mCherry-2B and mCherry-3A show slight co-
localisation with LDs but LDs have the typical distribution (Figure 4.11). Clear co-localisation 
was seen between mCherry-2C and LDs. In addition, the LDs were aggregated into punctate 
structures (Figure 4.11). EGFP-2BC co-localised with another LD stain, Lipotox, but did not 
seem to cause the same amount of LD aggregation (Figure 4.12). 
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FIGURE 4.9: Lipid droplets (LDs) and pmCherry-C1 vector. GMK cells were grown on 
coverslips and one sample was transfected with pmCherry-C1 using Turbofect.  Cells were 
fixed and stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then 
cells were washed twice with PBS. The coverslips were mounted with hard set mounting 
medium with DAPI. Images were visualized using a Nikon A1 confocal microscope. The blue 
filter detects the nucleus, the red filter detects mCherry vector  and the green filter detects 
neutral lipids in LDs. A) Untransfected cells. The white arrow indicates a cell showing the 
normal distribution of LDs as spherical structures in the cytoplasm. B) Cells transfected with 
pmCherry-C1. The yellow arrow shows a transfected cell (which shows an mCherry signal). 
There is no difference in the LD distribution between the transfected cell and an untransfected 
cell (white arrow) in the same field. The scale bar shown is 10 µm.  
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FIGURE 4.10: The effect of mCherry-2A and mCherry-3C on lipid droplets (LDs). GMK 
cells were grown on coverslips and transfected with the HPeV1 non-structural protein 
constructs pmCherry-2A or pmCherry-3C using Turbofect. Cells were fixed and stained with 
BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then cells were washed twice 
with PBS. The coverslips were mounted with hard set mounting medium with DAPI. Images 
were visualized using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the 
red filter detects mCherry-2A and mCherry-3C and the green filter detects neutral lipids in LDs.  
The yellow arrows indicate transfected cells (which show an mCherry signal). mCherry-2A and 
mCherry-3C (yellow arrows) have no effect on LD staining compared to non-transfected cells 
in the field (white arrows). The scale bar shown is 10 µm. 
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FIGURE 4.11: The effect of mCherry-2B, mChery-2C and mCherry-3A on lipid droplets 
(LDs). GMK cells were grown on coverslips and transfected with HPeV1 non-structural protein 
constructs pmCherry-2B, pmCherry-2C or pmChery-3A using Turbofect.  Cells were fixed and 
stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then cells were 
washed twice with PBS. The coverslips were mounted with hard set mounting medium with 
DAPI. Images were visualized using a Nikon A1 confocal microscope. The blue filter detects 
the nucleus, the red filter detects mCherry-2B, mCherry-2C and mCherry-3A and the green 
filter detects neutral lipids in LDs. The blue or yellow arrows indicate arrows indicate 
transfected cells (which show an mCherry signal). mCherry-2B and mCherry-3A (blue arrows) 
show slight co-localisation with LDs but LDs have the typical distribution. There is a co-
localisation between mCherry-2C (yellow arrow) and LDs. The LDs are greatly expanded 
compared to non-transfected cells (white arrows). The scale bar shown is 10 µm. 
10 µm 
C H A P T E R  F O U R    P a g e  | 134 
 
   
 







FIGURE 4.12: The effect of EGFP-2BC on lipid droplets (LDs). GMK cells were grown on 
coverslips and transfected with HPeV1 non-structural protein constructs pEGFP-2BC using 
Turbofect.  Cells were fixed and stained with BODIPY 493/503 for 10 min at a final 
concentration of 10 mg/ml then cells were washed twice with PBS. The coverslips were 
mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon A1 
confocal microscope. The blue filter detects the nucleus, the red filter detects neutral lipids in 
LDs the green filter detects EGFP-2BC. The yellow arrow indicates transfected cells (which 
show an EGFP signal). EGFP-2BC co-localised with the Lipotox LD stain in this cell. The scale 
bar shown is 10 µm. 
10 µm 
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4.4 2C protein and LD  
 2C of other picornaviruses 4.4.1
The results show co-localisation between HPeV1 2C and LDs. Although 2C is relatively well 
conserved among picornaviruses, there is some variation. A neighbour-joining tree of 2C 
sequence shows that the HPeV 2C is part of a distinct cluster from that containing enteroviruses 
(Figure 4.13).To compare the HPeV1 result with other 2Cs of picornaviruses we fused the 2C-
encoding region of CAV9 and HRV1B (Enterovirus genus) to the mCherry gene. 
mCherry-2C of CAV9 gave a rather diffuse distribution, with a few regions where it is more 
concentrated (Figure 4.14). Compared to untransfected cells the LD stain was more concentrated 
and there was some co-localisation with mCherry-2C. mCherry-2C of HRV1B was again more 
diffuse than mCherry-2C of HPeV1 (Figure 4.14). Several distinct spots were seen however. The 
LD stain was more concentrated in transfected cells than in the surrounding non-transfected cells 
and these was clear co-localisation with some of the mCherry-2C fluorescence. The results show 
that 2C from CAV9 and HRV1B (two highly similar picornaviruses) behave slightly differently. 
However, there seems to be some interaction with LDs, similar to, but not as clear as, that seen 
for 2C from the divergent picornavirus HPeV1. This suggests that LDs may play some role in 
infection by many picornaviruses. 
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FIGURE 4.13: A neighbor-joining tree based on 2C nucleotide sequences of some 
members of the Picornaviridae family. Bovine rhinitis A virus 1 (BRAV-1), Foot-and-
mouth disease virus O (FMDV-O), Seal aquamavirus A1 (SeAV-A1), Duck hepatitis A 
virus 1 (DHAV-1), Avisivirus A1 (AsV-A1), Encephalomyocarditis virus 1 (EMCV-1), 
Theiler's murine encephalomyelitis virus (TMEV), Human cosavirus A (HCoSV-A), 
Canine picodicistrovirus 1 (CaPdV-1), Coxsackievirus A9 (CAV9), Poliovirus 1 (PV-1), 
Human rhinovirus 1B (HRVB1), Equine rhinitis B virus 1 (ERBV-1), Human hepatitis A 
virus (HHAV), Hunnivirus A1 (HuV-A1), Aichi virus 1 (AiV-1), Mischivirus A1 , 
Oscivirus A1, Human parechovirus 1 (HPeV-1), Ljungan virus 1 (LV-1), Pasivirus A1 
(PaV-A1), Passerivirus A1 (PasV-A1), Sakobuvirus A1 (SakV-A1), Salivirus A1 (SaV-
A1), Porcine sapelovirus 1 (PSV-1), Sicinivirus A1 (SiV-1) and Porcine teschovirus 1 
(PTV-1). The arrows show different 2C proteins analysed in this thesis. 
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FIGURE 4.14: Relationship of mCherry-2C of CAV9 and HRV1B with  lipid droplets 
(LDs). GMK cells were grown on coverslips and transfected with constructs of mCherry 
fused to the 2C protein from either CAV9 or HRV1B (pmCherry-2C) using Turbofect. Cells 
were fixed and stained with BODIPY 493/503 for 10 min at a final concentration of 10 
mg/ml then cells were washed twice with PBS. The coverslips were mounted with hard set 
mounting medium with DAPI. Images were visualized using a Nikon A1 confocal 
microscope. The blue filter detects the nucleus, the red filter detects mCherry-2C of CAV9 
and mCherry-2C of HRB1V and the green filter detects neutral lipids in LDs. The yellow 
arrows indicate transfected cells (which show an mCherry signal). There is some co-
localisation between LDs and the 2C protein of both viruses and also some expansion of 
LDs compared to non-transfected cells in the field. A and B show close-up images of areas 
marked with white boxes to illustrate the co-localisation. The scale bar shown is 10 µm. 
10 µm 
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 ATPase activity site of 2C and LD 4.4.2
2C of all picornaviruses contains 3 perfectly conserved motifs (Figure 4.15). The Walker A and 
Walker B motifs are needed for NTPase activity. To investigate if these motifs are involved in 
the co-localisation of LDs to 2C, we used overlap PCR mutagenesis to make a K144A Walker A 
mutant (pmCherry-2CK) and a D188A Walker B mutant (pmCherry-2CD) fused to mCherry. 
These were transfected into GMK cells. Both mutants have punctate distribution and co-localise 
to LDs (Figure 4.16). Further investigation was carried out by combining these mutations 
(mutant KD) and the same results were found when transfected into GMK cells (Figure 4.17). In 
all cases, the mutants caused aggregation of the LDs into large clusters, as seen for the original 
mCherry-2C. This implies that the co-localisation and the ability to aggregate the LDs does not 
depend on the NTPase activity of 2C. We co-transfected pEGFP-2C with pmCherry-2CK and 
2CD and both mutants co-localise with EGFP-2C (Figure 4.18). 
 2C fragment and LDs 4.4.3
To investigate the distribution of 2C, a further 3 (2C1, 2C2 and 2C4 mutants) were used. These 
were originally produced by Arsalan Salimi as EGFP fusions and the mutant 2C DNA was 
transferred to mCherry (Figure 4.19). The three mutants were transfected into GMK cells to 
define which parts of 2C interact with LDs. mCherry-2C1 and mCherry-2C2 gave similar results, 
with most of the protein located around the nucleus. The distribution is not as punctate as 
mCherry-2C, but there are some spots and these partly co-localise to LD. Both mutants seemed 
to cause some clustering of LDs. The mCherry-2C4 protein is mainly localised in the nucleus 
and has no clustering effect on the LD distribution (Figure 4.20), in fact LDs appeared very 
dispersed in transfected cells. pmCherry-2C1, pmCherry-2C2 and pmCherry-2C4 were co-
transfected with pEGFP-2C into GMK cells, to define if the proteins co-localised. It can be seen 
that there is some similarity in the distribution of EGFP-2C with mCherry-2C1 and mCherry-
2C2, but the bright punctuate spots seen in EGFP-2C are not present in cells transfected with two 
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mutants (Figure 4.21). To investigate if combinations of these two mutants give the same 
distribution as EGFP-2C, a co-transfection was performed. The two deletion mutants had a 
similar distribution (Figure 4.22). Surprisingly, the combination of two mutants had a very 
similar distribution to EGFP-2C. 
To further investigate, a new mutant was made with mCherry fused to 2C1+2C2 i.e the part of 
2C from position 1 to 160 (2C12). The distribution of the new mutant mCherry-2C12 protein 
was mainly punctate and mostly co-localises to LDs (Figure 4.23). There was no clear clustering 
of LD compared to untransfected cells, suggesting that other regions participate in clustering. 
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BRAV-1           -------FSMKRLNDIFSFLKNGEWLIKFFLSIRSWVRTWLKQEETVMS----------- 
FMDV-O           -------LKARDINDIFAILKNGEWLVKLILAIRDWIKAWIASEEKFVT----------- 
CAV9             -----NDSWLKKFTEMTNACKRMEWIAIKIQKFIEWLKVKILPEVREKHEFLNRLKQLPL 
PV-1             -----GDSWLKKFTEACNAAKGLEWVSNKISKFIDWLKEKIIPQARDKLEFVTKLKQLEM 
HRVB1            -----SDSWLKKFTEMCNAARGLEWIGNKISKFIDWMKS-MLPQAQLKVKYLNEIKKLSL 
PSV-1            ----GPSDWLKDFNIAINSLKGFDFLCSKLMQLIEWIKQFFQRVEPEYKYFKELLESWPK 
EMCV-1           -------SPLKQVNDIFSLAKNLDWAVKTVEKVVDWFGTWVVQEEKEQT--LDQLLQR-- 
TMEV             -------GPLREANEGFTFAKNIEWATKTIQSIVNWLTSWFKQEEDHPQSKLDKLLME-- 
Mischivirus      --GDGFVKRAQDANHTFNFLKNLEWLTNLITKLFNWISSWFAKPEATKHEILDNKMKL-- 
HCoSV-A          ------GPDLRDFVTFFNAARGAQWMIDSLKALITWIKQWLELEEENEAVQLEKMLID-- 
HuV-A1           ------GPIMSEINQVLVLCRNAQWLAQQLQKILGWLGVWKQQEEDASEERFRERMQV-- 
PTV-1            -------GPMQDVSSLINILKGAEWIYHQFEKVIKWLKTWRTAEYEVSSDYLQNEMKN-- 
ERBV-1           ----GISSTLSVLNGFFNLFKNVQWFLDFLKSCYGKLSKQLKPMQSLRD----------- 
SakV-A1          -------AGVDDFNKWSLAAKNADWLFDRLMSCLKQLLDWVGLRVREDPRSEIWANHDKV 
SaV-A1           --------GVRDYNDIMSALRNTDWFFEKIMTHIKNLLEWLGVLVKDDPRTKLNGQHEKI 
AiV-1            --------GLKDFNDGALAMRNVEWIGETAWKWAHRLLDWIPGKAKTDPQAKLADVHDEI 
SiV-1            -------GPMRDYNDCMNALKNTDWLLHRILDLARILCEWLTKRSKEDPAAKLDELHQLV 
PasV-A1          --------GVKEYNDGVNALKNTEWLIKKIFEYIKDLLEWLGVRAKSEPSAQLAQSHDTI 
Oscivirus        ------AFKPKDFNDWANFFKNIDWAVTRLVVLIEKLIKQIQA-AKANPEIGISWYHDDI 
DHAV-1           ---SGKTTSPKSFNDWTTCAKNVQWWLESFVKVVNWLKEKIFPSKTDPTLQWLQDHEEHI 
AsV-A1           ----GPDATGKSFNTWTLVAKNLEWWVDKLKQFINWIRTKLFPSDARDKIEAMESVRDRM 
HPeV-1           -------GPFKGFNEVSTAFRHIDWWIHTLLKIKDMVLSVFKPSIESKAIQWLERNKEHV 
LV-1             --------GWREFNDVSMSFRHVEWWLTMFKKVYNVLKSIFAPSIEQKAVDWIDRNQEYI 
PaV-A1           --------SLAAFNALSLSARNCTWWIELFQKLHTFVRDLLKPDTSAKFHEWCRKNKMLI 
SeAV-A1          -----------GFASFTSALRACEWWIKTIAKFVSWVKTTCFSN------PLVGEARDQL 
CaPdV-1          DLFAKATKGVKLINDTATAVKNVKMFIDLIMWLLDEIKKWRTKVEDTPKYFVESNKDKVF 
HHAV             ----SFSNWLRDICSGITIFKNFKDAIYWLYTKLKDFYEVNYGKKKDILNILKDNQQKIE 
                                     :               .                        
 
BRAV-1           ------YNDLVPKIIQKQLELKEPSTFAQAKNWLVRQREILLTAG--QKDLAQLCEVKVK 
FMDV-O           ------MTDLVPGILEKQRDLNDPSKYKEAKEWLDNARQACLKSG--NVHIANLCKVVAP 
CAV9             LESQIATIEQSAPSQ--SDQEQLFSNVQYFAHYCRKYAPLYAAEAKRVFSLEKKMSNYIQ 
PV-1             LENQISTIHQSCPSQ--EHQEILFNNVRWLSIQSKRFAPLYAVEAKRIQKLEHTINNYIQ 
HRVB1            LEKQIENLRAADN----ATQEKIKCEIDTLHDLSCKFLPLYAHEAKRIKVLYNKCSNIIK 
PSV-1            VCAKVLEFKNCKTTLGQEDICQIKVYIDKLIELGNKYGHKFNLQMSQLLQCSNIINKAYS 
EMCV-1           ------FPEHAKRISDLRNGMAAYVECKESFDFFEKLYNQAVKEKRTGIAAVCEKFRQKH 
TMEV             ------FPDHCRNIMDMRNGRKAYCECTASFKYFDDLYNLAVTCKRIPLASLCEKFKNRH 
Mischivirus      ------FAAAVDEIQSYRSGESNTFPETS-VALVKEVFTLASETGKTGLANLASKYMITR 
HCoSV-A          ------SPRHCKAINDYNRGDSFQRPTNS-FEFMDRLVECATKLGKVQIATYFRNFTTAD 
HuV-A1           ------YPQMMEQYEQYKN-SPRHQKWNDCKTWFDEMRKLAVLHDPKLVN--LFPNMASI 
PTV-1            ------YPHYHRKYKECAN-NYRHPDRTEVANYFKKMRKCAAHVNPRLMG--MFPEFDPS 
ERBV-1           -----------KVLQTYADSIAEFMTPSAQKKELYLQNHYDAVEAGLNSIAAAWKDLANK 
SakV-A1          EKLYEDSISATTS-AKPPDSQAVQANLSIARALLETAGRASSSLHTSMLQRAISNYTSVL 
SaV-A1           LELYTDSVTASSTPPSELSADAIRSNLDLAKQLLTLSHAANSVTHIQLCTRAITNYSTAL 
AiV-1            MLHYSDSILALGS--EKLPIDHITKSISRCRELVSIAQEAKSGPHSSFLNQAVKNYTLAI 
SiV-1            TQLYSDSVDVLTA--PRVMRSAVEENLSRARAALPTASELRSPPHTTMLLRAITNYETKV 
PasV-A1          MALFQDSISATSA--PSLDLPAARSNLAKAQSLLPLATAAKSNTHSHILTQSIKNYTNAI 
Oscivirus        INLYSDSIKSLSL--EDVDKTQLSMNLGEVRRLLSMSLKAGNTGYQTLLKQALSNYTQAQ 
DHAV-1           AIMLALCDEHLCMLRTEKDYICEHNTRPKHQCLVEMVSGTLNQLQGISSARELAARLQHV 
AsV-A1           VLSLAAADKHLVTLKADKAYATSKAARDYHLKITNEIID-LNAMDLGPDFRDLGTKIGQI 
HPeV-1           CSILDYASDIIVESKDQSKMKTQDFYQRYSDCLAKFKPIMAICFRSCHN-SISNTVYRLF 
LV-1             ADVLDHASNIIIKMKDPKEQRRASTISEYFEVLEQLKPIVSLCMKVAPSTKFSSQVFRIY 
PaV-A1           SNFMYTLNEHLKDCATTCNLRKREFRDKHKWLLSVLNRLTEGFTTYGVQNDITRALLDMR 
SeAV-A1          SELLAAAEQLVLDVVNLAIPREVIEARR-----SNILDKLSYAKKLSVNIPELDALVNKA 
CaPdV-1          EYLELSYTFENGCNIDKSKVDEVLYFLKKMSVAANKIDDRHTVTLVNGLYNTYSKIKAKY 
HHAV             KAIEEADEFCILQIQDVEKFEQYQKGVDLIQKLRTVHSMAQVDPNLMVHLSPLRDCIARV 
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BRAV-1           EPVT------------GRPEPVVLVLRGKSGQGKSFMANILASAISRMLTGKPDSVWSCP 
FMDV-O           APSK------------SRPEPVVVCLRGKSGQGKSFLANVLAQAISAHFTGRTDSVWYCP 
CAV9             FKSK------------CRIEPVCLLLHGSPGAGKSVATNLIGRSLAEKLN---SSVYSLP 
PV-1             FKSK------------HRIEPVCLLVHGSPGTGKSVATNLIARAIAEKEN---TSTYSLP 
HRVB1            QR--------------KRSEPVAVMIHGPPGTGKSITTNFLARMITNES-----DVYSLP 
PSV-1            NMTR------------SRHEPVAMLIHGAPGTGKSLATEIIGRAIADKLDN--QRPYTLP 
EMCV-1           DHAT------------ARCEPVVIVLRGDAGQGKSLSSQIIAQAVSKTIFGR-QSVYSLP 
TMEV             DHSV------------TRPEPVVAVLRGAAGQGKSVTSQIIAQSVSKMAFGR-QSVYSMP 
Mischivirus      TNNT------------PRMEPVVVVLRGKPGTGKSVASHILAQAVSKQMTGQ-QSVYSFP 
HCoSV-A          S-DT------------SRPEPVVVVLRGKPGAGKSAAATVMAAAVSKLLVGS-QSVYTLS 
HuV-A1           PHEN------------SRQEPILIVLRGKPGQGKSVAASMLAQMFAHSLSGK-PDYYSYN 
PTV-1            PPDP------------TRPEPVVVVLRGAPGQGKSVCSEMLARMLSYTLVGK-SSYYAFN 
ERBV-1           CYAY------------SRPEPVCILLKGRAGQGKSVAATVIAKAVSIVNTGK-ESVWTLP 
SakV-A1          CNPQRTMS-------GTRPQPVVVYIHGAPGVGKSLVASLLARTLAAKLGTGPDDFYAPS 
SaV-A1           SAISLVGTP------GTRPEPLVVYLYGPPGTGKSLLASLLASTLAQALSGDPNNYYSPS 
AiV-1            SQHRKCQT-------GPRPEPVVVYLYGPPGTGKSLLASLLAQTLSQRLAGTPDDVYSPS 
SiV-1            ASLGHNQP-------HQRPEPYVVYIHGPPGCGKSLMGSLLASRLAQALSGDPDDVYSPA 
PasV-A1          ASQEALLA-------PPRPEPYVLYLYGKPGSGKSVFAQALARTLAYHLCGDPESVYAPS 
Oscivirus        NSLQRTIF-------AVRPEPVVVYIYGGPGSGKSVLAGLLARAISKALSGRADDIYAPS 
DHAV-1           LNKLHQVNFEPELEWTHRPEPLGIWISGGPGVGKSFLSNYIVKEIAKLKHWKS----YAN 
AsV-A1           LNRLQSVTFDSVDAGSMRQEPLGIWISGEPGCGKSFLSHLIIKHLKEKKGFSV----FCN 
HPeV-1           QELARIPNRISTNNDLIRIEPIGIWIQGEPGQGKSFLTHTLSRQLQKSCKLNG---VFTN 
LV-1             SEMMRVNVRVPANTDLTRLEPIGIWVSSEPGQGKSFFTHMLSTCLLKSCNLEG---IYTN 
PaV-A1           KSMLAVKLGQEYQNTCAREEPLGVLLRGEPGQGKSFMTHLLVRSVCNAMGWKVSESVFSH 
SeAV-A1          SLALRKVPATYVTPSHPRVEPLGVWLRGAPGSGKSILMCKLARDVSLIKNSSV----FYH 
CaPdV-1          NSRLY----------MERFEPVVIYLHGKPGCGKSLASAELAKAFARYFKLDFEECVYAS 
HHAV             HQKLKNLGSIN-QAMVTRCEPVVCYLYGKRGGGKSLTSIALATKICKHYGVEPEKNIYTK 
                                  * :*    : .  * ***     :   .                
 
BRAV-1           -PDPTYFDGYRGQSVVIMDDLGQNPDGKDFKYFAQMVSSTAFVVPMAALEDKGTLFTSPV 
FMDV-O           -PDPDHFDGYNQQTVVVMDDLGQNPDGKDFKYFAQMVSTTGFIPPMASLEDKGKPFNSKV 
CAV9             -PDPDHFDGYKQQAVVIMDDLCQNPDGKDVSLFCQMVSSVDFVPPMAALEEKGILFTSPF 
PV-1             -PDPSHFDGYKQQGVVIMDDLNQNPDGADMKLFCQMVSTVEFIPPMASLEEKGILFTSNY 
HRVB1            -PDPKYFDGYDNQSVVIMDDIMQNPDGEDMTLFCQMVSSVTFIPPMADLPDKGKPFDSRF 
PSV-1            -PDPKHFDGYNQQKVVIMDDLGQNPDGEDCKMFCQMVSTTTYIPPMASLDEKGLPFISDF 
EMCV-1           -PDSDFFDGYENQFAAIMDDLGQNPDGSDFTTFCQMVSTTNFLPNMASLERKGTPFTSQL 
TMEV             -PDSEYFDGYENQFSVIMDDLGQNPDGEDFTVFCQMVSSTNFLPNMAHLERKGTPFTSSF 
Mischivirus      -PDCDHLDGYTGQYAVVMDDLGQNPDGEDFSTFCQMVSTTNYIPPMAHLEDKGRPFCSNV 
HCoSV-A          -PDTEHMDGYHGQFVTLMDDLGQNPDGEDFRCFCQMVSCAQYRPAMADLKDKGILFTSRL 
HuV-A1           -SSTNYFDGYQQQPVVLIDDLGQDPAGTDFSVFCQMISTTPFLPNMASLNDKGIKFKSDV 
PTV-1            -SATKHFDGYKQQAVTIIDDLGQDTSGEDFRLFCQLVSTTECIVPMADLPDKGMHFKSEI 
ERBV-1           -TDSDFFDGYAGQNVVIIDDLGQNPDGKDFRNFCQMVSSTVFLPPVADLAHKGIPFTSPV 
SakV-A1          SADCQHYDGYTGQPVHYIDDIGQDVEGRDWADFPQLVCSSPFVLPMASLEQKGTYYTSRV 
SaV-A1           SPDCKFYDGYSGQPVHYIDDIGQDPDGADWADFVNIVSSAPFIVPMADVNDKGRFYTSRV 
AiV-1            SASCEYFDGYTGQTVHFIDDIGQDPEGRDWANFPNLVSSAPFIVPMASLEEKGTHYTSKV 
SiV-1            SVSCEYYDGYRGQSVHYIDDVGQDPEGKDWRDFAQLVSTAPFVLPMANLEEKGRMYTSKV 
PasV-A1          SSDCAYYDGYAQQCVHYIDDVGQDPEGKDWKDFAQLVSTSPFIVPMASLEKKGMLYNSKV 
Oscivirus        SFGTDHFDGYHQQTVHLIDDLGQAVDGSDWANFCNMVSSAPWAPPMAKLEEKGMYYTSKV 
DHAV-1           PTGSKHMDGYVSQEIHVFDDFGQNREEEDYSLICNLISSVPFITPKASVEAKGTQYRGRL 
AsV-A1           PSGSDHMDGYNGQEIHYFDDLGQIREEADIKLMCQLISSQQFIVPKADLTSKGTLYNAKV 
HPeV-1           PTASEFMDGYDNQDIHLIDDLGQTRKEKDIEMLCNCISSVPFIVPMAHLEEKGKFYTSKL 
LV-1             PTGSEFMDGYIGQDIHIIDDAGQNREEKDLALLCQCISSVPFTVPMADLTEKGTFYTSKI 
PaV-A1           PTSSEFFDGYAGQPIHLIDDFGQNVEEPEYKVLCQCMSSIPFSVPMASLEEKGLPYTSKL 
SeAV-A1          PTGSNFFSGYHGQYVHCIDDLGQNKDEKDISLICQCISSSHFTAPMANIEDKAMQYSSNL 
CaPdV-1          PPASEYLDGYGGHKIHLIDDLGQDPEAKDWKNFCQMVSTTKYLPNMASLEEKGIPYTSEI 
HHAV             PVASDYWDGYSGQLVCIIDDIGQNTTDEDWSDFCQLVSGCPMRLNMASLEEKGRHFSSPF 
                      . .**  :    :**  *     :   : : :.        * :  *.  : .   
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BRAV-1           IIATTNLSDAFTPITMACPEALQRRFHFDYNLEAK--WKKGYH----LDVKRALQPTG-- 
FMDV-O           IIATTNLYSGFTPRTMVCPDALNRRFHFDIDVSAKDGYKINNK----LDIIKALEDTH-- 
CAV9             VLASTNAG-SINAPTVSDSRALARRFHFDMNIEVISMYSQNGKINMPMSVKTCDEECC-- 
PV-1             VLASTNSS-RITPPTVAHSDALARRFAFDVDIQVMGEYSKDGKLNMAMATEMCKNCHQ-- 
HRVB1            VLCSTNHS-LLAPPTISSLPAMNRRFFFDLDIVVHDNYKDAQGKLNVSKAFQPCNVNT-- 
PSV-1            VLASTNQH-ALTPRTIAEPDAINRRWFMNVDIHLKKEYKDDRGR-LDMSKCLPCKDCK-- 
EMCV-1           VVATTNLP-EFRPVTIAHYPAVERRITFDYSVSAGPACMRTEAGCKVLDVEKAFRPIG-- 
TMEV             IVATTNLP-KFRPVTVAHYPAVDRRITFDFTVTAGPHCKTPAG---MLDIEKAFDEIPG- 
Mischivirus      IIATTNLA-AFAPVTVADPMAVERRIFLDLEVTPGVTCQINGK----LDLEAALEPIG-- 
HCoSV-A          LIATTNLP-DFNPVTISDPRALDRRITFDILVTPGSAATKNGK----LDLAAALKPDG-- 
HuV-A1           IIATTNLP-EFKPVTIADPGALQRRINFDFEVEAGQSYKTKAG---TLDLAKALEPTG-- 
PTV-1            LIANTNLP-SFNPITVSDPAAIKRRIFLDLTVEANRAYTKPDG---TLDLVRALQATG-- 
ERBV-1           IIATTNKNENFLPVTVSDQEAVTRRYWKVIDVSADDQYKTVDG---RLDYAKATQPTQ-- 
SakV-A1          IIITSNFS-GPNPRSVRCQPALERRLTIRLVAELGP-EPCSPAESVAPDG---------- 
SaV-A1           VIVTSNFP-GPNPRSARCVAALERRLHIRLNVTARD-GVAFSAAAALQPSNPP------- 
AiV-1            IVVTSNFH-EPNERAARSMGALRRRVHLRINVTSNG-VPFDPTNALNPIPG--------- 
SiV-1            IIMTSNFP-EPNPRSSRCPEALSRRLRLRLSVSPPPRGPKHLDVTAALAPSGN------- 
PasV-A1          IILTSNFS-EPNPRASRIPQALQRRLKCMIEIEPLSCPTQSNLHTLSSLPNQFNPETALR 
Oscivirus        IIVTANFN-LPNYASAREPKALERRLHFKMFMGGSLNVDFACAPDG-------------- 
DHAV-1           VVVTTNRR-DFTSCKLTDPDALERRFPIRLNIRPLQKYN-HKGRLDVATAMRDG------ 
AsV-A1           VIATTNKN-EFDSTVLNDSGALRRRFPIRLHVRPHSFYSTQDGRLDLNRAMKDG------ 
HPeV-1           VVATTNKS-DFSSTVLQDSGALKRRFPYIMHIRAAKAYS-KAGKLNVSQAMAT------- 
LV-1             VIATTNKF-DFTSMVLTDPAALERRFPFHLRIRAVASYS-RNNKLDVARSMAA------- 
PaV-A1           VIATTNKS-DWSSRTLCAPGALKRRFPIVYTVRARRTLT-KNGLLDVNAHMSA------- 
SeAV-A1          VIATTNMT-SFRTYTLTTPAALERRFPLVCDIVPKYSKP--NGTLNLN------------ 
CaPdV-1          IIATANFS-NPPDTASRDIGALRRRCKLCFEMTFAPDDGENTYKTEDSKLDVAAAFTP-- 
HHAV             IIATSNWS-NPSPKTVYVKEAIDRRLHFKVEVKPASFFKNPHNDMLNVNLAKTN------ 
                 :: .:*              *: **                                    
BRAV-1           --KPANELFEEDYPLLNGQAVMFVAN-----KMCPAIDSAYELIEAVYAAVIERRDVAKV 
FMDV-O           --TNPVAMFQYDCALLNGMAVEMKRMQQDMFKPQPPLQNVYQLVQEVIDRVELHEKVSSH 
CAV9             -----PVNFKKCCPLVCGKAIQFIDR------RTQVRYSLDMLVTEMFREYNHRHSVGAT 
PV-1             -----PANFKRCCPLVCGKAIQLMDK------SSRVRYSVDQITTMIINERNRRSNIGNC 
HRVB1            -----KIGNAKCCPFVCGKAVSFKDR------STCSTYTLAQVYNHILEEDKRRRQVVDV 
PSV-1            -----PTNFRKCNPLVCGKAIILLDR------KTQKNWTVDSAVTHLLEESERRKGFLNV 
EMCV-1           --EAPLPCFQNNCLFLEKAGLQFRDN------RSKEIISLVEVIERAVSRIERKKKVLTT 
TMEV             -SKPQLACFSADCPLLHKRGVMFTCN------RTKTVYNLQQVVKMVNDTITRKTENVKK 
Mischivirus      ---PAVGPFRQDCELLHTAGLCFTDR------RTRQQYSLYEVFQMVEERIKVKASVKKN 
HCoSV-A          ---PGEHPYTSDCPILHTTGLLLKNL------RNNQTMNLKDLVDMIVKRIKHKKEVGNM 
HuV-A1           -CSAPLHMVKADIHLFSSACLKFKDR------MARCECSLVGVYDRVMNSHKRRNDLANK 
PTV-1            -KESQSPLLRQDHNILYSDCVAFKH--------GRHTLSFLEVFDMIKRELQRRQNVSNS 
ERBV-1           -IPPELAVFKTHVPLLKGALRDCQRTN----RSGARVLNLYDVISAICVEVDRREQLRSN 
SakV-A1          ---PSSKHFSSSTPLTRFESIKLSWDQKSLFTSPENPKSLDELVDLVLELVARNSAISGD 
SaV-A1           ---SATRYCKFANPLTQFSMFNLAVDYKSVVLPNTPLTCFDELVDFVLSSLRDRASVNSL 
AiV-1            ---TQSKYFTAQTPLTLFQSNTVRLDRDSIWTP--TFTNMDELVDAIVTRLDRSTGVSNS 
SiV-1            ---GPTKYFSADCAFLRFESFVLRSEMG-----APNFTHMDELVDYIMSQLDNTERNTTA 
PasV-A1          VDGPATRYFANDCPMLRFEAFRLTSNHG--------FKHADDIVRHVLDKVKNSGGISNA 
Oscivirus        ---IPMRYFKSGCPLLRNSNGAIKESGSVLP---CKFSDMDDVVELVLAEVKKRSLGLTM 
DHAV-1           -------------SLQGGACWERDIGQLG--LECWNPINGQTLIDEIMSELQVRQEVASF 
AsV-A1           -------------DIDP-GCWEINVGTG---RSCWQTLNWDILIHEVEDELINRENINKF 
HPeV-1           --------------MSTGECWEVSKNG-----RDWETLKLKDLVDKITIDYNERVKNYNA 
LV-1             --------------MADGSCWEYSTDGG----RAWKTLSMDELVKQITAVYTQRSDALMV 
PaV-A1           --------------VRDGAAWEYTTNG-----YDWQPFSVNDLAAEIIKQLEQRRESFQL 
SeAV-A1          --------------FDPHDCWKITCNG--------QEMCYMDLFNLVLERLTEREKLHAD 
CaPdV-1          ----------DDDSMPDEYVGELTPFWN-----GKAVSLTRTGMAYNGPEKDCSFSLLEV 
HHAV             ------------DAIKDMSCVDLIMDG--------HNVSLMDLLSSLVMTVEIRKQNMTE 
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FIGURE 4.15: Multiple sequence alignment of the amino acid sequences of 2C in 
several members of the Picornaviridae family using protein BLAST. The predicted 
amphipathic helix is highlighted in grey and boxed in red, the Walker A motif boxed in 
blue, Walker B motif boxed in yellow and motif C in boxed in red. Bovine rhinitis A virus 
1 (BRAV-1), Foot-and-mouth disease virus O (FMDV-O), Seal aquamavirus A1 (SeAV-
A1), Duck hepatitis A virus 1 (DHAV-1), Avisivirus A1 (AsV-A1), Encephalomyocarditis 
virus 1 (EMCV-1), Theiler's murine encephalomyelitis virus (TMEV), Human cosavirus A 
(HCoSV-A), Canine picodicistrovirus 1 (CaPdV-1), Coxsackievirus A9 (CAV9), 
Poliovirus 1 (PV-1), Human rhinovirus 1B (HRVB1), Equine rhinitis B virus 1 (ERBV-1), 
Human hepatitis A virus (HHAV), Hunnivirus A1 (HuV-A1), Aichi virus 1 (AiV-1), 
Mischivirus A1 , Oscivirus A1, Human parechovirus 1 (HPeV-1), Ljungan virus 1 (LV-1), 
Pasivirus A1 (PaV-A1), Passerivirus A1 (PasV-A1), Sakobuvirus A1 (SakV-A1), Salivirus 
A1 (SaV-A1), Porcine sapelovirus 1 (PSV-1), Sicinivirus A1 (SiV-1) and Porcine 
teschovirus 1 (PTV-1).  
BRAV-1           GIVKQ---------------- 
FMDV-O           PIFKQGENUSAQUAMAVIRUS 
CAV9             LEALFQ--------------- 
PV-1             MEALFQ--------------- 
HRVB1            MSAIFQ--------------- 
PSV-1            VDAIFQ--------------- 
EMCV-1           VQTLVAQ-------------- 
TMEV             MNSLVAQ-------------- 
Mischivirus      LMALVFE-------------- 
HCoSV-A          LDSLVAQ-------------- 
HuV-A1           LVEIFNFQ------------- 
PTV-1            LTNLFTFQ------------- 
ERBV-1           LGGIFAQ-------------- 
SakV-A1          LNSLIKQ-------------- 
SaV-A1           LSGMVRTDVTRQ--------- 
AiV-1            LASLIRRQ------------- 
SiV-1            FRHLLPSTPKKQ--------- 
PasV-A1          LAALIPGVKPLARQQ------ 
Oscivirus        FDDLVGQ-------------- 
DHAV-1           MNQ------------------ 
AsV-A1           FSQ------------------ 
HPeV-1           WKQQLENQ------------- 
LV-1             WKRKLNTIRNE---------- 
PaV-A1           WNSFISQ-------------- 
SeAV-A1          --------------------- 
CaPdV-1          FYKAIAIYE------------ 
HHAV             FMELWSQ-------------- 
                                       
 
C H A P T E R  F O U R    P a g e  | 144 
 
   
 
  


































FIGURE 4.16: The effect of Walker A and Walker B mutations in HPeV1 2C on lipid 
droplets (LDs). GMK cells were grown on coverslips and transfected with mCherry-2C 
mutant K144 (pmChery-2CK) and D188 (pmCherry-2CD) using Turbofect.  Cells were 
fixed and stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml 
then cells were washed twice with PBS. The coverslips were mounted with hard set 
mounting medium with DAPI. Images were visualized using a Nikon A1 confocal 
microscope.  The blue filter detects the nucleus, the red filter detects mCherry-2C K144 and 
mCherry-2CD188 and the green filter detects neutral lipids in LDs. A and B show the close-
up images of the co-localisation. Yellow indicates overlap between the red and green 
images. The yellow arrows indicate transfected cells (which show an mCherry signal). 
mCherry-2CK144 and mCherry-2CD188 mutants still co-localises to LDs and this suggests 
that LDs does not depend on the NTPase activity of 2C. A and B show close-up images of 
areas marked with white boxes to illustrate the co-localisation. The scale bar shown is 10 
µm. 
10 µm 
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FIGURE 4.17: The effect of combining Walker A and Walker B mutations in HPeV1 
2C on lipid droplets (LDs). GMK cells were grown on coverslips and transfected with 
mCherry-2C mutant KD (pmCherry-2CKD) using Turbofect. Cells were fixed and stained 
with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then cells were 
washed twice with PBS. The coverslips were mounted with hard set mounting medium with 
DAPI. Images were visualized using a Nikon A1 confocal microscope.  The blue filter 
detects the nucleus, the red filter detects mCherry-2CKD and the green filter detects neutral 
lipids in LDs. A shows the close-up images of the co-localisation. Yellow indicates overlap 
between the red and green images. The yellow arrow indicates a transfected cell (which 
show an mCherry signal). The mCherry-2CKD mutant still co-localises to LDs and this 
suggests that LD localisation of 2C does not depend on the NTPase activity. A shows close-
up images of the co-localisation seen in the area marked with the white box. The scale bar 
shown is 10 µm. 
10 µm 
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FIGURE 4.18: Co-transfection of pmCherry-2CK and pmCherry-2CD mutants with 
pEGFP-2C. GMK cells were grown on coverslips and co-transfected with with  EGFP-2C  and 
either mCherry-2C mutant K144 (pmChery-2CK) or D188 (pmCherry-2CD using Turbofect.  
The coverslips were mounted with hard set mounting medium with DAPI. Images were 
visualized using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the red 
filter detects mCherry-2CK and mCherry-2CD and the green filter detects EGFP-2C. The 
yellow arrows indicate transfected cells (which show an mCherry and EGFP signals). mCherry-
2CK144 and mCherry-2CD188 mutants co-localise to EGFP-2C. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 4.19: Schematic diagram showing the regions of the 2C protein encoded   
in three deletion mutants. The predicted positions of the amphipathic helix, Walker 
A, Walker B and domain C are shown. The mutants are: pmCherry-2C1 (yellow), 
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FIGURE 4.20: The distribution and effect of pmCherry-2C1, pmChery-C2 and 
pmCherry-2C4 deletion mutants on lipid droplets (LDs). GMK cells were grown on 
coverslips and transfected with pmCherry-2C1, pmCherry-2C2 or pmCherry-2C4 using 
Turbofect. Cells were fixed and stained with BODIPY 493/503 for 10 min at a final 
concentration of 10 mg/ml then cells were washed twice with PBS. The coverslips were 
mounted with hard set mounting medium with DAPI. Images were visualized using a Nikon A1 
confocal microscope.  The blue filter detects the nucleus, the red filter detects mCherry-2C1, 
mCherry-2C2 and mCherry-2C4 and the green filter detects neutral lipids in LDs. A and B 
show the close-up images of the co-localisation. Yellow indicates overlap between the red and 
green images. The arrows indicate transfected cells (which show an mCherry signal). mCherry-
2C1 and mCherry-2C2 (yellow arrows) mutants partly co-localise to LDs and appear to cause 
them to aggregate. mCherry-2C4 (white arrow) has no aggregation effect on the LD staining 
compared to non-transfected cells in the field. A and B show close-up images of the co-
localisation seen in the area marked with the white box. The scale bar shown is 10 µm.  
10 µm 
C H A P T E R  F O U R    P a g e  | 149 
 








































Figure 4.21: Co-transfection of pmCherry-2C1, pmCherry-2C2 and pmCherry-2C4 
mutants with pEGFP-2C. GMK cells were grown on coverslips and co-transfected with  
pEGFP and either pmCherry-2C1, pmCherry-2C2 or pmCherry-2C4 using Turbofect. The 
coverslips were mounted with hard set mounting medium with DAPI. Images were visualized 
using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the red filter detects 
mCherry-2C1, mCherry-2C2 and mCherry-2C4 and the green filter detects EGFP-2C. The 
yellow arrows indicate transfected cells (which show mCherry and EGFP signals). There is 
some similarity in the distribution between EGFP-2C and mCherry-2C1 or mCherry-2C2.  
There is no similarity between the distribution of EGFP-2C and mCherry-2C4. The scale bar 
shown is 10 µm. 
10 µm 
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FIGURE 4.22: Co-transfection of pmCherry-2C1 and pmCherry-2C2 with pEGFP-2C 
and pmCherry-2C1 with pEGFP-2C2. GMK cells were grown on coverslips and co-
transfected with A) pmCherry-2C1 plus pmCherry-2C2 with EGFP-2C B) mCherry-2C1 with 
EGFP-2C2, using Turbofect. The coverslips were mounted with hard set mounting medium 
with DAPI. Images were visualized using a Nikon A1 confocal microscope. The blue filter 
detects the nucleus, the red filter detects  A) mCherry-2C1, 2C2 B) mCherry-2C1 and the green 
filter detects EGFP-2C2. The yellow arrows indicate transfected cells (which show mCherry 
and EGFP signals). A) mCherry-2C1 plus mCherry-2C2 mutants had a similar distribution of 
EGFP-2C. B) there is some similarity in the distribution between mCherry-2C1 and EGFP-2C2 
mutants. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 4.23: The effect of pmCherry-2C12 mutant on lipid droplets (LDs). GMK cells 
were grown on coverslips and transfected with pmCherry-2C12 using Turbofect. Cells were 
fixed and stained with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml then 
cells were washed twice with PBS. The coverslips were mounted with hard set mounting 
medium with DAPI. Images were visualized using a Nikon A1 confocal microscope.  The blue 
filter detects the nucleus, the red filter detects mCherry-2C12 and the green filter detects neutral 
lipids in LDs. The yellow arrow indicates a transfected cell (which show an mCherry signal). 
mCherry-2C12 mutant mostly seems to co-localise to LDs. A shows close-up images of the co-
localisation in the area marked by the white box.The scale bar shown is 10 µm. 
10 µm 
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 Location of the LD-interacting region of 2C 4.4.4
The N-terminal region of PV 2C (positions 19-36) was predicted to form an amphipathic helix, 
proposed to be responsible for its membrane binding property (Teterina et al., 2006). This is 
remarkably similar in terms of the sequence and structure to an amphipathic helix in the N-
terminal region of the NS5A protein of HCV (Figure 4.24). The ability to form an amphipathic 
helix seems to be conserved among all picornaviruses but the sequence similarity to HCV NS5A 
is not as great in other picornaviruses. Mutations in the helix in PV were shown to impair viral 
RNA synthesis, suggesting it has an important function (Teterina et al., 2006). We found that the 
corresponding region (positions 17-34) in HPeV1 may form a similar structure, although a strong 
amphipathic helix can also be predicted between positions 8 and 25 (Figure 4.24).  
The results on the localisation of the HPeV1 2C protein described above show that the region 
between positions 1-160, and not NTPase activity, is needed for localisation. To try to find 
which parts of the sequence are needed, 6 deletion mutants (Figure 4.25) were produced and 
transfected into GMK cells. The mutants are named from the start position e.g. 2C 7A contains 
2C positions 7 to the C-terminus and was made as there is a conserved KXFN motif (position 4-7 
in HPeV) in several 2C proteins from different picornaviruses (Figure 4.15). Mutants 2C 25A 
and 2C 53A remove the alternative amphipathic and alternative plus conserved amphipathic 
helices respectively. 
mCherry-2C 7A and mCherry-2C 25A had a similar distribution to wild-type 2C (Figure 4.26) 
suggesting that the conserved motif and the alternative amphipathic helix do not play a role in 
LD localisation. LDs are still clustered in transfected cells. mCherry-2C 53A has the same 
localisation as the first two mutants and mCherry-2C 75A is very similar (Figure 4.27). The 
close up image of mCherry-2C 75A is a little different from the other mutants as some non-
overlapping LD stain can be seen. To see if these mutants co-localise with wild-type mCherry-
2C, we co-transfected the DNA constructs with pEGFP-2C (Figure 4.28). Both mutants have a 
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similar distribution to EGFP-2C, but mCherry-2C 75A seems to not precisely co-localise, 
suggesting that the 2C region from position 53 to 74 may have some role in the LD interaction. 
mCherry-2C 87A has a round foci distribution which is not related to LDs, while mCherry-2C 
129A has an mCherry distribution with a lot of the protein localised in the nucleus (Figure 4.29). 
Neither of these mutants cluster the LDs, but LDs are still brighter than in the surrounding non-
transfected cells. The results suggest that all the sequences needed to bind to structures in the 
cytoplasm are in the first 128 amino acids of 2C and that positions 75-86 are important in 
interacting with LDs.  
Position 75-86 overlaps with sequences that can be predicted to form an amphipathic helix 
(position 74-91, Figure 4.30). This is in a larger region of 2C that is highly conserved between 
HPeV strains, but the HPeV sequences show some differences between strains. These 
differences are conserved in type and this suggests that a protein structure, not the sequence 
itself, is important. This is further evidence that an amphipathic helix forms (data not shown). In 
addition another Parechovirus, Ljungan virus, also appears to have an amphipathic helix at this 
position, even though the sequences making it up are mainly different from the HPeV sequences 
(Figure 4.30). 
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HCV NS5A (position 10-27)                                PV 2C (position 19-36) 
 FIGURE 4.24: The predicted region of amphipathic helix in HCV, PV and HPeV1. An 
alternative amphipathic helix for HPeV1 (position 17-34) is also shown. The prediction was 
performed using NetWheels (http://lbqp.unb.br/NetWheels/). 
 
HPeV 2C (position 8-25)                                HPeV 2C (position 17-34) 
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2C fragment 4 
FIGURE 4.25: The part of the HPeV1 2C protein located in a set of mCherry-2C 
deletion mutants. The black, green and orange boxes show the predicted position of 
possible amphipathic helices. The numbers in the names refer to the amino acid position 
where the remaining part of 2C starts. The red box represents the mCherry protein. 
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FIGURE 4.26: The effect of pmCherry-2C7A and pmCherry-2C25A mutants on lipid 
droplets (LDs) distribution. GMK cells were grown on coverslips and transfected with 
pmCherry-2C 7A and pmCherry-2C 25A using Turbofect. Cells were fixed, stained with 
BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml, then cells were washed twice 
with PBS. The coverslips were mounted with hard set mounting medium containing DAPI. 
Images were visualised using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry and the green filter detects neutral lipids in LDs. A and B 
show close-up images of the co-localisation site. The yellow arrows indicate transfected cells 
(which show an mCherry signal). mCherry-2C7A and mCherry-2C25A mutants still co-
localises with LDs. A and B show close-up images of the co-localisation seen in the area 
marked with the white box. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 4.27: The effect of pmCherry-2C53A and pmCherry-2C75A mutants on lipid 
droplets (LDs) distribution. GMK cells were grown on coverslips and transfected with 
pmCherry-2C 53A and pmCherry-2C 75A using Turbofect. Cells were fixed, stained with 
BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml, then cells were washed twice 
with PBS. The coverslips were mounted with hard set mounting medium containing DAPI. 
Images were visualised using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry and the green filter detects neutral lipids in LDs. A and B 
show close-up images of the co-localisation site. The yellow arrows indicate transfected cells 
(which show an mCherry signal). mCherry-2C53A and mCherry-2C75A mutants still co-
localises with LDs. A and B show close-up images of the co-localisation seen in the area 
marked with the white box. The scale bar shown is 10 µm. 
10 µm 
C H A P T E R  F O U R    P a g e  | 158 
 
   
 































FIGURE 4.28: Co-transfection for pmCherry-2C53A and pmCherry-2C75A to pEGFP-
2C. GMK cells were grown on coverslips and co-transfected with pEGFP-2C and A) 
pmCherry-2C53A or B) pmCherry-2C75A using Turbofect. Cells were fixed, then were washed 
twice with PBS. The coverslips were mounted with hard set mounting medium containing 
DAPI. Images were visualised using a Nikon A1 confocal microscope. The blue filter detects 
the nucleus, the red filter detects mCherry and the green filter detects EGFP. The yellow arrows 
indicate transfected cells (which show mCherry and EGFP signals). mCherry-2C53A and 
mCherry-2C75A mutants had a similar distribution to EGFP-2C. The scale bar shown is 10 µm.  
10 µm 
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FIGURE 4.29: The effect of pmCherry-2C87A and pmCherry-2C129A mutants on lipid 
droplets (LDs) distribution. GMK cells were grown on coverslips and transfected with 
pmCherry-2C87A and pmCherry-2C 129A using Turbofect. Cells were fixed, stained with 
BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml, then cells were washed twice 
with PBS. The coverslips were mounted with hard set mounting medium containing DAPI. 
Images were visualised using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry and the green filter detects neutral lipids in LDs. The 
yellow arrows indicate transfected cells (which show an mCherry signal). Neither mCherry-
2C87A nor mCherry-2C129A mutants co-localise with LDs. The scale bar shown is 10 µm.  
10 µm 
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HPeV1   63   IIVESKDQSKMKTQDFYQRYSDCLAKFKPIMAICFRSCHNS-ISNTVYRLF  112 
             +I+  KD  + +     + Y D L K KP++++C +   ++  S+ V+RL+ 
Ljungan 62   MIIRMKDPKQQRNPKTIEEYFDVLKKMKPLVSLCIKVAPSTKFSSQVFRLY  111 
 
FIGURE 4.30: A) A predicted amphipathic helix overlapping the region found to be 
important in HPeV 2C LD localisation. The corresponding region from another Parechovirus, 
Ljungan virus, also gives a predicted amphipathic helix. B) Blast alignment of the location of the 
region predicted to form an amphipathic helix in HPeV1 Harris and Ljungan virus strain 340. The 
helix region is marked in blue. + = similar amino acid. 
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 Cav1 and 2C of HPeV1  4.4.5
Caveolin-1 (Cav1) binds glycolipids and fatty acids and is thought to be engaged in intracellular 
lipid transport. Cav1 distributes in the caveolae and Golgi membranes under normal culture 
conditions, however when cells are loaded with lipids it translocates to the LD (Fujimoto et al., 
2008). To investigate if there was an interaction between 2C from HPeV1 and Cav1, we co-
transfected pEGFP-2C and pmCherry-Cav1 into GMK cells. mCherry-Cav1 has a perinuclear 
localisation and does not co-localise with LDs (Figure 4.31). In addition, there is no co-
localisation with EGFP-2C (Figure 4.32). 
 ADRP and 2C of HPeV1 4.4.6
ADRP is a protein found on the surface of LDs from the earliest time of their synthesis and helps 
to regulate lipid storage during LD formation. In addition, an increase in neutral lipid mass and 
LD accumulation occurs when ADRP is overexpressed. This slows down TAG turnover and 
simultaneously decreases TAG secretion in VLDL (Listenberger et al., 2007). To provide further 
evidence that the 2C-induced cytoplasmic structures are related to LDs, an mCherry-ADRP 
construct was used.  pmCherry-ADRP has a punctate distribution which partly co-localised to 
LDs (Figure 4.33). When mCherry-ADRP was co-transfected with pEGFP-2C or pEGFP-2BC 
some of the mCherry-ADRP concentrated into perinuclear spots which corresponded to EGFP-
2C and EGFP-2BC fluorescence (Figure 4.34). This suggests that ADRP is recruited by 2C to 
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FIGURE 4.31: pmCherry-CavI and lipid droplets (LDs). GMK cells were grown on 
coverslips and transfected with pmCherry-Cav1 using Turbofect. Cells were fixed, stained with 
BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml, then cells were washed twice 
with PBS. The coverslips were mounted with hard set mounting medium containing DAPI. 
Images were visualised using a Nikon A1 confocal microscope. The blue filter detects the 
nucleus, the red filter detects mCherry and the green filter detects neutral lipids in LDs. The 
yellow arrows indicate transfected cells (which show an mCherry signal). There is no co-
localisation between mCherry CavI and LDs. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 4.32: Co-transfection of pmCherry-Cav1 and pEGFP-2C. GMK cells were grown 
on coverslips and co-transfected with pEGFP-2C and pmCherry-Cav1 using Turbofect. Cells 
were fixed, then were washed twice with PBS. The coverslips were mounted with hard set 
mounting medium containing DAPI. Images were visualised using a Nikon A1 confocal 
microscope. The blue filter detects the nucleus, the red filter detects mCherry and the green 
filter detects EGFP. The yellow arrow indicate a transfected cell (which show mCherry and 
EGFP signals). There is no co-localisation between mCherry-CavI and EGFP-2C. The scale bar 
shown is 10 µm. 
10 µm 
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FIGURE 4.33: pmCherry-ADRP and lipid droplets (LDs). GMK cells were grown on 
coverslips and transfected with pmCherry-ADRP using Turbofect. Cells were fixed, stained 
with BODIPY 493/503 for 10 min at a final concentration of 10 mg/ml, then cells were washed 
twice with PBS. The coverslips were mounted with hard set mounting medium containing 
DAPI. Images were visualised using a Nikon A1 confocal microscope. The blue filter detects 
the nucleus, the red filter detects mCherry and the green filter detects neutral lipids in LDs. The 
yellow arrow indicates a transfected cell (which shows an mCherry signal). mCherry-ADRP 
partly co-localised with LDs. A shows close-up images of the co-localisation within the area 
marked with a white box. The scale bar shown is 10 µm. 
10 µm 
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FIGURE 4.34: Co-transfection of pmCherry-ADRP and pEGFP-2C/pEGFP-2BC. GMK 
cells were grown on coverslips and co-transfected with pmCherry-ADRP and A. pEGFP-2C or 
B. pEGFP-2BC using Turbofect. Cells were fixed, then were washed twice with PBS. The 
coverslips were mounted with hard set mounting medium containing DAPI. Images were 
visualised using a Nikon A1 confocal microscope. The blue filter detects the nucleus, the red 
filter detects mCherry and the green filter detects EGFP. The yellow arrow indicates a 
transfected cell (which show mCherry and EGFP signals). mCherry-ADRP partly co-localised 
to EGFP-2C and EGFP-2BC. A and B show close-up images of the co-localisation in the areas 
marked with the white boxes. The scale bar shown is 10 µm. 
10 µm 
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4.5 Discussion 
It has been shown that lipid synthesis and modifying enzymes are required in the replication of 
some positive sense RNA viruses. For example, phospholipid and/or sterol biosynthesis is 
required for efficient replication (Chukkapalli et al., 2012).  
In our work we saw only a slight effect on FAs in HPeV1-infected cells and in cells infected 
with CAV9. mCherry-2A of HPeV1 seemed to accumulate fatty acids (FAs) around the nuclei 
while there some co-localisation of FAs with mCherry-2B and -3A. In the case of mCherry-2C, 
some of the FA stain is located in foci and these correspond to the concentrations of 2C. The 
results suggest some interaction between HPeV proteins and FAs. It has been reported that in 
mock-infected cells FAs are mostly channelled to lipid droplets, while in cells infected with PV 
they are immediately utilized for highly upregulated PC synthesis. Poliovirus 2A protein 
stimulates FAs import (Nchoutmboube et al., 2013). It would be interesting to investigate this in 
HPeV infection. Many other viruses use FAs during replication. Inhibition of FA synthesis 
inhibits HCV replication, maturation and release of HCV (Syed et al., 2010). NS5B of HCV 
interacts with fatty acid synthase and contributes to HCV replication (Huang et al., 2013). 
DENV infection controls fatty acid biosynthesis to increase lipid biogenesis to establish or 
expand its replications complex (Heaton et al., 2010).  
There was clear co-localisation between EGFP-2BC and mCherry-2C of HPeV1 with LDs and 
these proteins caused large foci or aggregates of LDs.  
Several viruses seem to use or manipulate LDs during infection, but these organelles have been 
largely unstudied in picornavirus infections. HCV affects host lipid metabolism and induces LDs 
which then play a crucial role in viral replication and assembly (Fukasawa, 2010). HCV 
assembly occurs close to LDs (Vogt et al., 2013). Dengue virus decreased LD number during 
infection due to autophagy-dependent lipolysis to release free fatty acid (Heaton and Randall, 
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2010; Herker and Ott, 2012). The C protein of Dengue virus (DENV) accumulates on the surface 
and localises to LDs (Herker and Ott, 2012; Liu et al., 2010).  
The rotavirus protein NSP4 contributes to LD metabolism using an autophagy pathway (Cheung 
et al., 2010; Herker et al., 2010). It would be interesting to study the role of LDs in HPeV and 
enterovirus infection as these seem affect LDs differently. 
We focused our efforts on understanding the basis of the interaction between 2C and LDs. We 
find that ATPase activity is not needed for the interaction with LDs.  Mutation of the equivalent 
active site amino acids in FMDV 2C completely abolished ATPase activity (Sweeney et al., 
2010) and gave non-viable viruses in poliovirus (Mirzayan and Wimmer, 1992; Teterina et al., 
1992).  
If the ATPase activity of 2C is not involved in LD interactions, it is likely that regions which 
interact with membranes, such as the N-terminal amphipathic helix are involved. The poliovirus 
2C N-terminus allows binding to cell membranes (Echeverri et al., 1998; Echeverri and 
Dasgupta, 1995). To investigate which parts of HPeV1 2C may interact with LDs, 3 further 
mutants, 2C1(1-79), 2C2(79-160) and 2C4(161-329) were used. mCherry-2C1 and 2C2 partially 
co-localised to LDs. As the combination of the two mutants restores co-localisation with EGFP-
2C, it is possible that there is an interaction between regions within the two mutant proteins 
which is necessary for efficient LD binding. A new mutant was produced fused to mCherry, 
mCherry-2C12, with positions 1-160 of 2C. The distribution of the new mutant seems to be 
punctate and mostly co-localise to LDs. The mutant seems to contain enough information to 
localise well with LDs but does not have the ability to aggregate LDs. This suggests that 
sequences in the second half of the protein could be involved. As this part of 2C is mainly the 
NTPase, which does not affect aggregation, it is unclear how aggregation occurs. A C-terminal 
cysteine-rich motif in the poliovirus 2C protein, located downstream of the NTPase domain, has 
been shown to bind zinc and be involved in RNA replication (Pfister et al., 2000). HPeV 2C does 
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not have a similar motif, but it is possible that other motifs in this region could have critical roles 
independent of the NTPase activity. 
Several more deletion mutants were produced and these suggested that amino acids 75-86 play 
an important role in the interaction. Looking at the HPeV1 sequence, these amino acids are part 
of an amphipathic helix which can be predicted. This is conserved in another Parechovirus 
species Ljungan virus. This is probably important in the LD localisation and this should be tested 
by making more precise mutants. The critical 75-86 region at the junction of the mCherry-2C1 
(position 1-79) and mCherry-2C2 (79-160), which may explain why neither of these mutants 
fully localise to LDs.  
Two proteins associated with LDs were also used. Caveolin 1 (Cav1) localises to LDs when 
over-expressed or when cells are treated with Brefeldin A (van Meer, 2001). mCherry-Cav1 did 
not co-localise to LDs or to EGFP-2C. The cells could be treated with Brefeldin A in future 
experiments to understand the relationship between 2C and LDs. Another protein, ADRP, is a 
key component of LDs (Listenberger et al., 2007). 2C concentrated the ADRP into strong foci 
which corresponded with 2C. This shows that the 2C-derived structures do contain LD markers 
and are probably aggregated LDs. 
The best-studied virus with close ties to host LDs is HCV. In HCV-infected cells, the C protein 
localises to LDs, which may be involved in assembly. An amphipathic helix motif in C protein 
(D2 domain) has strong similarities to LD-binding domains. Localizing C to LDs involved 
triglyceride-synthesizing enzyme DGAT1. NS5A is also found in LDs and is thought to recruit 
viral RNA for encapsidation (Herker and Ott, 2012). HCV protein NS4B also targets LDs, using 
hydrophobic residues in amphipathic helices at the N- and C-termini (Tanaka et al., 2013). Given 
that the N-terminal amphipathic helix is found in many picornavirus 2C proteins, it is surprising 
that it does not seem to play a role in LD association as it can be deleted without affecting 
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distribution. However, the identification of a putative amphipathic helix spanning the 75-86 
region may suggest that HPeV 2C LD interactions also depend on an amphipathic helix. 
HCV is an enveloped virus and so different from the naked picornavirus particle. LDs may not 
therefore play a similar role in assembly, but LDs could be involved in other processes such as 
RNA replication, although there is no overlap between HPeV replication complexes and LDs. 
The interaction between 2C and LDs should be investigated further to better understand how 
HPeVs replicate and possibly provide information for the development of antivirus agents. This 
will be further looked at in chapter 5. 
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Using vaccines to prevent disease, or drugs to inhibit viral replication, are the two main 
strategies currently used to fight viral infections (van der Schaar et al., 2013). Vaccines are not 
useful for non-poliovirus enteroviruses as there are many virus serotypes and there are also 
several (16) HPeV serotypes. Despite decades of research on picornaviruses, there are no 
clinically-used antivirals for important enteroviruses/rhinoviruses or for parechoviruses (van der 
Schaar et al., 2013; Whitton et al., 2005; Zuo et al., 2016). New insights into the molecular 
biology of these viruses will hopefully open up new approaches to developing drugs (van der 
Linden et al., 2015).Viral proteins have been the usual targets of antiviral drugs in the past and 
this approach had some successes in a few virus families. For example, viral proteins such as 
proteases, polymerases and integrases have been targets for classical antiviral agents. These 
antivirals do suffer from the problems of drug resistance, as many virus polymerases lack proof-
reading mechanisms. Another approach is to target host factors that support viral replication, for 
example protein kinases involved in virus entry. These include serine/threonine kinase PAK1 for 
echoviruses, adenoviruses or vaccinia virus, as well as tyrosine kinases for coxsackievirus B3-
RD (Jurgeit et al., 2010). It could be hypothesised that drug resistant mutants should be selected 
more rarely against a cellular target. While this is sometimes the case, in other cases resistant 
mutants have been produced relatively easily (Arita et al., 2011; Geller et al., 2007).  
To select a cellular target for antiviral drugs we need to understand its role in the viral life cycle 
as well as  identifying a target where drug resistant mutants cannot replicate efficiently in cells 
relevant to the development of the disease.  
As we learn more about how picornaviruses replicate, potential cellular targets can be identified 
and useful drugs against some of these may already exist. Scanning large drug libraries for 
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molecules which have an effect on picornavirus replication has also given promising results 
recently (Gao et al., 2015).  
The work described in chapter 4 suggests that HPeV 2C interacts with LDs and this virus may 
also target lipid metabolism, as is being found for several other viruses (van der Schaar et al., 
2016).  Many drugs target fatty acid biosynthesis, such as 5-tetradecyloxy-2-furoic acid (TOFA). 
TOFA inhibits the biosynthesis of fatty acids acetyl-CoA carboxylase (ACC) and has been 
shown to block replication of HCMV and influenza A virus. Treatment with trans-4-carboxy-5-
octyl-3-methylene-butyrolactone (C75), an inhibitor of FASN (a key enzyme of the fatty acid 
biosynthetic pathway), also resulted in inhibition of the replication in HCMV, influenza A virus, 
DENV, yellow fever virus (YFV), WNV, HCV CVB3 and PV (Martin-Acebes et al., 2013).  
The aim of the work described in this chapter is to analyse the effect on HPeV replication of 
drugs known to target lipids/membranes, using CAV9 as a comparison. 4 drugs were used, 
Itraconazole, Brefeldin A, the DGAT inhibitor A922500 and betulinic acid. 
 Itraconazole 5.1.1
Itraconazole (ITZ, Figure 5.1) is an antifungal drug which is lipophilic. It inhibits CYP51, a 
cytochrome P450 required for sterol biosynthesis also has antiviral effects against HIV, 
cardioviruses, and HCV. It may also be a potential anti-cancer drug by affecting cholesterol 
trafficking (Shim et al., 2016; Strating et al., 2015). It was identified as an antiviral agent against 
rhinoviruses and enteroviruses in screens of the Food and Drug Administration (FDA)-approved 
drug library (Gao et al., 2015; Shim et al., 2016).  
 Brefeldin A  5.1.2
Brefeldin A (BFA, Figure 5.1) has been used to study membrane trafficking in eukaryotic cells 
and blocks ER to Golgi protein transport. BFA prevents membrane binding of COPI and 
formation of COPI-coated vesicles, while the formation of COPII-coated vesicles is not affected  
(Colanzi et al., 2013; Wang et al., 2012b) (Figure 5.1). BFA inhibits several enteroviruses, 
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including PV, SVDV and EV71 (Colanzi et al., 2013; Vázquez-Calvo et al., 2016; Wang et al., 
2012b). 
 Diacylglycerol acyltransferase inhibitor 5.1.3
Diacylglycerol acyltransferase (DGAT) enzymes are essential in LD biogenesis. DGAT1 and 
DGAT2 both localise to the ER, and DGAT1 is involved in LD formation (Herker et al., 2010). 
A922500 (Figure 5.1) is a potent inhibitor of DGAT1 and inhibits HCV, DENV and rotavirus 
replication (Camus et al., 2013; Crawford and Desselberger, 2016).  
 Betulinic acid 5.1.4
Betulinic acid (BetA, Figure 5.1) is a pentacyclic triterpenoid with anti-bacterial, anti-malarial, 
anti-inflammatory and anti- cancer activities. It also inhibits HSV-1, HIV and rotaviruses. 
DGAT1 is one of its targets (Crawford and Desselberger, 2016; Moghaddam et al., 2012; Potze 
et al., 2014).  
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Betulinic acid Brefeldin A 
FIGURE 5.1: Chemical structure of drugs and inhibitor used in this study. Images were 
taken from https://www.sigmaaldrich.com/united-kingdom.html.  
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5.2 Immunofluorescence study  
We first studied if there is any effect of these drugs on HPeV and CAV9. Cells were seeded in a 
6 well plate containing glass coverslips 24 hours before the experiment. After 24 hours, 1.5 ml of 
the medium was removed and cells were treated with drugs for 30 min then were infected with 
100 μl CAV9 or HPeV1 (MOI 10) and were placed on a rocking platform for 45 minutes then 
incubated at 37°C incubator for 8 hours. Cells were fixed, followed by permeablization and 
blocking. Primary antibody of dsRNA were added and kept overnight at 4°C. Alexa Fluor 488 
secondary antibody was added and incubated for 2 hours at 4˚C then were washed with PBS for 
10 minutes. The coverslips were mounted with hard set mounting medium with DAPI and 
visualized using BX41 microscope. Infected cells were counted manually.  
Cells were infected with HPeV1 or CAV9 and visualised by BX41 microscope and count the 
number of  infected cells. In HPeV1, this number with cell treated with drugs seems to be less 
than that untreated cell (Figure 5.2). all four drugs affected the virus replication and DGAT 
inhibitor is the most effective drugs comparing to others and it reduced the infection rate up to 
two third (Figure 5.3). BetA and BFA reduce the number of infected cells to the half, where ITZ 
seem to be had less effect on HPeV1 but it reduced infection to the third. 
BFA almost completely inhibit the CAV9 and image  show few number of infected cell (Figure 
5.2). DGAT inhibitor and BetA show less effective drugs with cells infected with CAV9 where 
the ITZ reduced the number of infected cells by two third (Figure 5.4)     
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(ITZ) (33 µM) 
  
Brefeldin A 
(BFA) (20 µM) 
  
FIGURE 5.2: The effect of inhibitors on HPeV1 and CAV9 infection using 
immunofluorescence microscopy. HT29 or GMK cells were seeded in 6 well plate containing 
glass coverslips and were confluent before the start of the experiment. Cells were treated with 
the concentrations of the drugs shown for 30 min then were infected with HPeV1 or CAV9 
(MOI 10) and incubated at 37C for 8 hours. Then cells were fixed, permeabilized and blocked.  
A monoclonal antibody against dsRNA was used and recognised with secondary antibody 
labelled with Alexa Fluor 488. The coverslips were mounted with hard set mounting medium 
with DAPI. Images were visualized using BX41 microscope. A blue filter detects the nucleus 
and the green filter detects dsRNA in HPeV1 or CAV9 replication complexes. The blue/green 
merged image is shown. 
C H A P T E R  F I V E    P a g e  | 177 
 
























FIGURE 5.3: Bar chart showing the effect of drugs on HPeV infection. HT29 
cells were treated with drugs, infected with HPeV1 and processed as described in 
Figure 5.2. The number of infected cells was then counted in 20 random fields and 
the average taken. Images were visualized using a BX41 microscope. (ITZ) 
Itraconazole, (BFA) Brefeldin A, (BetA) Betulinic acid and DGAT (inhibitor 
A922500). Error bars are standard deviations. 
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FIGURE 5.4: Bar chart showing the effect of drugs on CAV9 infection. GMK 
cells were treated with drugs, infected with CAV9 and processed as described in 
Figure 5.2. The number of infected cells was then counted in 20 random fields and 
the average taken. Images were visualized using a BX41 microscope. (ITZ) 
Itraconazole, (BFA) Brefeldin A, (BetA) Betulinic acid and DGAT (inhibitor 
A922500). Error bars are standard deviations. 
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5.3 Plaque assay 
As an alternative method, after drug treatment the virus yield was determined by a standard 
plaque assay on cell monolayer. A trial shows that the HPeV1 plaques are much smaller than 
those seen for CAV9, but are visible and countable (Figure 5.5). 
5.4  Screening study of drugs 
A series of dilutions of the drugs or inhibitors in growth medium was prepared (Table 5.1) from 
DMSO (for ITZ, DGAT inhibitor and BetA) or ethanol (BFA) stocks. These all had the same 
concentration of the solvent and an equivalent concentration of the solvent was in growth 
medium was also prepared. Cells were incubated for 30 minutes before infection with one of the 
drug concentrations. Cells were then infected with 100 µl CAV9 or HPeV1 (MOI 1) and were 
incubated in a 37°C incubator for 36 or 42 hours. Then cells were frozen and thawed three times 
and stored at -80°C before a plaque assay was performed to quantify the amount of virus 
produced by the cells. Examples of these plaques are shown in Figure 5.6 and 5.7.  
The DGAT inhibitor reduced the viral titre of HPeV1 by more than 1.5 log10 at the greatest 
concentration (75 mM) and this effect gradually reduced as lower concentrations were used. The 
effect of the DGAT inhibitor was less in cells infected with CAV9 and the viral titre was reduced 
by less than 1 log10 (Figure 5.8). CAV9 was not affected by DGAT inhibitor at concentrations 
less than 25 µM. There is little effect of BetA on both viruses and the reduction in viral titre was 
less than 1 log10 (Figure 5.9). Similar results were found with ITZ (Figure 5.10). BFA had a 
large effect especially on CAV9 and it reduce the viral titre by almost 2 log10. In HPeV1 it 
reduce the viral titre by approximately 1 log10. In both viruses, a reduction was seen even at low 
concentrations (Figure 5.11). 
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Table 5.1: List of all concentration of drugs that used in this study 
Drugs Concentration (µM) 
Itraconzol 33 10 3.3 1 0.33 0.1 .033 0.1 0.0033 
DGAT-1 Inhibitor 75 25 7.5 2.5 0.75 0.25 0.075   
Betulinic acid 75 25 7.5 2.5 0.75 0.25 0.075   
Brefeldin A 20 15 10 5      
Itraconzol (Gao et al., 2015) 
DGAT-1 Inhibitor A922500 (Camus et al., 2013) 
Betulinic acid (Camus et al., 2013) 
Brefeldin A (Maynell et al., 1992)  
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FIGURE 5.5: Plaque assays of CAV9 (GMK cells) and HPeV1 (HT29 cells). GMK and 
HT29 cell monolayers were infected with CAV9 or HPeV1, at the dilutions shown, for 45 min 
then the monolayer was covered with overlay medium containing 2% CMC and further cultured 
at 37°C under 5% CO2 for 3-4 days. Then, the overlay medium was removed, and the cell 









C H A P T E R  F I V E    P a g e  | 182 
 


























FIGURE 5.6: An example of a plaque assay for HPeV1 treated with DGAT inhibitor 
A922500. A plaque assay was performed on HT29 cells as described in Figure 5.5. Samples 
were taken from cells pre-treated (30 minutes) with the drug at the concentrations shown, 
infected at MOI1 then incubated for 42 hours in the presence of the drug at the same 
concentration. 
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Virus DMSO 2.5 µM 0.75 µM 0.0075 µM Control 
      
      
75 µM 25 µM 7.5 µM 0.25 µM 0.075 µM 0.025 µM 
FIGURE 5.7: An example of a plaque assay for CAV9 treated with DGAT inhibitor 
A922500. Samples were taken from cells pre-treated (30 minutes) with the drug at the 
concentrations shown, infected at MOI1 then incubated for 36 hours in the presence of the 
drug at the same concentration. 
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FIGURE 5.8: Bar chart of viral titres obtained when plaque assays were done to 
measure the amount of virus produced at different drug concentrations, when the 
DGAT inhibitor A922500 was used. Cells were pre-treated (30 minutes) with the drug at 
the concentrations shown, infected at MOI1 then incubated for 36 hours for CAV9 and 42 
hours for HPeV1 in the presence of the drug at the same concentration. The samples were 
then freeze thawed and plaque assays were used to quantitate the amount of virus present. 
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FIGURE 5.9: Bar chart of plaque assays done to measure the amount of virus 
produced at different drug concentrations, when the betulinic acid was used. Cells 
were pre-treated (30 minutes) with the drug at the concentrations shown, infected at MOI1 
then incubated for 36 hours for CAV9 and 42 hours for HPeV1 in the presence of the drug 
at the same concentration. The samples were then freeze thawed and plaque assays were 
used to quantitate the amount of virus present. The experiment was performed three times 
and error bars are standard deviations. 
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FIGURE 5.10: Bar chart of plaque assays done to measure the amount of virus 
produced at different drug concentrations, when Itraconazole was used. Cells were 
pre-treated (30 minutes) with the drug at the concentrations shown, infected at MOI1 then 
incubated for 36 hours for CAV9 and 42 hours for HPeV1in the presence of the drug at the 
same concentration. The samples were then freeze thawed and plaque assays were used to 
quantitate the amount of virus present. The experiment was performed three times and 
error bars are standard deviations. 
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FIGURE 5.11: Bar chart of plaque assays done to measure the amount of virus 
produced at different drug concentrations, when Brefeldin A was used. Cells were 
pre-treated (30 minutes) with the drug at the concentrations shown, infected at MOI1 then 
incubated for 36 hours for CAV9 and 42 hours for HPeV1 hours in the presence of the 
drug at the same concentration. The samples were then freeze thawed and plaque assays 
were used to quantitate the amount of virus present. The experiment was performed three 
times and error bars are standard deviations. 
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5.5 Time-of-addition study 
To identify the step(s) at which drugs suppresses virus infection, we analysed the drugs in a 
time-of-addition assay. The drug was added to one well which was the zero time point, and 
incubated for 30 minutes. Then all cell samples were infected with 100 µl CAV9 or HPeV1 
(MOI 10) and the drugs were added at 1, 3, 5 and 8 hours post- infection. The plate was 
incubated at 37C incubators for (36 hours for CAV9 and 42 hours for HPeV1). The plate was 
frozen-then-thawed three times and a plaque assay was applied. 
In HPeV1 the inhibitory effect of drugs on viral titre gradually decreased when the drug was 
added after infection for ITZ and BFA, suggesting that the replication steps affected occur 
through the replication cycle. The effect of both the DGAT inhibitors, A922500 and BetA 
reduced quite a lot when the drug was added after 5 hours, which suggests that they block a 
middle stage event in replication. Except BFA, the drugs did not have a great effect on CAV9 
infection. BFA also seems to work mainly at an middle stage in replication. It seems that drugs 
do not function at an early (attachment or entry) or late (assembly or release) stage (Figure 5.10 
and 5.11). 
5.6 Attempts to generate drug resistant 
mutants 
Passaging virus on cells line in the presence of the drugs or inhibitors to generate drug-resistant 
mutants was done.  For each round of passaging, cells in 6 well plates were infected with (10 µl 
of previous passaging for HPeV1 and 100 µl of a 102 dilution of CAV9) in the presence of 
increasing concentrations of drugs or inhibitors. In the first round of infection 0.1 MOI was used. 
We started with the 0.075 µM of DGAT and BetA and it was .033 µM for ITZ. 7 passages were 
run and the 6 passage the plaque assay was run with and without drugs. In ITZ and BetA we did 
not find a resistant mutation with CAV9 (data not shown). 
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FIGURE 5.12: Graph of HPeV titre obtained after the drug shown was added at 
different times before (zero time) or after infection. The drug was added to one well 
which was the zero time point, and incubated for 30 minutes. Then all cell samples were 
infected with HPeV1 (MOI 1) and the drugs were added at 1, 3, 5 and 8 hours post- 
infection. The plate was then incubated for 42 hours. The plate was frozen-then-thawed 
three times and a plaque assay was applied. The experiment was done three times and error 
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FIGURE 5.13: Graph of CAV9 titre obtained after drug was added at different times 
before (zero time) or after infection. The drug was added to one well which was the zero 
time point, and incubated for 30 minutes. Then all cell samples were infected with CAV9 
(MOI 1) and the drugs were added at 1, 3, 5 and 8 hours post- infection. The plate was 
then incubated for 36 hours. The plate was frozen-then-thawed three times and a plaque 
assay was applied. The experiment was done three times and error bars are standard 
deviations. 
 
Zero ti  
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5.7 Discussion 
Generally for RNA viruses, drugs that target host factors are potentially at low risk of giving  
resistant viruses (van der Schaar et al., 2013).  Exploiting these host factors as targets could be a 
way of producing effective antivirus drugs. RNA virus replication is highly dependent on 
cellular membranes and lipid metabolism (van der Schaar et al., 2016). Much research has been 
done in recent years to study drugs that target fatty acid biosynthesis or PI4KIIIβ. Examples of 
these drugs are TOFA , C75 and AL-9 (Martin-Acebes et al., 2013).  
Because we identified co-localisation of HPeV 2C with LDs, we were interested in testing drugs 
which may interfere with LDs to see if they inhibited HPeV infection. We investigated the effect 
of the DGAT inhibitor A922500 and also BetA, which has a number of effects on the cell, 
including inhibiting DGAT1 (Crawford and Desselberger, 2016). DGAT1 is important for LD 
development (Harris et al., 2011). Another drug, ITZ, has a different mode of action, but this is 
also related to cellular lipids. It has been shown to target the oxysterol-binding protein, which 
shuttles cholesterol and PI4P between membranes, and ITZ can inhibit enterovirus replication 
(Strating et al., 2015). It also inhibits cardiovirus replication, but not the aphthovirus equine 
rhinitis virus A. There was no information on its effect on HPeV replication and it was studied to 
find if it could also have an effect against this virus, which is genetically diverse from 
enteroviruses and cardioviruses. BFA was used as a control and because it has a potent effect on 
enteroviruses, but is reported to be only partially effective against HPeV (Gazina et al., 2002).  
In HPeV1, DGAT1 inhibitor A922500 was the most effective drug and gave a high level of 
blocking replication at 75 µM. The other DGAT1 inhibitor, BetA, had a weaker effect. These 
drugs had less effect on CAV9, which could be related to the less clear effect of CAV9 infection 
and expression of CAV9 2C on LDs compared to HPeV. The findings suggest that A922500 
could potentially be a useful drug against HPeV infections and that other compounds targeting 
LDs, or derivatives of A922500, could also be explored.  
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DGAT1 was shown to be required for HCV replication and this is blocked by knock-down of 
DGAT1 or by inhibitors(Herker et al., 2010). Although DGAT1 plays a role in LD generation, 
this may not be directly related to HCV replication as in HCV-infected cells it recruits the core 
protein onto the surface of LDs and this plays a critical role in HCV infection. DGAT1 also 
forms a complex with the HCV NS5A protein and facilitates the interaction between these viral 
proteins (Camus et al., 2013). Production of infectious viral particles of HCV is reduced in cells 
treated with the DGAT1 inhibitor A922500. The core protein still interacts with DGAT1 but 
cannot access LDs (Herker et al., 2010). Rotavirus infection is affected by both A922500 and 
BetA, which both target DGAT1 (Crawford and Desselberger, 2016). How DGAT1 may be 
involved in HPeV replication is not yet clear, but A922500 could be a tool to investigate this.  
ITZ showed antiviral activity against HRV, CVB3, EV-71, CAV16, poliovirus, cardioviruses 
and HCV (Shim et al., 2016; Strating et al., 2015). ITZ blocks intracellular cholesterol 
trafficking and so decreases the level of plasma membrane cholesterol. In addition, the antiviral 
activity of ITZ seems to be due to inhibiting oxysterol-binding protein (OSBP) in CVB3 and EV-
71. Binding ITZ to OSBP blocked its cholesterol-shuttling function and inhibited cholesterol 
trafficking (Shim et al., 2016; Strating et al., 2015). Non-structural protein 3A was found to 
accumulate mutations in drug resistant EV-71. As expected, as CAV9 is very similar to CVB3, 
our results show some inhibition of CAV9. The effect is modest, but comparable to that shown 
by several enteroviruses (Shim et al., 2016; Strating et al., 2015).  
The effect on HPeV1 is a novel observation. The inhibition is not as great as that shown by the 
DGAT1 inhibitor, but is greater than the effect of ITZ on CAV9. Again this suggests that ITZ 
could be potentially useful clinically. The advantage in using the well-established antifungal 
drug IZT or obesity therapy A922500, is that they have already been extensively tested for these 
different purposes, and found to be safe.  
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BFA inhibits the replication of several enteroviruses, including poliovirus, SVDV and EV-71 
and so it is expected to inhibit CAV9 (Gazina et al., 2002). It has been reported that HPeV is 
only partially resistant to BFA (Gazina et al., 2002) and this is supported by the results we 
obtained, which show much less effect on HPeV1 than on CAV9. BFA inhibits enterovirus 
replication by targeting the cellular protein GBF1, a guanine nucleotide exchange factor for the 
small cellular GTPase Arf1, which in uninfected cells organizes the formation of COPI vesicles 
between cis-Golgi membranes and the endoplasmic reticulum (Belov et al., 2008; Lanke et al., 
2009). BFA prevents the activated form of Arf1, Arf-GTP being formed from Arf-GDP by 
GBF1 (Szul et al., 2007). It has been suggested that activated Arf1 is important for enterovirus 
replication, possibly to recruit other cellular factors needed for replication such as PI4KIIIβ (Hsu 
et al., 2010). However, poliovirus 3A interacts with GBF1 and it may be this direct interaction 
that is needed for replication, by being involved in replication complex formation (Viktorova et 
al., 2015). The normal cellular function of GBF1 seems to be inhibited at a much lower 
concentration of BFA than was poliovirus replication, suggesting that replication is not 
dependent on GBF1’s Arf-GTP regeneration activity (Viktorova et al., 2015).  
Poliovirus variants resistant to BFA have been generated by 5 passages in the presence of 
increasing levels of BFA (0.1-1 µg/ml), where the lowest concentration is sufficient to inhibit 
more than 90 % of virus production, to allow for the need for multiple mutations to achieve 
resistance, or simply by 10 serial passages in the presence of 2 µg/ml BFA (Crotty et al., 2004; 
Viktorova et al., 2015). In both cases, resistant mutants were produced and show point mutations 
located in the 2C and 3A proteins, although the mutations observed are not the same. In similar 
work, a single amino acid change is seen in the 2C protein of SVDV (Crotty et al., 2004; 
Vázquez-Calvo et al., 2016; Viktorova et al., 2015). It is known that 2C and 3A interact and it is 
likely that mutations giving BFA-resistance affect the same process, rather than that changes in 
2C and 3A provide separate mechanisms of resistance.  Interestingly, poliovirus easily generated 
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BFA-resistant mutants in HeLa cells, but it was impossible to select resistant viruses in Vero 
cells, although the virus grows well in both these cells in the absence of the drug (Viktorova et 
al., 2015). Similarly, BFA-resistant mutants selected on HeLa cells were not resistant on Vero 
cells. This difference seems to be due to the lower availability of GBF1 in Vero cells. Vero cells 
are monkey cells, while HeLa cells are human, but other human cells also did not allow 
resistance to BFA, showing that this is not a species effect (Viktorova et al., 2015). 
To obtain more information on how the DGAT1 inhibitors A922500 and BetA, as well as ITZ, 
can block HPeV1 and CAV9 replication, we attempted to produce drug resistant mutants. These 
attempts were unsuccessful. 7 passages were performed with increasing concentrations of the 
drugs, as done in one of the poliovirus BFA experiments, where only 5 passages were performed 
and it was expected that this should allow mutants to be produced (Crotty et al., 2004). There are 
several reasons why the experiment may have been unsuccessful. One is that none of the other 
drugs were as effective against the viruses as BFA was against CAV9, and this may have 
reduced the selective pressure. In addition, more care could have been taken to establish the 
optimal starting conditions for the passaging, so that a too high drug concentration was not used. 
Simply performing more passages may also have been eventually successful. A more interesting 
reason could be that, as for BFA on Vero cells, there was a cell-type restriction which did not 
allow resistant mutants to be generated (Viktorova et al., 2015). This could be overcome by 
attempting a similar experiment with different cells. It could also be that it is not possible for 
mutants to be selected because the virus host cell target of the drug is essential and no virus 
mutants can adapt to different pathways, which would be the optimal scenario for a drug based 
on a cellular target. 
The work on BFA, which targets the cellular target GBF1, shows that it can be easy, in the 
correct cells, for a virus to adapt to the presence of the drug and weakens the idea that a cell 
target may be less susceptible to selecting drug resistant mutants. However, as we find out more 
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 CHAPTER SIX  6
GENERAL DISCUSSION
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Picornaviruses are non-enveloped, positive sense single-stranded RNA viruses which cause 
many diseases ranging from slight illness to fatal meningitis and encephalitis. There is no 
effective human vaccine for picornaviruses except for poliovirus and hepatitis A virus and no 
efficient drug treatment is currently available (van der Schaar et al., 2013). Human 
parechoviruses (HPeVs) can cause serious diseases but have been studied relatively little and are 
also genetically diverse from several picornaviruses. We therefore need to understand the details 
of virus replication, such as the changes to the host cell which occur during HPeV infection, 
which components of the secretory system are affected by infection and which virus proteins are 
needed to generate replication complexes to improve the opportunities to develop antiviral drugs 
(van der Linden et al., 2015). The aim of our studies was therefore to understand the effects of 
HPeV infection on the secretory system and the origin of HPeV replication complexes (chapter 
3). During our work we discovered that the not only does the HPeV 2C protein localise to lipid 
droplets (LDs) as previously reported (Krogerus et al. 2007), but it also aggregates these into 
large complexes. This led to a detailed study of this protein to find the basis of this aggregation 
and LD localisation (chapter 4). The possible involvement of LDs in HPeV replication then led 
to work to assess LDs as possible cellular targets for drugs against HPeV infection (chapter 5). 
The main findings are summarised below. 
Studies of several different positive-strand RNA viruses have suggested the ER, Golgi, 
endosomes or lysosomes as sources for structures needed for replication (Salonen et al., 2005; 
Suhy et al., 2000). These membrane structures are used for several reasons, such as 
concentrating components needed for virus replication, holding replication complexs in place, 
and hiding dsRNA and so avoiding host defence mechanisms which respond to dsRNA (Miller 
and Krijnse-Locker, 2008; Sasaki et al., 2012). Some picornaviruses change the distribution of 
secretory pathway compartment and our results show that HPeV1 infection affects the ER, Golgi 
and ERGIC in the HT29 cell line. ER (PDI was used as the marker) almost completely 
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disappears in infected cells, while the number of spots of ERGIC-53 (ERGIC marker) is reduced. 
The Golgi (GM130 was used as a cis-Golgi marker) is also very much reduced by infection. We 
also found that infection with the Enterovirus CAV9 leads to reduction in staining and dispersal 
of the GM130 marker. The Golgi pattern seen in CAV9-infected cells is similar to that in 
previous work on enteroviruses (Cornell et al., 2006; Mousnier et al., 2014). In fact, disruption of 
the Golgi by infection seems to be a common feature for picornaviruses as several diverse 
picornaviruses have this effect (Gazina et al., 2002; Midgley et al., 2013). For another 
Enterovirus, rhinovirus 1A, it has been reported that disrupted Golgi membranes form virus 
replication complexes (Quiner and Jackson, 2010). We found for HPeV1 that there was no co-
localisation between dsRNA, marking the site of replication, and GM130 marking the Golgi and 
this suggests that these viruses have a different requirement for Golgi material. However, 
previously it was reported that HPeV1 replication complexes show partial co-localisation with 
the trans-Golgi marker GalT (Krogerus et al., 2003). The rhinovirus 1A work used the Golgi 
cisternae marker Giantin (Quiner and Jackson, 2010). A wider panel of antibodies needs to be 
used to study the relationship between the Golgi and HPeV infection, as trans-Golgi and/or Golgi 
cisternae may be involved in replication complex formation, but not cis-Golgi.  
A surprising finding was the almost complete loss of the ER in HPeV-infected cells. This is quite 
different from infection by two genetically distinct picornaviruses, FMDV and rhinovirus 1A, 
where there is no change seen in infected cells (Quiner and Jackson, 2010; Midgley et al., 2013; 
Wang et al., 2012). Infection by both these viruses causes some disruption of the ERGIC. The 
FMDV result is interpreted as showing an involvement of ER exit sites in formation of the virus 
replication complex. Diverting the normal flow of vesicles from the ER to ERGIC/Golgi would 
lead to a reduction in these compartments (Midgley et al., 2013). Our observation of almost 
complete loss of the ER may suggest that retrograde movement of vesicles from the 
Golgi/ERGIC to reform the ER, is disrupted, leading to less material in the ER. This is consistent 
C H A P T E R  S I X    P a g e  | 199 
 
   
 
with the loss of COPI in HPeV-infected cells, as COPI coated vesicles are involved in retrograde 
traffic back to the ER (Gazina et al.,2002).  
2B, 2BC/2C and 3A are the main non-structural proteins that affect the secretory pathway in 
picornaviruses. 2B, 2BC or 3A (but not 2C) of poliovirus disrupt protein trafficking and cell 
surface protein expression, while expression of 2B and 2C or of the 2BC precursor (but not 3A) 
is sufficient to inhibit trafficking between the ER and Golgi in FMDV (Sweeney et al., 2010; 
Midgely et al., 2013). In For HPeV1 we found that expression of 2C greatly affects all these 
compartments, giving similar results to the effects of infection. 3A also has an effect on some of 
them. 2C also had a major effect on lysosomes, suggesting that this protein is probably 
responsible for remodelling the secretory system in infected cells. There was some co-
localisation of 2B with the ER and lysosomes and 3A with Golgi, ERGIC and lysosomes. We 
found a clear co-localisation between 2BC and 2C with LDs and these proteins caused large foci 
or aggregates of LDs.  
When expressed individually, the non-structural proteins 2B and 3A had a similar reticular 
pattern in the cytoplasm, partially corresponding to ER (2B) or ERGIC and Golgi (3A). This is 
not surprising as both these proteins have transmembrane domains and amphipathic helices 
which locate them to membranes (Martinez-Gil et al., 2011). Surprisingly, 2A is found 
throughout the cell with no clear association with membranes although it is also predicted to 
have a transmembrane domain (Hughes and Stanway, 2000). 2C had the most distinctive 
distribution, large spots in the cytoplasm. This was suggested to be due to localisation to lipid 
droplets (LDs) (Krogerus et al., 2007). 2BC seemed to have a similar distribution but with a faint 
diffusion.  
The interaction between 2C/2BC and LDs led us to study LDs further. Initially we investigated 
the effect of HPeV infection on lipids using BODIPY 500/510 C4-C9 long chain. There was 
little effect in HPeV-infected cells, and also in cells infected with CAV9 used as a comparison. 
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The non-structural proteins of HPeV1 were then used. Interestingly we found that 2A seems to 
accumulate fatty acids around the nuclei, while there is some co-localisation of FAs with 2B and 
3A. In the case of 2C some of the fatty acid stain is located in foci and these correspond to the 
concentrations of 2C. This adds further weight to the idea that 2C is associating with fatty 
acid/lipid structures. It has been reported that inhibition of fatty acid synthesis inhibits HCV 
replication, maturation and release of HCV (Syed et al., 2010).  NS5B of HCV interacts with 
fatty acid synthase and contributes to HCV replication (Huang et al., 2013). 
We investigated the possible effect of HPeV1 and CAV9 on LD. In cells infected with HPeV, 
late in infection LDs become more prominent. In contrast LDs in CAV9-infected cells become 
less prominent later in infection. This suggests that replication of these viruses, belonging to 
different Picornaviridae genera, has a different requirement for LDs. We found that the ability of 
2C to interact with LDs does not depend on the ATPase activity (Sweeney et al., 2010), nor on 
the N-terminal amphipathic helix found to be involved in membrane interactions in other 
picornaviruses (Echeverri and Dasgupta, 1995; Echeverri et al., 1998). Instead, we found that 
amino acids 75-86 of 2C play an important role in the LD localisation as deletion of amino acids 
1-74 gives a mutant 2C which can localise to LDs, but deletion of 1-86 destroys this ability. This 
region is part of a novel amphipathic helix which is conserved in another Parechovirus species 
Ljungan virus.  
Several viruses seem to use or manipulate LDs during infection, but these organelles have been 
largely unstudied in picornavirus infections. The best-studied virus with close ties to host LDs is 
HCV. In HCV-infected cells, the C protein localise to LDs which may be involved in assembly. 
HCV assembly occurs close to LDs (Vogt et al., 2013). An amphipathic helix motif in C protein  
(D2 domain) has strong similarities to LD-binding domains (Herker and Ott, 2012).  
Dengue virus decreased LD number during infection and due to autophagy-dependent lipolysis 
to release free fatty acid (Heaton and Randall, 2010; Herker and Ott, 2012). The C protein of 
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Dengue virus (DENV) accumulates on the surface and localises to LDs (Herker and Ott, 2012; 
Liu et al., 2010). The rotavirus protein NSP4 contributes to LD metabolism using an autophagy 
pathway (Cheung et al., 2010; Herker et al., 2010). Several diverse viruses therefore exploit LDs 
during replication.  
We investigated the effect of drugs which target lipid droplet formation and lipid homeostasis on 
HPeV replication. We demonstrated that drugs which target the enzyme DGAT1, which is 
involved in LD formation, have a potent effect on HPeV replication, but were less effective 
against CAV9. Our results suggest that blocking LD formation could be an important strategy for 
the treatment of HPeV infection. DGAT1 is a potential target for drugs against other viruses. 
DGAT1 forms a complex with the HCV NS5A protein and facilitates the interaction between 
these viral proteins (Camus et al., 2013). Production of infectious viral particles of HCV is 
reduced with cells treated with the DGAT1 inhibitor A922500. Rotavirus infection is affected by 
both A922500 and BetA, which both target DGAT1 (Crawford and Desselberger, 2016). Our 
results add to the idea that drugs interfering with LDs could be useful antivirus agents. 
Our results show that HPeV 2C is a major player in remodelling the secretory system and in 
interacting with LDs. Our drug studies showed that LDs are important in HPeV replication as 
drugs which target them inhibit the virus. The work described in this thesis therefore has 
potentially laid the foundations for the development of effective antivirus agents against these 
important human pathogens. 
Future Work 
The work has highlighted several differences between the intracellular events which occur in 
HPeV-infected cells and in cells infected with other viruses, such as enteroviruses and FMDV. 
HPeV infection has previously been shown have a different requirement for COPI coats from 
enteroviruses and cardioviruses (Gazina et al., 2002). It is clear that these intracellular events 
need to be studied further to understand HPeV infection and develop useful drugs. Infection with 
C H A P T E R  S I X    P a g e  | 202 
 
   
 
poliovirus or transfection of poliovirus 3A protein blocks ER-Golgi protein transport (Choe et 
al., 2005; Richards et al., 2014). PV proteins 2B protein localises to vesicles containing Sec13 
and Sec31, both of which are components of the COPII vesicles. (den Boon et al., 2010). The 
formation of enterovirus replication organelles also specifically requires COPI (Morosky et al., 
2016). Poliovirus 3A protein binds GBF1 and modulates recruitment of Arf1 effectors to favour 
phosphatidylinositol 4-kinase (PI4K) over COPI components. It may also inhibit ER-to-Golgi 
transport by stabilizing Arf1-GDP-GBF1 complexes, reducing the supply of Arf1-GTP for COPI 
coats. This creates membranes lacking COPI and enriched for PI4P, which promotes membrane 
binding of viral RNA-dependent RNA polymerases and formation of the viral replication 
complex (Midgley et al., 2013; Pierini et al., 2009). In FMDV, 2B plus 2C, or the 2BC precursor 
(but not 3A) can block trafficking of proteins between the ER and Golgi and their expression on 
the cell surface in FDMV (Sweeney et al., 2010). The requirement of HPeV for molecules such 
as GBF1 and PI4K, as well as COPI and COPII coats needs to be studied further. This could be 
done using siRNA to knock-down the appropriate molecules and investigate the effect on virus 
replication. A wider panel of antibodies could also be useful, to probe the effect of infection on 
some of these molecules.  
A major focus of the study was the HPeV 2C protein. In other picornaviruses this protein seems 
to have a number of different functions, including RNA binding, helicase activity and membrane 
rearrangement, and could be a useful target for new drugs (Ulferts et al., 2016). One limitation in 
our studies is the lack of an antibody against HPeV 2C and generating a useful antibody will 
allow the location of 2C to be established in the infected cell, to find if it is present in replication 
complexes or demonstrate interactions with other proteins for instance. This cannot be achieved 
with EGFP/mCherry-2C as we find that expression of these prevents infection of the cell. 
Interactions with other molecules should also be probed by using mass spectrometry to identify 
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novel cellular proteins which interact with 2C and then explore how these may contribute to 
replication through co-localisation studies and siRNA knock-down. 
LDs seem to be important for HPeV replication and their role should be studied more fully, again 
by siRNA knock-down of critical components, such as DGAT1 and ADRP. The interaction 
between HPeV 2C and LDs may involve a novel amphipathic helix in 2C, located between 
amino acids 74 and 91. This should be explored further to confirm if it sufficient to allow LD 
binding by producing shorter constructs and by finding the key amino acids by making point 
mutants, as done for the HCV NS4B amphipathic helix (Tanaka et al., 2013). As well as doing 
this by transfecting EGFP/mCherry constructs, point mutations should also be introduced into 
the virus to investigate the effect on replication.   
The work in chapter 5 shows that drugs targeting LDs could be useful against HPeV infection 
and a wider panel of drugs which affect LDs and lipid metabolism in general should be tested to 
find more candidates (Crawford and Desselberger, 2016). Selection of drug resistant mutants 
against A922500 and BetA should be retried using different conditions, to confirm they cannot 
be produced or identify mutations which should give insights into how the drugs function. 
 
These experiments should greatly increase our understanding of HPeV replication and lead to the 
identification of ways to treat infections by these important pathogens.
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